

# Marc A. Silver M.D., FACP, FACC, FCCP, FAHA, FHFA, FCRS

1998-2017  
Chief, Division of Medical Services  
Chairman, Department of Medicine  
Founder, Heart Failure Institute  
Advocate Christ Medical Center  
2018-  
President, MASGroupUSA  
Founder, Strategic Heart Failure

## ADDRESS

3057 E Libra Pl, Chandler, AZ 85249  
Direct email: Marc@MASGroupUSA.com Mobile: 708-212-0355

## PLACE OF BIRTH

Chicago, Illinois

## EDUCATION

**Rush Medical College** Chicago, IL  
Doctor of Medicine 1979

**2017 Rush Medical College Distinguished Alumni Award** Chicago, IL  
**Clinical Excellence** 2017

## TRAINING

**Rush-Presbyterian St. Luke's Medical Center** Chicago, IL  
Resident, Internal Medicine, Department of Medicine 1979-1982  
Medical Staff Fellow, Pathology Branch,

**National Heart, Lung and Blood Institute**  
**National Institute of Health** Bethesda, Maryland  
Medical Staff Fellow, Pathology Branch 1982-1984

**Rush-Presbyterian-St. Luke's Medical Center** Chicago, IL  
Fellow, Cardiovascular Disease June 1984-December 1985  
Section of Cardiovascular Diseases

## CURRENT ACADEMIC APPOINTMENTS

**Clinical Professor of Medicine, Department of Medicine** Chicago, IL  
University of Illinois at Chicago July 1999-present

**Adjunct Professor, Department of Biomedical Engineering** Chicago, IL  
Illinois Institute of Technology May 2004 - 2011

**Lecturer** Chicago, IL  
Rosalind Franklin University of Medicine and Science September 2006-present

*CURRENT MEDICAL CENTER ROLES*

<b>Advocate Christ Medical Center</b>	<b>Oak Lawn, IL</b>
<i>Chairman, Department of Medicine</i>	<b>2001-November 2017</b>
<i>Chief, Division of Medical Services</i>	<b>2014-November, 2017</b>
<i>Founder, Heart Failure Institute</i>	<b>1998</b>
<i>Director, Cardiovascular Disease Fellowship</i>	<b>August 1998-June 2003</b>

**Key physician leader for the Department (400+) and Medical Staff (1200 +) including moving key result areas and metrics.**

**Lead/oversight on issues ranging from physician, nursing and patient relations to quality, performance improvement, and safety. Also broad experience in mentoring physician performance, evaluations and accountability. Also experience in GME, CME, and community service and relations, supporting internal and external communications and energizing philanthropy.**

**Division of Medical Services encompasses the following operational units and their teams: Departments of Internal Medicine, Family Medicine, Physical Medicine and Rehabilitation, Psychiatry and Neurology, and the Sections of Cardiology, General Internal Medicine, Allergy and Immunology, Endocrinology, Hematology/Oncology, Hospital Medicine, Gastroenterology, Infection Disease, Pulmonary/Critical Care, Nephrology, Dermatology and Rheumatology.**

*PREVIOUS ACADEMIC APPOINTMENTS*

<b>Loyola University, Stritch School of Medicine</b>	<b>Chicago, IL</b>
<i>Professor of Medicine, Department of Medicine</i>	<b>July 1996-June 1998</b>
<i>Associate Professor of Medicine,</i>	
<i>Department of Medicine</i>	June 1994-June 1996
<i>Clinical Associate Professor of Medicine</i>	November 1992-June 1994

<b>University of Illinois, College of Medicine</b>	<b>Chicago, IL</b>
<i>Visiting Associate Professor of Medicine and Pathology</i>	July 1990-Feb. 1992

<b>The University of Chicago, Pritzker School of Medicine</b>	<b>Chicago, IL</b>
<i>Assistant Professor of Medicine</i>	July 1988-June 1990

<b>Loyola University Medical Center, Stritch School of Medicine</b>	<b>Chicago, IL</b>
<i>Lecturer, Cardiovascular Pathology,</i>	
<i>Department of Pathology</i>	July 1988-November 1992
<i>Assistant Professor of Medicine,</i>	
<i>Department of Medicine</i>	January 1986-June 1988
<i>Assistant Professor of Pathology</i>	
<i>Department of Pathology</i>	January 1986-June 1988
<i>Transplant Cardiologist, Cardiac Transplant Program</i>	January 1986-June 1988

**HOSPITAL/PROFESSIONAL  
APPOINTMENTS/PHYSICIAN LEADERSHIP/GOVERNANCE/FOUNDATION MEMBERSHIP**

**Physician Leadership Institute (PLI)** April 2012  
*Initial Cohort Member*  
A training program for physician leaders. Dyad based.  
SG2 (Dr. M. Guthrie) and Organizational Development Led  
2 year journey to enrich and train physician leaders

**PLI Steering Committee** April 2012  
Steering committee for initial and subsequent cohorts

**ADVOCATE HEALTH CARE System wide Physician Leader  
Heart Failure** 1998-  
Established a system wide heart failure structure in the largest integrated Healthcare  
system in Illinois. Specifically impacted “dashboard” indicators including: CHF length  
of stay, 30-day re-admission rates, measurement of LVEF and utilization of ACEI  
and Beta Blockers. Led the organization through successful JCAHO Disease  
Specific Certification (and Re-Certification)) in Heart Failure across the entire  
system. One of 14 Programs. Certified Nationally.

*OTHER JCAHO CERTIFICATIONS (ROLE PHYSICIAN/TEAM LEADER)*

<b>Advocate Health Care System-Wide Heart Failure DSC</b>	2002
<b>Advocate Health Care System-Wide Heart Failure DSC</b>	
<b>Advocate Christ Medical Center Heart Failure DSC</b>	2007
<b>Advocate Health Care System-Wide Heart Failure DSC</b>	2004
<b>Advocate Christ Medical Center Heart Failure DSC</b>	2007
<b>Advocate Christ Medical Center Heart Failure DSC Intracycle Review</b>	2008
<b>Advocate Christ Medical Center LVAD Advanced DSC</b>	2008
<b>Advocate Christ Medical Center Advanced Heart Failure DSC</b>	2009
<b>Advocate Christ Medical Center LVAD Advanced DSC (re-cert)</b>	2009
<b>Advocate Christ Medical Center, Physician Lead, Certificate of Need for Heart Transplant Program and Initial Designation Advocate Health Care Network</b>	
<i>Member, Board of Directors, Foundation Board</i>	October 2004 - 2008
<b>Advocate Charitable Foundation</b>	
<i>Director, Class II category, Board of Directors</i>	September 2001-Oct. 2004
<b>Advocate Christ Medical Center</b>	
<i>Member, Cancer Institute Research and Education Strategy Committee</i>	August 2008-present
<i>Member/Chair, Medical Staff Nominating Committee</i>	June 2008-Oct. 2008
<i>Member, Medical Fund Board</i>	November 2004-present
<i>Member, Palliative Care Task Force Committee</i>	September 2002-present
<i>Advisory Board, Diabetes Mellitus Center</i>	October 2003-present

<i>Member, Vendor Relations Task Force Committee</i>	Sep.2001-Dec 2002
<i>Member, Research &amp; Ed Strategic Planning Taskforce</i>	Feb 2002-present
<i>Member, Credentialing Committee</i>	September 2000- present
<i>Member, Advocate System wide Research Taskforce</i>	May 2000-present
<i>Member Advocate System wide CAM Taskforce</i>	February 2000-present
<i>Member, Ethics Committee</i>	March 1999 - 2002
<i>Member, Pharmacy, Therapeutics &amp; Drug Usage Comm.</i>	April 1999-present
<i>Chairman, Fellowship Evaluation Committee</i>	July 1998 -2003
<i>Co-Chairman, Heart Failure Team</i>	July 1998- present
<i>Member, Ambulatory Care Steering Committee</i>	July 1998- present
<i>Member, Medical Education Committee</i>	July 1998-present
<i>Member, Graduate Medical Education Committee</i>	July 1998- present
<i>Member, Performance Improvement Committee</i>	July 1998-present
<i>Member, Acute MI Committee</i>	July 1998-present

*ADDITIONAL LEADERSHIP ROLES*

<b>University of Illinois at Chicago</b>	<b>Chicago, IL</b>
<i>Medical Director, Heart Transplant Program</i>	October 2002 – June 2004
<b>Loyola University Medical Center</b>	<b>Chicago, IL</b>
<i>Director, Loyola University Heart Failure Center</i>	July 1994 – June 1998
<i>Associate Medical Director</i>	
<i>Heart Transplant/Heart Failure Program</i>	July 1994-June 1998
<i>Attending Physician</i>	January 1986 - June 1988
<b>Midwest Center for Heart Failure</b>	
<i>Director</i>	February 1992 – June 1994
<b>Midwest Heart Research Foundation</b>	
<i>Midwest Heart Specialist</i>	February 1992 – June 1994
<b>Good Samaritan Hospital</b>	
<i>Attending Physician</i>	February 1992 – June 1994
<b>Michael Reese Hospital and Medical Center</b>	
<i>Chief, Division of Cardiology</i>	June 1991 – February 1992
<i>Director, Cardiovascular Institute</i>	March 1991 – February 1992
<i>Director, Cardiovascular Disease Training Program</i>	April 1990 – Feb.1992
<i>Acting Chief, Division of Cardiology</i>	April 1990 - February 1991
<i>Acting Director, Cardiovascular Institute</i>	April 1990 – February 1992
<i>Director, Heart Failure Program</i>	April 1990 - February 1992
<i>Medical Director,</i>	
<i>Cardiac Surveillance and Telemetry Units</i>	August 1989-April 1990
<i>Co-Director, Heart Failure Program</i>	August 1989 - April 1990
<b>Mercy Center for Health Services</b>	<b>Aurora, Illinois</b>
<i>Director, Heart Failure Program</i>	October 1990 – 1994
<b>Rush-Presbyterian-St. Luke's Medical Center</b>	<b>Chicago, IL</b>
<i>Adjunct Attending Physician</i>	June 1984 - December 1985

## LICENSURE & CERTIFICATION

**Diplomate, National Board of Medical Examiners (#190603)** July 1, 1980  
**Diplomate, American Board of Internal Medicine (#085972)** Sep. 15, 1982  
**Diplomate, Subspecialty Board, Cardiovascular Disease (#085972)** Nov. 8, 1989  
**Diplomate, Subspecialty Board  
Advanced Heart Failure / Transplant Cardiology (#085972)** Nov. 8, 2010  
**State of Illinois (#036-060821)** Expiration Date July 31, 2017

## AWARDS

**Mosby Scholarship Award** 1979  
**John B. Drake Award (Intern of the Year)** 1979 - 1980  
**Resident of the Year Award** 1980-1981 and 1981-1982

**Illinois Hospital Association Distinguished Service Award** 2004  
*"In recognition of his commitment to improving the lives of patients suffering from heart disease through compassionate treatment, research, innovative therapies, and early detection"*

**Advocate Christ Medical Center/Hope Children's Hospital** Nov. 16, 2012  
*Physician recognition award for excellence in academics*

## EDITORIAL ACTIVITIES

**Am College of Physicians CP/Dynamed Collaboration Reviewer** 2019-  
*(Hypertrophic cardiomyopathy, Myocarditis, Dilated cardiomyopathy, Beta blockers for heart failure or ACE inhibitors for heart failure)*

**Heliyon, OA Mega Journal (Elsevier)** 2018-  
*Editorial Board Member*

**Congestive Heart Failure**  
*Editor-in-Chief* 2009-2013  
*CO-Editor-in-Chief* 1998-2009

**Journal of Cardiac Failure**  
*Editorial Board Member* 1999-2005, 2007-2013

**JACC: Heart Failure**  
*Editorial Board* 2012-2018, **Renewed 2018-2020**

**American Journal of Cardiology**  
*Editorial Board Member*

**Journal of Heart Disease**  
*Scientific Advisory Board*

**Journal of Women's Health**  
*Editorial Reviewer* 2018-

**Cardiac and Vascular Regeneration**  
*Associate Editor*

**Current Issues in Heart Failure**  
*Associate Editor*

**American Journal of Medical Sciences**

*Editorial Reviewer*

**American Journal of Medicine and Sports**

*Editorial Board Member*

**Journal of Noninvasive Cardiology**

*Editorial Board Member*

**Alternative Therapies in Health and Medicine**

*Editorial Advisory Board*

**Cardiac Transplantation**

*Editor-at-Large, Marcel Dekker, Inc*

**Journal of Heart and Lung Transplantation**

*Editorial Board*

**Preventive Cardiology**

*Editorial Board*

1998-2010

**Journal of the American College of Cardiology (JACC),**

*Editorial Board*

2000-2007

*Guest Editor*

2003

**Faculty of 1000 Medicine**

*Evaluation Board*

2005-2008

***Success with Heart Failure***

*Author, Insight Books/Plenum Press (Editions 1, 2 and 3)*

*JCAHO ACTIVITIES*

**Member, LVAD Certification Task Force**

**Member, Advanced Certification for Heart Failure Standards Task Force**

**Member, Advanced Certification for Heart Failure Technical Advisory Panel**

**Member, Comprehensive Cardiac Center (CCC) Certification**

**Technical Advisory Panel (2018)**

**As a Medical Staff and Subspecialty Leader for our Health System, participated in and collaborated for multiple JCO accreditation reviews including initial reviews for LVAD and Transplant programs. Was a medical center and system leader was a constant resource for quality, patient, medical staff and healthcare outcomes matters.**

**As our health care system transitioned to DNV for accreditation I similarly participated in those reviews and also continued my professional and consulting roles within the Joint Commission.**

*MANUSCRIPT REVIEWS*

**Alternative Therapies in Health and Medicine**

**American Heart Journal**

**American Journal of Cardiology**

**American of Graduate Medical Education**

**American Journal of Obstetrics and Gynecology**

**American Journal of Physiology**

**Archives of Internal Medicine**

**Canadian Medical Association Reviewer**

**Cardiovascular Pathology**  
**Circulation**  
**Circulation Research**  
**Coronary Artery Disease**  
**Drug Therapy**  
**International Journal of Cardiology**  
**Journal of American Medical Association**  
**Journal of American College of Cardiology**  
**Journal of Cardiac Failure**  
**Journal of Heart and Lung Transplantation**  
**Journal of Parenteral and Enteral Nutrition**  
**Mayo Clinic Proceedings**

*PROFESSIONAL ASSOCIATIONS*

**Advocate Charitable Foundation**  
*Class II Foundation Director* 2008-2010  
**American Academy of Hospice and Palliative Medicine**  
*Voting Member*  
**American College of Physicians**  
*Fellow*  
**American College of Chest Physicians**  
*Fellow*  
*Credentials Committee* 1998-2000  
*CHEST 2000 Scientific Program Committee*  
*National Program Committee*  
**American College of Cardiology**  
*Fellow*  
**ACC Council on Heart Failure and Transplant** 2014-present  
**Workgroup on Chronic Heart Failure and Outpatient Care** 2014-present  
**ACC/AHA Physician Consortium for Performance Improvement Heart Failure Performance Measure Set**  
*Content Reviewer* 2009-2010  
**ACC/ACR Writing Panel for the ACR/ACC Appropriate Utilization of Imaging for Heart Failure.** 2009-present  
**Re-Appointed to the Writing Committee for Update to the Heart Failure Guidelines**  
2009  
**Re-appointed to Writing Committee for Guideline Update** 2003  
**ACC/AHA Committee to Revise the 1995 Guidelines for the Evaluation & Management of Heart Failure** 1999-2000  
**Abstract Reviewer for Scientific Sessions** 2003 – 2008  
**Education Working Group on Live Programs**  
**Strategic Planning, Subgroup on Multi-Topic Symposia/Certification & Recertification** January, 2004  
**Special Opinion Panel** 2000-present  
**Information Technology Committee** 1999-2001  
**Board of Councilors, Illinois Chapter, 1999-2004 & 2008**  
**Steering Committee, Illinois Chapter**  
**Councilor, Illinois Chapter 1990-1993**  
**Chairman, Program Committee 1991-1993**  
**Alternate Chairman, Program Committee 1996-1997**

**Cardiovascular Economics Committee**  
**Public Sector Subcommittee**  
**Quality of Health Care Committee**  
**Research, Education and Manpower Committee**  
**ACC/IHI Hospital to Home (H2H),**  
**Measurement and Evaluation Subgroup** 2009-present  
**Chronic Heart Failure and Outpatient Care Work Group (Heart Failure and Transplant Section)** 2014

**American College of Physician Executives**  
**American Federation for Clinical Research**  
**American Heart Association**  
*Fellow*  
*ACC/AHA Committee to Revise the 1995 Guidelines for the Evaluation & Management of Heart Failure* 1999-2000  
*Medical Committee Heart Ball, Co-Chair* 2004  
*Abstract Consultant/Grader for Scientific Sessions* 2003-2005, 2009-2017  
*Heart of Chicago Award, Judges Panel* 2000-2001  
*Council on Basic Science*  
*Council on Clinical Cardiology, Fellow*  
*Research Review Committee (Grant Review)* 1987-88 and 1989-90  
**American Heart Association, Metropolitan Chicago, IL**  
*Board of Governors* 1996-2000, 1990-1993  
*Patient Care Committee* 1990-1994  
*Heartbeat Newsletter Editorial Board* 1992-1998  
*Chairman, West Cook Division* 1996-1998  
*Chairman, West Suburban Branch* 1995-1996  
**American Medical Association**  
**Association of Chairs & Chiefs of Medicine**  
**Association of Subspecialty Professors, 2000**  
**CardioRenal Society of America**  
*Board of Directors* 2017-  
*Fellow, (FCRSA)* 2018  
**Central Society for Clinical Research**  
**Chicago Cardiology Group**  
*Secretary-Treasurer* May 1990 - May 1992  
*Vice-Chairman* May 1992 - May 1994  
**Chicago Medical Society**  
**Heart Failure Society of America**  
*Founding Member*  
*Executive Council* 1995-2003  
*Membership Committee, Chair* 1995-2000  
*Program Committee* 1995-2000  
*Publications Committee* 1996-2000  
*Guidelines / Clinical Positions Committee* 1997  
*Heart Failure Awareness Committee* 1995-2003



*Lifetime Achievement Committee* 2014-2017  
*Abstract Reviewer for Scientific Sessions*  
**Illinois Geriatric Society**  
**Illinois Medical Society**  
**International Society for Heart and Lung Transplantation**  
*Council on Heart Failure and Transplant*  
*Medicine Council on Pathology & Basic Science*  
*Scientific Council on Mechanical Circulatory Support Devices*  
*Abstract Reviewer for Scientific Sessions*  
**Joint Commission Disease Specific Care**  
**Heart Failure Expert Panel** August 2002-October 2002  
**Joint Commission LVAD Task Force Panel Member** October 2004  
**Joint Commission Disease-Specific Care**  
**Heart Failure Expert Panel** 2006

**Heart Failure Society of America**

**Inaugural Fellow, FHFSA 2016**  
**Founding Member**  
**Chairman of Membership 1995-1999**  
**Member Program Committee 1995- 1998**  
**Executive Council 1995-2002**  
**Numerous committee and roles, presentations 1995- Present**

**Society for Cardiovascular Pathology**

*Member, Finance Committee* 1986 – 1988  
*Member, Program Committee* 1989 – 1991  
*Member, Editorial Committee* 1993 - 1995

**Society of Geriatric Cardiology (Fellow)**

*Publications Committee* 1995 – 1997  
*Credentials Committee* 1996 – 1999  
*Membership Committee* 1998 - 2001

**Southern Society for Clinical Investigation - Member**

**Rush Medical College Alumni Association**  
*Executive Council and Class Agent* 1984 - 1987

**United Network for Organ Sharing (UNOS)**

*Region 7 Heart Transplant Review Board Member* 2008-present  
*ACMC, Medical Director, Heart Transplant Program* 2007-April 20, 2010

**International Center for Health Outcomes & Innovation Research (InCHOIR) Eric Rose, MD Chair**

*(SCCOR) Steering Committee Member* 2006-present  
*Columbia University*

**University of Illinois at Chicago**

*Member, Heart Transplant Evaluation Committee* July 1998 – 2000

**Loyola University Medical Center**

*Chairman, Pharmacy and Therapeutics Committee* Nov 1994-June 1998  
*Chairman, Heart Failure Continuum of Care Committee*  
*Member, Institutional Review Board (IRB)* 1994 –1995  
*Co-Chairman, Task Force on Complementary and Alternative Medicine*

Member JCAHO Education Committee  
 Resident Faculty Advisor  
 Member, Research Funding Committee  
 Cardiology Research Committee Board Member  
 Executive Committee Member, Cardiovascular Institute 1987 – 1988  
**University Hospital Consortium**  
 Member, CHF Benchmarking Committee  
 Cardiology Research Committee Board Member  
 Executive Committee Member, Cardiovascular Institute 1987 – 1988  
**International Center for Health Outcomes & Innovation Research (InCHOIR) Eric Rose, MD Chair**  
 (SCCOR) Steering Committee Member  
 Columbia University 2006-present  
**University of Illinois at Chicago**  
 Member, Heart Transplant Evaluation Committee July 1998 – 2000  
**Stritch School of Medicine**  
 Medical School Admissions Committee  
**Michael Reese Hospital and Medical Center**  
 Cardiac Services Task Force 1988 – 1992  
 Faculty, Cook County Graduate School of Medicine 1988  
 Member, Research Committee July 1986 - June 1988  
**Rush Presbyterian St. Luke's Medical Center**  
 University Committee of Research January – December 1985

*BIOGRAPHY APPEARS IN:*

**Chicago Magazine TOP DOCTORS** Multiple Years  
**Top Doctors: Chicago Metro Area**  
**Castle Connelly Medical Ltd.** 2001, 2002, 2003, 2004 & 2009  
**America's Top Cardiologists** 2007, 2010  
**Consumer's Research Council of America**  
**Who's Who in Medicine & Healthcare** 1st Edition  
**Who's Who in the Midwest** 22nd Edition  
**Who's Who in Science and Engineering** 1st Edition  
**Who's Who in Medicine and Healthcare** 3rd Edition  
**Who's Who in the World, 18th Edition**  
**Who's Who in Finance and Industry** 32nd Edition  
**World Heart Corporation, Clinical Advisory Board**  
**Who's Who in the World** 19th Edition

*COMMUNITY ACTIVITIES*

**La Grange Park Library, Member, Board of Trustees** 2007-2009  
**American Youth Soccer Organization (AYSO)**  
*Referee* 1990-2004  
*Assistant Coach* 2002  
**Advocate Charitable Foundation**  
*Member Board of Directors* 2000-present  
**Advocate Christ Medical Center,**  
*Development Council Member* 2000-Present  
**Advocate Christ Medical Center**

<i>President's Campaign Cabinet</i>	2013-Present
<b>La Grange Babe Ruth Baseball League</b>	
<i>Executive Board</i>	
<i>Player Agent</i>	2001-2003
<b>St. Francis Xavier</b>	
<i>Basketball Team Coach</i>	
<i>Various Years Grades 5th, 6th, 7th and 8<sup>th</sup></i>	

*DISCLOSURE / CONFLICTS OF INTEREST (2015)*

**Current: None**

**Recent/Prior:**

*No Stock or other current financial relationships to disclose*

*UNIVERSITY SERVICE*

<b>University of Illinois Hospital and Health Sciences System</b>	
<i>Cardiology Search Committee</i>	May 2014-present

## **SPONSORED RESEARCH GRANTS & CLINICAL TRIALS**

1. Metoprolol in Dilated Cardiomyopathy (MDC) Multicenter International Trial. Principal Investigator, 1986-1992 (IND # 28,069), Sponsor: Ciba-Geigy.
2. Coxsackie Viral Myocarditis: Inflammatory Infiltrate Distribution and Density. Principal Investigator, Sponsor: Loyola University Research Committee.
3. A randomized, phase III, placebo-controlled survival study of oral milrinone in patients with severe heart failure (#1064) PROMISE. Principal Investigator, Sponsor: Sterling Winthrop.
4. A prospective, three month, randomized, placebo-controlled phase III study of oral milrinone in addition to digoxin/angiotensin-converting enzyme inhibitor and diuretic therapies in patients with congestive heart failure (#1078). Principal Investigator, Sponsor: Sterling Winthrop.
5. A phase II, III clinical evaluation: study of patients receiving oral milrinone (P-553, Revised 1987). Principal Investigator.
6. Effect of 24-hour intravenous infusion of RGW-2938 in patients with congestive heart failure patients on concomitant, orally administered background therapy (#RGW-2938-133). Principal Investigator, Sponsor: Rorer Central Research.
7. A three month double-blind, randomized, placebo-controlled, follow-up safety study on oral RGW 2938-109 followed by open-label long-term treatment in patients with congestive heart failure. Principal Investigator, Sponsor: Rorer Central Research.
8. A double-blind, placebo controlled study of oral RGW-2938-105 on exercise performance in heart failure patients. Principal Investigator, Sponsor: Rorer Central Research.
9. A multicenter, double blind, placebo controlled study of the effects of manoplax (flosequinan) for 16 weeks on duration of exercise treadmill testing and disease symptoms in CHF patients on angiotensin-converting enzyme inhibitors (BPI 932 and 932X). Principal Investigator, Sponsor: Boots Pharmaceuticals.
10. Trial to evaluate the effect of digitalis on mortality in heart failure. Digitalis Investigation Group (DIG) Principal Investigator, Sponsor: National Heart, Lung and Blood Institute.
11. Flosequinan Survival Trial (PRAISE) #933. Sponsor: Principal Investigator, Boots Pharmaceuticals.
12. Influence of Systemic Hypertension on the development and progression of Coxsackie B3 myocarditis. Principal Investigator, Funding agency: Medical Research Institute Council Award: \$40,000.
13. Amlodipine in heart failure trials Amlodipine Study Group a) Hemodynamic b) Exercise c) Survival (Co-Director, Core Gas Exchange Committee) Principal Investigator, Sponsor: Pfizer.
14. A phase 2, double blind randomized evaluation of the pharmacodynamics and pharmacokinetics of OPC-18,790 (Bolus dose ranging trial. Protocol #103-92-204) Principal Investigator, Sponsor: Otsuka America Pharmaceuticals.
15. Open label OPC 8212-202. Follow up oral trial following #103-92-204, Principal Investigator, Sponsor: Otsuka America Pharmaceuticals.
16. Otsuka America Pharmaceuticals #103-92-206. Oral vesnarinone in heart failure. Principal Investigator, Member Executive Steering Committee.
17. Evaluation of the oxygen-sensor rate responsive pacing lead technology. (Oxy-Elite), Associate Principal Investigator, Sponsor: Medtronic, Inc.
18. Dual chamber pacing in Ischemic Cardiomyopathy Pilot Trial. Principal Investigator, Sponsor: Medtronic.
19. Cardiomyoplasty Randomized Trial Phase III. Principal Investigator, Sponsor: Medtronic, Inc.
20. ELITE (Losartan) Trial in the Elderly with Heart Failure, Principal Investigator, Sponsor: Merck, Inc.
21. BEST Trial (Bucindolol in Heart Failure), Principal Investigator, Sponsor: NIH/ VA Cooperative Studies.
22. hBNP (Natrecor) Clinical Evaluation Trials, Principal Investigator, Sponsor: Scios-Nova.

23. Oral vesnarinone in heart failure #22-94-201 (VEST) Principal Investigator, Sponsor: Otsuka America Pharmaceuticals.
24. EECF for unstable Angina (MUST-EECP). Principal Investigator, Sponsor: Vasomedical.
25. Val-HeFT, Valsartan 107 Trial. Principal Investigator, Sponsor: Novartis.
26. Sudden Cardiac Death in Heart Failure (SCD-HeFT) Trial. Sponsor: National Institutes of Health.
27. Principal Investigator and Member Steering Committee, OPTIME Study (Outcomes of a Prospective Trial of Intravenous Milrinone for exacerbations of Chronic Heart Failure). Principal Investigator and Member of Operations Committee, Sponsor: Sanofi Pharmaceuticals.
28. Toborinone (OPC 18790) Protocol 103-97-201. Principal Investigator, Sponsor: Otsuka America.
29. Eplerenone--Phase 2 Trials. Principal Investigator, Sponsor: SEARLE Pharmaceuticals.
30. A pilot multicentered, randomized, double blind trial of Intravenous TBC 11251 NA to determine Acute Hemodynamics in Congestive Heart Failure. (IND # 52,527) Co-Principal Investigator, Sponsor: Texas Biotechnology Corporation.
31. Carvedilol in Advanced Heart Failure (COPERNICUS). Principal Investigator, Sponsor: SmithKline Beecham.
32. Randomized Evaluation of Oral Levosimendan in End-Stage Heart Failure (Orion REVOLVE Study), Principal Investigator, Sponsor: Orion Pharmaceuticals.
33. Protocol Phase II/III Study of the Effect of Recombinant Human Necrosis Factor Receptor (p75) Fc Fusion Protein (TNFR:Fc) etanercept on Clinical Improvement in patients with Chronic Heart Failure. Principal Investigator, Sponsor: Immunex Corporation.
34. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE), RFP NHLBI-HV-98-24. Principal Investigator, Sponsor: National Heart, Lung, & Blood Institute
35. The Effect of Sustained Released Moxonidine on Mortality and Morbidity in with Congestive Heart Failure (MOXCON Study) Protocol B3N-MC-EUBC. Principal Investigator, Sponsors: Eli Lilly & Co./Solvay.
36. Candesartan Cilexetil in Heart Failure (CHARM) Principal Investigator, Sponsor: Astra Pharmaceuticals.
37. EPHESUS Trial IE 3-99-02-035: Clinical Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Eplerenone in Patients with Heart Failure Following Acute Myocardial Infarction, IND #51,780, Principal Investigator, Sponsor: Quintiles.
38. Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) MIC Project #834; Principal Investigator, Sponsor: VA Cooperative Studies Program.
39. Depression and Chronic Heart Failure. MIC Project # 818, Principal Investigator, Advocate Christ Hospital.
40. Randomized Etanercept North American Strategy to Study Antagonism of Cytokines (RENNAISSANCE). MIC Project #838; Principal Investigator, Sponsor: Immunex.
41. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor® (nesiritide) Compared with Nitroglycerin Therapy for Symptomatic Decompensated CHF (VMAC). Protocol: 704.339, Principal Investigator, Sponsor: Scios Inc.
42. International Enhanced External Counterpulsation Patient (EECP) Registry MIC Project # 861; Principal Investigator, Sponsor: VasoMedical Corporation.
43. Initial troponin release following adriamycin administration predicts chronic myocardial dysfunction. MIC Project #848. Co-Principal Investigator,
44. Thoratec TLC-II Portable Driver System, MIC Project #849; Co-Principal Investigator, Sponsor: Thoratec Lab.
45. Identifying spiritual risk in patients with CHF, MIC Project #854; Co-Principal Investigator, Advocate Christ Medical Center.
46. Multi-center InSync™ ICD: Randomizing Clinical Evaluations. MIC Project #872; Co-Principal Investigator, Sponsor: Medtronic.

47. Effect of intravenous milrinone and dobutamine on levels of tumor necrosis alpha and plasma norepinephrine in patients with advanced heart failure. MIC Project #875; Co-Principal Investigator, Advocate Christ Hospital.
48. MIRACLE ICD Multi-center InSync™ ICD: Clinical Study Evaluating Cardiac Resynchronization Therapy for Heart Failure Patients with ICD Indications. MIC Project #876; Co-Principal Investigator, Sponsor: Medtronic.
49. Oral Enoximone in intravenous inotrope-dependent subjects (EMOTE) A phase III, randomized, double-blind, placebo-controlled study or Oral Enoximone in intravenous inotrope dependent patients. (EMOTE). MIC Project # 898; Co-Principal Investigator, Sponsor: Myogen.
50. Evaluation of Impact of Plasma Coenzyme Q10 Levels and Left Ventricular Function in Hypercholesterolemic Patients Treated with a Statin Based Lipid Lowering Agent. MIC Project #906; Principal Investigator, International Coenzyme Q10 Association, Advocate Christ Medical Center.
51. Comparison of Medical therapy, pacing and defibrillation in heart failure (COMPANION) MIC Project #883; Co-Principal Investigator, Sponsor: Guidant.
52. Cardiovascular response of normals during cardiopulmonary exercise testing: Evaluation of a constant speed, variable grade treadmill exercise protocol. MIC Project #919; Co-Principal Investigator, Sponsor: Guidant.
53. Enhanced External Counterpulsation (EECP) in Heart Failure: A single blind, controlled, randomized evaluation of efficacy and safety. MIC Project # 919; Principal Investigator, Sponsor: VasoMedical Corporation.
54. The prospective randomized outcomes study of acutely decompensated CHF treated initially in patients with Natrekor (nesiritide). (PROACTION).MIC Project # RR52; Principal Investigator, Sponsor: Scios.
55. InSync (R) III Investigational Plan. MIC Project #3150; Co- Principal Investigator, Sponsor: Medtronic.
56. ADHERE Longitudinal Model – registry of severe heart failure patients at high risk for rehospitalization. Principal Investigator, Sponsor: Scios.
57. Enoximone plus extended release metoprolol succinate in subjects with advanced chronic heart failure (EMPOWER). Principal Investigator, Sponsor: Myogen.
58. Heart failure adherence and retention trial (HART). Principal Investigator, Sponsor: University of Illinois.
59. INSYNC ICD Registry – FDA mandated long-term 3 years post-implant, data collection. Principal Investigator, Sponsor: Medtronic.
60. Enhanced external counterpulsation in heart failure (PEECH). Principal Investigator, Sponsor: Vasomedical.
61. Rapid assessment of bedside BNP in treatment of heart failure (RABBIT). Principal Investigator, Sponsor: Biosite.
62. Pilot study investigating the role of acute and chronic oral magnesium on endothelial function, exercise capacity, functional status and outcome in patients with heart failure. Principal Investigator, Advocate Christ Hospital.
63. A phase IV, randomized, double-blind, placebo controlled study demonstrating extended VTE prophylaxis with enoxaparin (EXCLAIM). Protocol XRP4563C/3501. Principal Investigator, Sponsors: Aventis & Covance.
64. Safety and efficacy of sildenafil citrate in heart failure. A single center safety and efficacy investigation. Funding: \$40,000.00, Principal Investigator, Sponsor: Pfizer Pharmaceuticals.
65. A placebo-controlled double blind randomized trial with a composite endpoint of death and/or all-cause hospitalization. (FUSION II). Steering Committee, Sponsor: Scios.
66. Follow-up serial infusions of nesiritide for the management of patients with heart failure. (FUSION II). Principal Investigator, Sponsor: Scios.

67. MOMENTUM Trial: Multicenter trial of the Orqis medical CRS for the enhanced treatment of CHF unresponsive to medical therapy. IRB # 3738. Principal Investigator, Sponsor: Orqis Medical.
68. Relationship between daily pedometer activity, six-minute walk, and oxygen consumption in patients with heart failure. IRB # 3736, Principal Investigator, Advocate Christ Medical Center.
69. Nesiritide effects on C-reactive protein levels in patients with decompensated heart failure. IRB #3671, Principal Investigator, Advocate Christ Medical Center.
70. Multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). Co-Investigator, Sponsor: Guidant.
71. Exercise limitation in chronic heart failure – The role of nutrition. Principal Investigator, Advocate Christ Medical Center.
72. A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of darbepoetin alfa treatment on mortality and morbidity in heart failure subjects with symptomatic left ventricular systolic dysfunction and anemia. Principal Investigator.
73. A phase II, randomized, double blind, placebo controlled exploratory efficacy study of sitaxsentan sodium to improve impaired exercise tolerance in subjects with diastolic heart failure, IRB #4063, Co-Principal investigator, Sponsor: Encysive.
74. The BALANCE Study: Treatment of hyponatremia Based on Lixiuaptan in NYHA Class III/IV cardiac patient evaluation, IRB #4501, Principal Investigator, Sponsor: Cardiokine Biopharma LLC.
75. Champion Trial. Evaluation of an implantable pulmonary artery monitor in heart failure. IRB # xxxx, Principle Investigator. Sponsor: Cardiomems.
76. THAOS- Pfizer Pharmaceuticals, Principal Investigator, Advisory Member, Writing Committee
77. Tafamadis Trial. Pfizer Pharmaceutical Sponsor. Principal Investigator.

## PUBLICATIONS

1. **Silver MA**, Oranburg PR, Roberts WC. Severe mitral regurgitation immediately after mitral valve replacement with a parietal pericardial bovine bioprosthesis. *Am J Cardiol.* 1983;52:218-219.
2. **Silver MA**, Roberts WC. Active infective endocarditis complicating idiopathic dilated cardiomyopathy. *Am J Cardiol.* 1983;52:647.
3. Roberts WC, **Silver MA**. Norman Jefferis Holter and ambulatory ECG monitoring. *Am J Cardiol.* 1983;52:903-906.
4. **Silver MA**, Macher AM, Reichert CM, Levens DL, Parrillo JE, Longo DL, Roberts WC. Cardiac involvement by Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS). *Am J Cardiol.* 1984;53:983-985.
5. **Silver MA**, Bonow RO, Deglin SM, Maron BJ, Cannon RO III, Roberts WC. Acquired left ventricular endocardial constriction from mural calcific deposits: a newly recognized cause of impairment to left ventricular filling. *Am J Cardiol.* 1984;53:1468-1470.
6. Cohen SR, **Silver MA**, McIntosh CL, Roberts WC. Comparison of late (62-140 months) degenerative changes in simultaneously implanted and explanted porcine (Hancock) ioprotheses in the tricuspid and mitral positions in six patients. *Am J Cardiol.* 1984;53:1599-1602.
7. **Silver MA**, Cohen AI, Katz NM, Fletcher RD, Ferrans VJ, Roberts WC. Cardiac morphologic findings late after partial left ventricular endomyocardial resection for recurrent ventricular tachycardia. *Am J Cardiol.* 1984;233-235.
8. **Silver MA**, Cohen SR, McIntosh CL, Rosing DR, Roberts WC. Late (5 -132 months) clinical and hemodynamic results after either tricuspid valve replacement or anuloplasty for Ebstein's anomaly of the tricuspid valve. *Am J Cardiol.* 1984;54:627-632.
9. **Silver MA**, Roberts WC. Detailed anatomy of the normally functioning aortic valve in hearts of normal and increased weight. *Am J Cardiol.* 1985;55:454-461.
10. **Silver MA**. Early complications following prosthetic replacement of the mitral of aortic valves. *Cardiology in Practice.* 1985;2:72-80.
11. Roberts WC, **Silver MA**, Sapala JC. Intussusception of a coronary artery associated with sudden death in a college football player. *Am J Cardiol.* 1986;57:179-180.
12. **Silver MA**, Hilgard JH, Murabit I, Bloom KJ. Right atrial tamponade simulating tricuspid stenosis following acute myocardial infarction. *Am Heart J.* 1986;111:984-986.
13. **Silver MA**. Morphologic substrates of ventricular arrhythmias. *Clin Prog Electrophysiol and Pacing.* 1986;4:1-13.
14. O'Connell JB, Pifarre R, Sullivan HJ, Costanzo-Nordin MR, Montoya A, Bakhos M, Grieco J, Foy BK, Jones RN, **Silver MA**, Grady KL, Szepelak L, Robinson JA. Heart transplantation at Loyola University Medical Center: the first two years. *J Heart Transplant.* 1986;5:54.
15. Costanzo-Nordin MR, **Silver MA**, O'Connell JB, Pifarre R, Grady KL, Winters GL, Murdock DK, Sullivan HJ, Grieco JG, Scalon PJ, O'Connell JB, Robinson JA. Successful treatment of cardiac allograft rejection with OKT\*3 monoclonal antibody. *Circulation.* 1987;76:V71-V80.
16. **Silver MA**. Benign essential tremor and leukocytes in the heart-revisited. *Cor notes.* 1987;2:4.
17. Costanzo-Nordin MR, **Silver MA**, O'Connell JB, Scanlon PJ, Robinson JA. Giant cell myocarditis: dramatic hemodynamic and histologic improvement with immunosuppressive therapy. *Eur Heart J.* 1987;8(Suppl.J):271-274.
18. Grigg MM, Costanzo-Nordin MR, Celesia GG, Kelly MA, **Silver MA**, Sobotka PA, Robinson JA. The etiology of seizures after cardiac transplantation. *Transplantation Proceedings.* 1988; 20:937-944.
19. **Silver MA**, Rowley NE. The functional anatomy of the human coronary sinus. *Am Heart J.* 1988;115:1080-1084.



20. Studemeister AE, Kozak K, Loyola University Cardiac Transplant Team (**Silver MA**, Nordin MR) Garrity E, Venezio FR: Survival of a heart transplant recipient after pulmonary cavitory mucormycosis. *J Heart Transplant*. 1988;7:159-161.
21. **Silver MA**. For subspecialty board certification of cardiovascular pathologists: a no vote from a non-qualified non-pathologist, cardiovascular pathologist, other individual. *Cor Notes*. 1988;3:1.
22. Robinson JA, Costanzo-Nordin MR, Grusk BB, **Silver MA**, Sobotka PA, O'Connell JB, Pifarre R. The use of low-dose methotrexate for the treatment of allograft rejection is associated with significant drug toxicity. *Bibliotheca Cardiol*. 1988;43:35-38.
23. Lakier JB, Brookfield LA, Silver MA, Weber KT. Management of heart failure in dilated cardiomyopathy. *Progress in Cardiology*. 1989;2/1:71-83.
24. Costanzo-Nordin MR, Grusk BB, Silver MA, Sobotka PA, Winters GL, O'Connell JB, Pifarre R, Robinson JA. Reversal of recalcitrant allograft rejection with methotrexate. *Circulation*. 1988; 78 (Suppl III):47-57.
25. **Silver MA**, Kowalczyk D. Coronary microvascular narrowing in acute murine Cocksackie B3 myocarditis. *Am Heart J*. 1989;118:173-174.
26. Winters GL, Costanzo-Nordin MR, O'Sullivan EJ, Pifarre R, Silver MA, Zucker MJ, Robinson JA, Scanlon PJ. Predictors of late acute orthotopic heart transplant rejection. *Circulation*. 1989;8 (Suppl III):106-110.
27. Weber KT, Pick R, **Silver MA**, Moe GW, Janicki JS, Zucker IH, Armstrong PW. Fibrillar collagen and remodeling of dilated canine left ventricle. *Circulation*. 1990;82:1387-1401.
28. Bieber E, Quinn JP, Venezio FR, Miller JB, **Silver MA** (Loyola University Cardiac Transplant Team). Salmonella empyema in a heart transplant recipient. *J Heart Transplant*. 1989;8:262-263.
29. **Silver MA**, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrillar collagen remodeling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. *Cardiovasc Res*. 1990;24:741-747.
30. Weber KT, Brilla CG, Pick R, Janicki JS, **Silver MA**. Cell biology of myocardial remodeling: contribution of nonmyocyte cells. *J Vasc Med and Biol*. 1991;3:44-49.
31. Shirani J, Bonin MA, Gould N, **Silver MA**. Left ventricular free wall rupture following acute myocardial infarction and cardiac amyloid. *Clinical Cardiology*. 1990;13:729-731.
32. **Silver MA**. Strut fracture and embolization of Bjork-Shiley valve from the tricuspid valve position. *Am J Cardiol*. 1991;68:1253.
33. Shirani J, Pick R, Guo Y, **Silver MA**. Usefulness of the electrocardiogram and echocardiogram in predicting the amount of interstitial myocardial collagen in endomyocardial biopsy specimens of patients with chronic heart failure. *Am J Cardiol*. 1992;69:1502-1503.
34. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, **Silver MA**, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Results of the metoprolol in dilated cardiomyopathy (MDC) trial. A randomized controlled multicenter study. *Lancet*. 1993;342:1441-1446.
35. **Silver MA**. Difficult cases in heart failure: Diastolic dysfunction. *Congestive Heart Failure*. 1994;1(1); 51-54.
36. **Silver MA**. Difficult cases in heart failure: Tailored medical therapy. *Congestive Heart Failure*. 1995;1(2):46-47.
37. **Silver MA**. Difficult cases in heart failure: Severe valvular aortic stenosis. *Congestive Heart Failure*. 1995;1(3):37-40.
38. **Silver MA**. Difficult cases in heart failure. Severe chronotropic incompetence. *Congestive Heart Failure*. 1995:40-41.
39. **Silver MA**. Difficult cases in heart failure:  $\beta$ -blockers in the treatment of heart failure. *Congestive Heart Failure*. 1995;1(5):36-37.
40. **Silver MA**. Difficult cases in heart failure: Hypertrophic cardiomyopathy. *Congestive Heart Failure*. 1995;1(6):36-37.

41. Bhatt MA, **Silver MA**. Difficult cases in heart failure: The etiology of a patient's heart failure. *Congestive Heart Failure*. 1995;1(7):32-34.
42. Rector TS, Tschumperlin LK, Kubo SH, Bank AJ, Francis GS, McDonald KM, Keeler CA, **Silver MA**. Use of the Living with Heart Failure questionnaire to ascertain patients' perspectives on worthwhile improvement in quality of life and risk of drug-induced death. *Journal of Cardiac Failure*. 1995;1:201-206.
43. **Silver MA**. Modern approaches to evaluating and treating patients with heart failure. *Journal of Canadian Cardiovascular Society Annual Meeting*. Oct. 27, 1995.
44. **Silver MA**, Keeler CA, Malinowska K. Safety and efficacy of intermittent out-patient intravenous inotropes in patients with advanced symptomatic heart failure. *Circulation: Heart Failure*. 2008;1:9-16. doi: 10.1161/circheartfailure.108.767483
45. **Silver MA**. An economic algorithm for patients with systolic congestive heart failure. *Cardiology*. 1996;2(1):19-20.
46. **Silver MA**. Patient knowledge of fundamentals in chronic heart failure. *Congestive Heart Failure*. 1996;2(2):11-13.
47. **Silver MA**. Difficult cases in heart failure: Ventricular tachycardia in cardiac sarcoid. *Congestive Heart Failure*. 1996;2(1):34-37.
48. Bhatt DM, **Silver MA**. Difficult cases in heart failure: Idiopathic dilated cardiomyopathy. *Congestive Heart Failure*. 1996;2(2):35-36.
49. **Silver MA**. (The Digitalis Investigation Group). Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure. *Controlled Clinical Trials*. 1996;17:77-97.
50. Bhatt DM, **Silver MA**. Difficult cases in heart failure: Alcoholic heart disease; Case report. *Congestive Heart Failure*. 1996;2(3):39-41.
51. Packer M, O'Connor CM, Ghali JK, et al and the Prospective Randomized Amlodipine Survival Evaluation Study Group (**Silver MA**, Keeler CA). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *New England Journal of Medicine*. 1996;335:1107-1114.
52. **Silver MA**. Monitoring the heart failure patient: traditional and new opportunities. In "Current and Future Applications for Ambulatory Cardiac Monitoring". Prystowsky EN. Editor. *Indiana Heart Institute/St. Vincent's Hospital*. Dec., 1996
53. The Digitalis Investigation Group (**Silver MA**). The effect of digoxin on mortality and morbidity in patients with heart failure. *New England Journal of Medicine*. 1997;336:525-533.
54. **Silver MA**. Difficult cases in heart failure: Obstructive sleep apnea, hypertension and heart failure: A clinical conundrum. *Congestive Heart Failure*. 1997;3(1):36-38.
55. **Silver MA**, Ventura, H. Difficult cases in heart failure: Exploring the therapeutic potential of intravenous thyroid hormone in cardiogenic shock. *Congestive Heart Failure*. 1997;3(2):35-37.
56. **Silver MA**. The "Dead" Files. *Congestive Heart Failure*. (Editorial) Mar./ Apr. 1998.
57. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Lichtenberg RC, Barath PC, O'Keefe PJ, Robinson JA, Yeldandi V. Effective oral gancyclovir prophylaxis against cytomegalovirus disease in heart transplant recipients. *Transpl. Proceedings*. 1998; Dec 30(8):4110-4112
58. Mills RM, Lefemtel TH, Horton DP, Liang CS, Lang R, **Silver MA**, Lui C, Chatterjee K, *On Behalf of the Natrecor® Study Group*. Sustained hemodynamic effects of a 24-hour infusion of nesiritide (human B-type natriuretic peptide) in heart failure; A randomized, double-blind, placebo-controlled clinical trial. *Journal of the American College of Cardiology*. 1999;34(1):155-162.
59. **Silver MA**. Perceptions Editorial - Medicine and Sports. *Amer J of Med and Sports*. 1999;1(1):5-6.
60. Kieso HA, **Silver MA**. Newer inotropic agents for decompensated heart failure. *ACC Curr J Review*. Jul./Aug. 1999;35-38.
61. **Silver MA**, Cianci P. Impact of heart failure education on function status and quality of life. *J of Advocate Health Care*. 1999;1(1):40-42.

62. Mehra MR, **Silver MA**. Pulsed inotropic therapy: An evangelical haven or justified sanctuary. *Congestive Heart Failure*. 1999;5(2):59-61.
63. **Silver MA**, Ventura HO. Difficult cases in heart failure: Importance of patient selection in the use of intermittent inotrope infusions for advanced heart failure. *Cong. Heart Failure*. 1999;5(2):86-90.
64. **Silver MA**. Intermittent inotropes for advanced heart failure: Inquiring minds want to know. *American Heart J*. 1999;138(2)Part 1:191-192.
65. Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, **Silver MA**, Radvany R, Robinson JA. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. *J Heart Lung Transplant*. 1999; Jul;18(7):701-6.
66. **Silver MA**, Ventura HO. Difficult cases in heart failure: Left ventricular assist device implantation for the treatment of recurrent ventricular tachycardia in end stage heart failure. *Congestive Heart Failure*. 1999;5(3):129-130.
67. **Silver MA**. Heart failure monitoring: Innovation Awaits. *Congestive Heart Failure*. 1999;5(3):103-4.
68. **Silver MA**, Ventura HO. Difficult cases in heart failure: Reversible heart failure secondary to thyrotoxicosis. *Congestive Heart Failure*. 1999;5(4):180-182.
69. **Silver MA**, Ventura HO. Difficult cases in heart failure. Role of continuous ambulatory peritoneal dialysis in refractory heart failure. *Congestive Heart Failure*. 1999;5:283-285, 287.
70. Baughman KL, Dec WG, Elkayam U, Forker AD, Gheorghide M, Hermann D, Konstam MA, Liu P, Massie BM, Patterson JH, **Silver MA**, Stevenson LW. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. *J of Card Failure*. 1999;5(4):357-382, and *Congestive Heart Failure*. 2000;6(1):11-39.
71. Udelson JE, DeAbate CA, Berk M, et al, for the **Amlodipine Exercise Trial Investigators**. Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. *American Heart J*. 2000;139(3):503-510.
72. Strobeck JE, **Silver MA**, Ventura H. Impedance cardiography: Noninvasive measurement of cardiac stroke volume and thoracic fluid content. *Congestive Heart Failure*. 2000;6(2):56-59.
73. **Silver MA**, Ventura HO. Difficult cases in heart failure: Beneficial effects of aldosterone blockade in heart failure. *Congestive Heart Failure*. 2000;6(2):115-117.
74. Patil HM, **Silver MA**. Clinical depression is common in patients with advanced heart failure. Presented at Eighth Annual Naurice Nasset Research Forum. sponsored by Advocate HealthCare.
75. Craig A, Hefferan C, Mau JM, Pisano C, Sedlarz P, **Silver MA**, Trella B. Heart failure: A system wide care management initiative. Presented at Eighth Annual Naurice Nasset Research Forum, sponsored by Advocate HealthCare.
76. Philbin EF, Hunsberger S, Garg R, Lader E, Thadani U, McSherry F, **Silver MA**, *On behalf of the Digitalis Investigation Group*. Differentiating normal from low left ventricular ejection fraction in chronic heart failure using clinical parameters: Results of application of a multivariate model. Submitted to *Archives of Internal Medicine* for publication.
77. Strobeck JE, **Silver MA**. Home is where the heart is . . . Or is it? *Congestive Heart Failure*. 2000;6(3):135-136
78. **Silver MA** Ventura HO. Difficult cases in heart failure: Bridge to beta blockade in severe heart failure: The use of phosphodiesterase inhibitors. *Congestive Heart Failure*. 2000;6(3):164-166.
79. **Silver MA** (Article consultant) The Advocate Health System approach to heart failure care. *Cardiovascular Disease Management*. 2000;6(5):1-4.
80. Feldman AM, Rich MW, **Silver MA** (Article consultants). A step-by-step guide to the best heart failure care. *Patient Care*. 2000;34(11):154-170.

81. **Silver MA.** Improving heart failure care: HCFA reports in. (Editorial) *Congestive Heart Failure.* 2000;6(5):237
82. **Silver MA.** The holy grail of heart failure: Hold on--It's coming. *Cardiac and Vascular Regeneration.* 2000;1(2):75.
83. **Silver MA,** Ventura HO. Difficult cases in heart failure: Ventricular resynchronization in refractory heart failure. *Congestive Heart Failure.* 2000;6(6):333-336.
84. O'Connor, Gottlieb S, Carson P, Anand I, **Silver MA,** Plehn J, White M, Anderson JL, Krause-Steinrauf H (for the BEST Investigators). The impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure: Clinical characteristics, prognosis and the effect of beta-blocker therapy. *JACC.* 2001.
85. Slaughter MS, **Silver MA,** Farrar DJ, Tatooles AJ, Pappas PS. A new method of monitoring recovery and weaning the Thoratec left ventricular assist device. *Ann Thorac Surg.* 2001;71:215-218.
86. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW for the **BEST Investigators.** A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med.* 2001;344(22):1659-67.
87. **Silver MA,** Cianci P. Images in clinical medicine. *Journal of Advocate Health Care.* Spring/Summer 2001;(3)1:38.
88. Pisano C, Cianci P, **Silver MA.** Non-invasive revascularization by enhanced external counterpulsation (EECP) : One-year post treatment analysis. *Journal of Advocate Health Care.* Spring/Summer 2001;(3)1:51.
89. **Silver MA.** Familial dilated cardiomyopathy—more than meets the eye. (Editorial) *Congestive Heart Failure.* 2001;7(3):162.
90. Pahlevan I, Lonergan-Thomas H, Ande S, Burks J, Robin E, Petropulos T, **Silver MA.** Difficult cases in heart failure: Familial dilated cardiomyopathy. *Cong. Heart Failure.* 2001;7(3):163-165.
91. **Silver MA.** It takes a village . . . to improve heart failure care. (Editorial) *Congestive Heart Failure.* 2001;7(4):186.
92. Latza C, Craig A, Heffernan C, Ludwig-Beymer P, Pisano C, **Silver MA.** Heart failure: A comprehensive systemwide approach to improving patient care. *Journal of Advocate Health Care.* Spring/Summer 2001;(3)1:46.
93. Craig A, Hefferan C, Ludwig-Beymer P, Pisano C, **Silver MA.** Heart Failure: A comparison of program patients over time. *Journal of Advocate Health Care.* Fall/Winter 2001;(3)2:5-7.
94. **Silver MA.** Thinking of heart failure as a medical emergency. (Editorial) *Congestive Heart Failure.* 2001;7(3):123.
95. **Silver MA.** Are you ready for another paradigm shift? (Editorial) *Congestive Heart Failure.* 2001;7(5):242-43.
96. **Silver MA.** The Gift, Introduction to Masters of Heart Failure Series. *Congestive Heart Failure.* 2001;7(5):244.
97. Leier CV, **Silver MA,** Massie BM, Young JB, Fowler MB, Ventura HO, Hershberger. Nuggets, pearls, and vignettes of master heart failure clinicians. Part 1—the medical history. *Congestive Heart Failure.* 2001;7(5):245-249.
98. **Silver MA.** Yet Another Milestone for CHF (Editorial). *Congestive Heart Failure.* 2001;7(6):294.
99. Philbin E, Hunsberger S, Garg R, Lader E, Thadani U, McSherry F, **Silver MA** on behalf of the Digitalis Investigation Group. Usefulness of clinical information to distinguish patients with normal from those with low ejection fractions in heart failure. *Am J Cardiol.* 2002;89:1218-1221.
100. Burger AJ, Horton D, LeJemtel T, Ghali J, Torre G, Dennish G, Koren M, Dinerman J, **Silver MA,** Elkayan U. Differential Effects of Nesiritide (B-type Natriuretic Peptide) and Dobutamine on Ventricular Arrhythmias: The PRECEDENT Study. *Am H Journal.* 2002;144 (6):1102-1108.
101. Parvatheneni L, Harp J, Zelinger AB, **Silver MA.** Relationship between brachial artery reactivity and non-invasive large and small arterial compliance as a measure of endothelial function.

*American Journal of Cardiology*. (Impact Factor:3.28). May, 2002;89(7):894-5. Doi: 10.1016/500029149(02)02212.9

102. Young JB on behalf of the Publication Committee for the **VMAC Investigators**. Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. *JAMA*. 2002;287(12):1531-1540.
103. Hunt SA Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Related Articles Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, **Silver MA**, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Jacobs AK, Hiratzka LF, Russell RO, Smith SC. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) Developed in Collaboration with the International Society for Heart and Lung Transplantation Endorsed by the Heart Failure Society of America. *J Heart Lung Transplant*. Feb 2002; ;21(2):189-203. No abstract available. PMID: 11834347. *Circulation*. Dec 11 2001; 104(24):2996-3007. No abstract available. PMID: 11739319. *JACC*. Dec 2001;38(7):2102-2113.
104. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, **Silver MA**, Gheorghide M. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. A randomized controlled trial. *JAMA*. 2002;287(12):1541-47.
105. **Silver MA**, Horton DP, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. *JACC*. 2002;39(5):798-803.
106. Fuentes J, **Silver MA**, Chalupczak R. Clinico-Pathological Conference: A thirty-three year old female with syncope. *Journal of Advocate Health Care*. Fall/Winter 2002;(4)2:28.
107. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren, M, Dinerman J, **Silver MA**, Cheng MI, Elkayam U. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study. *Amer Heart J*. 2002;144(6):1102-1107.
108. Cianci P, Lonergan-Thomas H, Slaughter M, **Silver MA**. Current and potential applications of left ventricular assist devices. *J of Cardiovascular Nursing*. 2003;18(1):17-22.
109. Langsjoen PH, Littarru GP, Silver MA. Potential role of concomitant coenzyme Q10 with statins for patients with hyperlipidemia. *Current Topics in Nutraceutical Research*. 05/2002.
110. Keating GM, Goa KL, and various sections of the manuscript reviewed by: Aronson D, Burger AJ, Cleland JG, Ghali JK, LeJemtel TH, Mills RM, **Silver MA**. Nesiritide: A review of its use in acute decompensated heart failure. *Drugs*. 2003;63(1):47-70.
111. Cianci P, Lonergan-Thomas H, Slaughter M, **Silver MA**. Current and potential applications of left ventricular assist devices. *J of Advocate Health Care*. 2003;5(1):8-11.
112. **Silver MA**, Pisano C. High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (Stage A): Implications for heart failure screening programs. *Congestive Heart Failure*. 2003;9(3):127.
113. **Silver MA**, Cianci P, Pisano C. Outpatient management of heart failure: Program development and experience in clinical practice. A roadmap for the clinician. *Critical Pathways in Cardiology*. 003;2(2) Supplement 1:S1-S26.
114. Fuentes J, **Silver MA**, Chalupczak R. A Thirty-three year old female with syncope. *J of Advocate Health Care*. 2003;4(2):28-34.
115. Yancy CW, Saltzberg M, Berkowitz RL, Bertolet B, Vijayaraghavan K, Burnham K, Oren RM, Walker K, Horton DP, **Silver MA**. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting – (from the FUSION trial). *Am Journal of Card*. 2004;94:595-601.

116. **Silver MA**, Langsjoen PH, Szabo S, Patil H, Zelinger A. Statin cardiomyopathy? A potential role for Co-enzyme Q-10 therapy for statin-induced changes in diastolic LV performance: Description of a clinical protocol. *Biofactors*. 2003;19(1-4):125-127.
117. Strobeck J, **Silver MA**. Happy New Decade, CHF: Withstanding the test of time (Editorial). *Congestive Heart Failure*. 2004;10(1):10-11.
118. Cheruki KK, Ghani A, Ahmad F, Pappas P, Silverman P, Zelinger A, **Silver MA**. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. *Preventive Cardiology*. 2004; VII(1)13-18.
119. **Silver MA**, Cianci P, Brennan S, Longeran-Thomas H, Ahmad F. Evaluation of impedance cardiography as an alternative to pulmonary artery catheterization in critically ill patients. *Congestive Heart Failure*. 2004;10(2)Supplement 2:17-21.
120. Strobeck J, **Silver MA**. Beyond the Four Quadrants: The critical and emerging role of impedance cardiography in heart failure (Editorial). *Congestive Heart Failure*. 2004;10(2) Supplement 2:1-6.
121. Lawson WE, **Silver MA**, Hui JCK, Kennard ED, Kelsey SF for the IEPR investigators. Angina patients with diastolic versus systolic heart failure demonstrate comparable immediate and one year benefit from enhanced external counterpulsation. *J of Card Failure*. 2005;11(1):61-66.
122. Lonergan-Thomas H, Brennan S, Cianci P, **Silver MA**. Enhanced External Counterpulsation. *Dimensions of Critical Care Nursing*. 2004;23(3):119-121.
123. **Silver MA**, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of Coenzyme Q10 to reverse that dysfunction. *Am J of Cardiology*. 2004;94(10):1306-1310.
124. **Silver MA**, Maisel A, Yancy CW, McCullough PA, Burnett JC, Francis GS, Mehra MR, Peacock WF, Fonarow G, Gibler WB, Morrow DA, Hollander J. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. *Congestive Heart Failure*. 2004;10(5) Supplement 3.
125. Peacock WF, Emerman CL, **Silver MA**. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with decompensated heart failure. *Am J of Emergency Medicine*. 2005;23:327-331.
126. Heywood T, Berkowitz R, Saltzberg M, **Silver MA**, LeJemtel T. Optimizing treatment of chronic decompensated heart failure in the outpatient setting. *Reviews in Cardiovascular Medicine*. Fall 2004 Supplement.
127. Yancy CW, Burnett JC, Fonarow GC, **Silver MA**. Decompensated heart failure: Is there a role for the outpatient use of nesiritide? *Congestive Heart Failure*. 2004;10(5):230-236.
128. Increasing self-management skills in heart failure patients: a pilot study. Flynn, K.J., Powell, L.H., Mendes de Leon, C.F., Muñoz, R., Eaton, C.B., Downs, D.L., **Silver, M.A.**, Calvin, J.E. *Congestive heart failure*. 2005;11 issue 6: 297-302.
129. Feldman AM, **Silver MA**, Francis GS, De Lame PA, Parmley WW. Treating heart failure with enhanced external counterpulsation (EECP): Design of the prospective evaluation of EECP in heart failure (PEECH) trial. *Journal of Cardiac Failure*. 2005;11(3)240-245.
130. Long JW, Kfoury AG, Slaughter M, **Silver MA**, Milano C, Rogers J., Delgado R, Frazier OH. Long-Term "Destination Therapy" with the HeartMate XVE Left Ventricular Assist Device: Improved Outcomes since the REMATCH Study. *Congestive Heart Failure*. May/June 2005;11(3):133-138.
131. **Silver, MA**. Heart failure advances . . . Going to the dogs. *Congestive Heart Failure*. Jul/Aug 2005; 11(4):215.
132. **Silver, MA**, Peacock IV, WF, McCullough, P, Rosendorff, C., Berkowitz, R. Update on clinical approaches for the use of natriuretic peptides in cardiovascular disease. On line CME Course sponsor: *Bayer Healthcare Diagnostics*.

133. **Silver MA**, Preface for the Inter-American Society of Heart Failure conference. *Ediciones medicas actualizadas S.A. Mexico* 2005.
134. **Silver, MA**, Raghuvir, R., Fedirko, B, Elser, D. Systemic hypertension among women with uterine leiomyomata: Potential final common pathways of target end organ remodeling. *Journal of Clinical Hypertension*. 2005. Nov;7(11):664-8.
135. **Silver, MA**. Advancing the advances in heart failure: Updates on newer therapies. *Congestive Heart Failure*. Jul./Aug 2005;11(4):176.
136. **Silver, MA**. The Natriuretic Peptide System: Kidney and Cardiovascular Effects: Hormones, autocoids, neurotransmitters and growth factors. *Current Opinion in Nephrology and Hypertension*. 2006;15(1):14-21.
137. Hunt SA, Abraham WT, Chin M, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, **Silver MA**, Stevenson LW, Yancy CW. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) *JACC*. Sep 2005;46: 1116 – 1143.
138. **Silver MA**, Heart Failure: Dealing with Difficult Cases - End of Life Decisions: What we should tell our patients and when? *Audio-Digest Family Practice*. August 28, 2005;53:Issue 32 ISSN 0271-1362
139. Slaughter MS, Sobieski MA, Koenig SC, Pappas PS, Tatoes AJ, **Silver MA**. Left ventricular assist device weaning: Hemodynamic response and relationship to stroke volume and rate reduction protocols. *ASAIO J*. May-June 2006;52(3):228-233.
140. Januzzi JL, Maisel AS, **Silver MA**, Hutter AM. BNP: Understanding its clinical utility (12/2005). ACC Conversations with experts. *Clinical Conversations Proceedings*. 2005:62-66.
141. **Silver MA**, Peacock F, Diercks D. Optimizing treatment options in acute heart failure: Beyond initial triage. *Congestive Heart Failure*. May/June 2006;12 (3):137-145.
142. **Silver MA**. Mechanisms and evidence for the role of enhanced external counterpulsation in heart failure management. *Current Heart Failure Reports*. 2006. Apr;3(1):25-32. ISSN 1546-9530.
143. Yancy C, **Silver MA**. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial. *Am J of Card*. 2006, July 15;98(2):226-9.
144. Fuentes JC, Salmon AA, **Silver MA**. Acute and Chronic Oral Magnesium Supplementation: Effects on Endothelial Function, Exercise Capacity, and Quality of Life in Patients with Symptomatic Heart Failure. *Congestive Heart Failure*. January/February 2006;12 (1):9-13.
145. Adams KF, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, Baughman KL, Boehmer JP, Deedwania P, Dunbar SB, Elkayam U, Gheorghiade M, Howlett JG, Konstam MA, Kronenberg MW, Massie BM, Mehra MR, Miller AB, Moser DK, Patterson JH, Rodeheffer RJ, Sackner Bernstein J, **Silver MA**, Starling RC, Stevenson LW, Wagoner LE. HFSA 2006 Comprehensive Heart Failure Practice Guideline. *J Cardiac Failure*. 2006;12e1-e122.
146. **Silver MA**. Mechanisms and evidence for the role of enhanced external counterpulsation in heart failure management. *Current Heart Failure Reports*. 2006;3:25-32.
147. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Bijou R, O'Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge RC, Strobeck JE, Srinivas M, Schocken D, Teerlink JR, Levy WC, Trupp RJ, **Silver MA**, for the Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study investigators and coordinators. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. *JACC*. 2006;47(11):2245-2252.

148. **Silver MA**, Lawson WE. Mechanisms and evidence for the role of external enhanced counterpulsation (EECP) in heart failure management. *Curr Heart Failure Rep.* 2006. Apr;3(1):25-32.
149. Abbottsmith CW, Chung ES, Varricchione T, de Lame PA, **Silver MA**, Francis GS, Feldman AM for the Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) Investigators. EECP improves exercise duration and peak oxygen consumption in older patients with heart failure: a subgroup analysis of the PEECH trial. *Congestive Heart Failure.* 2006. Nov-Dec;12(6):307-311
150. Feldman AM, **Silver MA**, Francis GS, Abbottsmith CW, Fleishman BL, Soran O, deLame PA, Varricchione T for the Prospective Evaluation of EECP In Congestive Heart Failure (PEECH) Investigators. Enhanced external counterpulsation improves exercise tolerance in patients with chronic heart failure. *JACC.* 2006;48(6):1198-1205. ISSN: 0735-1097/06
151. Feldman CM, **Silver MA**, Sobieski MA, Slaughter MS. Management of aortic insufficiency with continuous flow left ventricular assist devices: Bioprosthetic valve replacement. *J of Heart & Lung Transplantation.* 2006;25(12):1410-1412.
152. Slaughter MS, Sobieski MA, Martin M, Dia M, **Silver MA**. Home discharge experience with the Thoratec TLC-II portable driver. *ASAIO.* 2007; Mar-Apr 53:132-135.
153. Weber AA, **Silver MA**. Heat therapy in the management of heart failure. *CHF.* 2007;13(2):81-83.
154. Yancy CW, Krum H, Massie BM, **Silver MA**, Warner-Stevenson L, Cheng M, Kim SS, Evans R, for the FUSION II Investigators. The second follow-up serial infusions of nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design. *Am Heart J.* April 2007; 153(4): 478-84.
155. Slaughter MS, Feldman CM, **Silver MA**, Sobieski MA, Martin M, Kurien S, et al. Utilization of acoustic signatures to identify heartmate XVE end of device life. *J Heart Lung Transplant.* 2007. June;26(6):579-83
156. Lietz K, Long JW, Kfoury AG, Slaughter MS, **Silver MA**, Milano CA, Rogers JG, Naka Y, Mancini D, Miller LW. Outcomes of left-ventricular assist device implantation as destination therapy in the post-rematch era: Implications for patient selection. *Circulation.* Jul. 31, 2007:497-505. DOI: 10.1161/CIRCULATIONAHA.107.691972
157. **Silver MA**, Yancy CW. Using homeostatic peptides in decompensated heart failure-A reasonable paradigm but a flawed practice? *JACC.* 2007;50: 1841-1843
158. **Silver MA**. New approaches to hemodynamic measurement: Cool devices but a shaky infrastructure. (Editorial to accompany JACC 35953 – Comparison of a radiofrequency based wireless pressure sensor to Swan-Ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heart failure.) *JACC.* 2007; 50:2383-2384.
159. Slaughter M, Sobieski MA, Graham JD, Feldman C, **Silver MA**, Tatroles AJ, Pappas PS. Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. *ASAIO.* 2007;53:35A.
160. Coyle LA, Martin MM, Kurien S, Graham JD, Gallagher C, **Silver MA**, Slaughter MS. Destination Therapy: Safety and feasibility of national and international travel. 2007 Oral presentation at 53<sup>rd</sup> Annual ASAIO meeting and ASAIO Journal, 54(2):172-176, March/April 2008.
161. Slaughter, MD, M. S., Sobieski, CCP, M. A., Gallagher, RN, C., Dia, MD, M., & **Silver, MD, M. A.** (2008). Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. *Texas Heart Institute Journal*, 35(3), 245-249.
162. Feldman CM, Khan SA, **Silver MA**, Sobieski MA, Graham JD, Eaheart B, Slaughter MS. Improvement in early oxygen uptake kinetics with left ventricular assist device support. *ASAIO.* July-August 2008.
163. Yancy CW, Krum H, Massie BM, **Silver MA**, Stevenson LW, Cheng M, Kim SS, Evans R, for the FUSION II Investigators. Safety and Efficacy of Outpatient Nesiritide in Patients with Advanced Heart Failure: Results of the Second Follow-up Serial Infusions of Nesiritide (FUSION II) Trial.



*Circulation Heart Failure* (Inaugural Issue). 2008;1:9-16.  
doi:10.1161/CIRCHEARTFAILURE.108.767483

164. Greenberg B, Czernska B, Delgado RM, Bourge RC, Zile MR, **Silver MA**, Klapholz M, Haeusslein E, Mehra MR, Mather P, Abraham WT, Neaton JD, Brown S, Parker IC, Konstam MA. Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure, inadequately responsive to medical therapy: Results of the multi-center trial of the Orqis® Medical Cancion® System of the enhanced treatment of heart failure unresponsive to medical therapy (MOMENTUM). *Circulation*. 2008; 118:1241-1249.
165. Snyder GP, Ferretti EB, Wenger NK, Strobeck JE, **Silver MA**, Sowers JR, Engler MM, Amsterdam EA, Weinberg SL, Parish LC, Moser M. Accountability and transparency in medical publishing: position and policies of LeJacq on authorship, acknowledgments, conflicts of interest, and secondary and redundant publication. *AM Heart Hosp J*. 2008 Winter;6(1):5-8.
166. **Silver MA**. Honoring our dead: Creating worth from the passing of our patients. *J Cardiac Failure*. 2008; 14:659-660.
167. Mussivand T, Alshaer H, Haddad H, Beanlands DS, Beanlands R, Chan KL, Higginson L, Leenen F, Ruddy TD, Mesana T, **Silver MA**. Thermal therapy: A viable adjunct in the treatment of heart failure? *Congestive Heart Failure*. 2008;14(4):180-186
168. Leitz K, Long J, Kfoury AG, Slaughter MS, **Silver MA**, Milano CA, Rogers JG, Miller LW, Deng M, Naka Y, Mancini D. The impact of center volumes of left ventricular assist device implantation as destination therapy—analysis of Thoratec Heartmate Registry 1998-2005. *Circulation: Heart Failure*. 2009;2:3-10.
169. Sharon Ann Hunt, MD, FACC, FAHA, Chair, William T. Abraham, MD, FACC, FAHA, Marshall H. Chin, MD, MPH, FACP, Arthur M. Feldman, MD, PhD, FACC, FAHA, Gary S. Francis, MD, FACC, FAHA, Theodore G. Ganiats, MD, Mariell Jessup, MD, FACC, FAHA, Marvin A. Konstam, MD, FACC, Donna M. Mancini, MD, Keith Michl, MD, FACP, John A. Oates, MD, FAHA, Peter S. Rahko, MD, FACC, FAHA, **Marc A. Silver, MD, FACC, FAHA**, Lynne Warner Stevenson, MD, FACC, FAHA, Clyde W. Yancy, MD, FACC, FAHA. Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Col Cardiology*. 2009;53:1353-1382.
170. William E. Lawson MD<sup>1</sup>, John CK Hui PhD<sup>1</sup>, Elizabeth D. Kennard PhD<sup>2</sup>, **Marc A. Silver MD<sup>3</sup>**, Sheryl F. Kelsey PhD<sup>2</sup>, Gregory Barsness MD<sup>4</sup>, Andrew D. Michaels MD, MAS<sup>5</sup>. IEPR investigators **1-Year Mortality in Patients with Severe Refractory Angina Treated with Enhanced External Counterpulsation**. 2010;.
171. Carson P, Fiuzat M, O'Connor C, Anand I, MD, Plehn J, MD<sup>e</sup>; Lindenfeld J, **Silver MA**, et al. Determination of Hospitalization Type by Investigator Case Report Form or Adjudication Committee in a Large Heart Failure Clinical Trial (BEST). *American Heart Journal*. 2010;160:649-654.
172. Nutter AL, Tanawuttiwat T, **Silver MA**. Evaluation of Six Prognostic Models used to Calculate Mortality Rates in Heart Failure Patients with a Fatal Heart Failure Admission. *Congestive Heart Failure*. 2010;16:196-201.
173. Bristow MR, O'Connor CM, Fiuzat M, Carson PE, Anand I, Plehn JF, Gottlieb SS, **Silver MA**, Lindenfeld J, Miller AB, White M, Davis G, Robertson AD, Port D, Carr J, Murphy GA, Lazzeroni LC, Liggett SB. Combinatorial Pharmacogenetic Interactions of Bucindolol and  $\alpha_1$ ,  $\alpha_2c$  Adrenergic Receptor Polymorphisms. *JAMA*. 2011.
174. Tanawuttiwat T, Brennan S, Ward S, **Silver MA**. Symptomatic Calcific Constrictive Pericarditis Presenting Years After Presumed Resolved Inflammatory Heart Disease. *Am Heart Hosp*. 2010;8(2):130-132.
175. Luay Rifai, James Winters, Eli Friedman, **Marc A. Silver**. Initial Description of Cerebral Oximetry Measurement in Heart Failure Patients. *Congestive Heart Failure*. 2012;March-April:Press.

176. Ventura HO, **Silver MA**. Natriuretic Peptides as Markers of Cardiovascular Risk: The Story Continues. *Mayo Clin Proc*. December, 2011;86(12):1143-1145.
177. O'Connor CM, Fiuzat, M, Carson, PE, Anand, IS, Plehm, JF, Gottlieb, SS, **Silver MA**, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial Pharmacogenetic Interactions of Bucindolol and B1 and a2c Adrenergic Receptor Polymorphisms. *PLOS ONE*. 2010; 7(10): e44324. doi:10.1371/journal.pone.0044324
178. Peter S. Pang MD, Yang Xue MD, Christopher DeFilippi MD, **Marc Silver MD**, James Januzzi MD, Alan Maisel MD. The Role of Natriuretic Peptides: From the Emergency Department throughout Hospitalization. *Congestive Heart Failure*. September/October 2012;18s1:s5-s8. DOI: 10.1111/j.1751-7133.2012.00307.x
179. James L. Januzzi Jr MD, Alan S. Maisel MD, **Marc Silver MD**, Yang Xue MD, Christopher DeFilippi MD. Natriuretic Peptide Testing for Predicting Adverse Events Following Heart Failure Hospitalization. *Congestive Heart Failure*. September/October 2012;18s1:s9-s13. DOI: 10.1111/j.1751-7133.2012.00306.x
180. Alan Maisel MD, James Januzzi MD, Yang Xue MD, **Marc A. Silver MD**. Post-Acute Care: The Role of Natriuretic Peptides. *Congestive Heart Failure*. September/October 2012;18s1:s14-s16. DOI: 10.1111/j.1751-7133.2012.00304.x
181. David P Kao, Gordon Davis, Ryan Aleong, Christopher M O'Connor, Mona Fiuzat, Peter E Carson, Inder S Anand, Jonathan F Plehn, Stephen S Gottlieb, **Marc A Silver**, Joann Lindenfeld, Alan B Miller, Michel White, Guinevere A Murphy, Will Sauer, Michael R Bristow. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. *Eur J Heart Fail*. 2012;15(3):324-333. DOI: 10.1093/eurjhf/hfs181. Epub 2012 Dec 7.
182. Januzzi JI, Maisel AS, **Silver MA**, Xue Y, DeFilippi C. Natriuretic Peptide Monitoring for Predicting Adverse Events Following Heart Failure Hospitalization. *Congestive Heart Failure*. 2012; Sep-Oct; (18 Suppl 1):S9-S13. DOI 10.1111/j.1751-7133.2012.00306.x
183. Pang, P., Xue, Y., DeFilippi, C., **Silver, M.**, Januzzi, J., & Maisel, A. The Role of Natriuretic Peptides: From the Emergency Department Throughout Hospitalization. *Congestive Heart Failure*. 2012;18(5 Suppl. 1):S5-S8. DOI: 10.1111/j.1751-7133.2012.00307.x
184. Manesh R. Patel MD, Richard D. White MD, Suhny Abbara MD, David A. Bluemke MD, Robert J. Herfkens MD, Michael Picard MD, Leslee J. Shaw PhD, **Marc Silver MD**, Arthur E. Stillman MD, James Udelson MD. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR Appropriate Utilization of Cardiovascular Imaging in Heart Failure. *Journal of the American College of Cardiology*. May 28, 2013;61(21). Doi:10.1016/j.jacc.2013.02.005
185. Novel Agents for the Prevention and Management of Hyperkalemia. Peter A. McCullough, MD, Maria Rosa Costanzo, MD, **Marc Silver, MD**, Bruce Spinowitz, MD, Jun Zhang, MD, Norman E. Lepor, MD. *Reviews in Cardiovascular Medicine*. 2015;16 (2):140-155 doi: 10.3909/ricm0782
186. Effect of Bucindolol on Heart Failure Outcomes and Heart Rate Response in Patients With Reduced Ejection Fraction Heart Failure and Atrial Fibrillation. David P. Kao, Gordon Davis, Ryan Aleong, Christopher M. O'Connor, Mona Fiuzat, Peter E. Carson, Inder S. Anand, Jonathan F. Plehn, Stephen S. Gottlieb, **Marc A. Silver**, JoAnn Lindenfeld, Alan B. Miller, Michel White, Guinevere A. Murphy, Will Sauer, Michael R. Bristow. *European Journal of Heart Failure*. 2013;15(3):324-333
187. Impact of the DASH diet on endothelial function, exercise capacity, and quality of life in patients with heart failure. Luay Rifai, **Marc A. Silver**. *Proceedings (Baylor University Medical Center)*. 2015;28(2):151-156
188. Luay Rifai, Marc A. Silver. A Review of the DASH Diet as an Optimal Dietary Plan for Symptomatic Heart Heart Failure. *Progress in Cardiovascular Disease*. 2015. doi: 10.1016/j.pcad.2015.11.001

189. Tecson KM, **Silver MA**, Brune SD, Cauthen C, Kwan MD, Schussler JM, Vasudevan A, Watts JA, McCullough PA, Impact of Enhanced External Counterpulsation on Heart Failure Rehospitalization Among Patients with Ischemic Cardiomyopathy, *Am J Cardiol* 2016;117;:901-905, doi: 10.1016/j.amjcard.2015.12.024.
190. Genotypic and Phenotypic Spectrum of Transthyretin-Related Cardiac Amyloidosis in the United States: A Report from the Transthyretin Amyloidosis in the United States: A Report from the Transthyretin Amyloid Outcome Survey (THAOS). Mathew S. Maurer, Mazen Hanna, Martha Grogan, Angela Dispenzieri, Rodney Falk, Ronald Witteles, Brian Drachman, Daniel P. Judge, Daniel J Lenihan, Stephen S. Gottlieb, Sanjiv J. Shah, D. Eric Steidley, Hector Ventura, Srinivas Murali, **Marc A. Silver**, Daniel Jacoby, Savitri Fedson, Scott L. Hummel, Arnt V. Kristen, Thibaud Damy, Violaine Planté-Bordeneuve, Teresa Coelho, Rajiv Mundayat, Ole B Suhr, Márcia Waddington Cruz and Claudio Rapezzi. *JACC*; 2016; 68(2): 161-172.
191. Mussivand T; Thipse, M; Niragira, O; Rayani, A; Mesana, T; Davies, R, Leenen, F, Ruel M, **Silver, MA**, Armstrong, PA. **Can Heat Therapy Help Heart Failure Patients? 2017, Submitted**
192. Voudris K, **Silver MA**. Home Hospitalization for Acute Decompensated Heart Failure: Opportunities and Strategies for Improved Health Outcomes. *Healthcare* 2018, 6(2), 31; <https://doi.org/10.3390/healthcare6020031>
193. **Silver MA**. Yet Another (Important) Goal for Heart Failure Patients. (Editorial) *JACC HF* 2018;6:49-51.

BOOK CHAPTERS / EDITORIALS/ OTHER PUBLICATIONS

1. **Silver MA.** Anatomy of the failing heart in dilated cardiomyopathy. In, Drug Therapy of Dilated Cardiomyopathy and Myocarditis. Engelmeier R, O'Connell JB eds. Marcel Dekker, Inc., New York, 1988.
2. **Silver MA,** Winters GA. Evaluation of operatively excised prosthetic mechanical valves. In, Pathology of the Heart and Great Vessels. Waller BF, ed. Churchill Livingstone Inc. New York, 1988.
3. **Silver MA,** Winters GA. Pathology of cardiac transplantation. In, Pathology of the Heart and Great Vessels. Waller BF ed. Churchill Livingstone Inc. New York, 1988.
4. O'Connell JB, **Silver MA.** Cardiac disease diagnosed by endomyocardial biopsy. In Pathology of the Heart and Great Vessels. Waller BF, ed. Churchill Livingstone Inc. New York, 1988.
5. **Silver MA,** Weber KT. Structural basis of left ventricular dysfunction: role of collagen network remodeling and potential therapeutic interventions. In, Heart Failure and Arrhythmias. Brachmann J and Dietz R, eds. Springer-Verlag, Berlin, 1990.
6. **Silver MA.** Goals for the prevention and treatment of heart failure. Heartbeat, American Heart Association of Metropolitan Chicago. January/Feb., 1991.
7. **Silver MA.** Systemic Hypertension. Heartbeat, American Heart Association of Metropolitan Chicago. January/Feb., 1992.
8. **Silver MA.** An approach to the patient with Heart Failure. In, Merging Advances in Cardiology with Bedside Medicine. Silver MA, ed. Futura, Inc.,.
9. **Silver MA.** Heart failure: Challenge for the 90's. The Problem. Viewpoint, Midwest Cardiovascular Institute. 1992;2(2):6-7.
10. **Silver MA.** Heart failure: Challenge for the 90's. The Diagnostic Approach - Part I. Viewpoint, Midwest Cardiovascular Institute. 1992;2(3):2-3.
11. **Silver MA.** The role of pacemakers for treating congestive heart failure. Viewpoint, Midwest Cardiovascular Institute. 1994;4(1):6-7.
12. **Silver MA.** Success with Heart Failure. Help and hope for the millions with congestive heart failure--one of our nation's major healthcare problems. Plenum Press, 1994 New York.
13. Mullen GM, **Silver MA.** Heart transplantation. Heartbeat. American Heart Association 1995.
14. **Silver MA.** Book Review of Wendt SJ. The radiant heart: Healing the heart, healing the soul. Radiant Heart Press: 1995. Munster, IN.
15. **Silver MA.** Success with Heart Failure. Help and hope for the millions with congestive heart failure 2nd Edition. Plenum Press, 1998 New York.
16. **Silver MA.** The Heart Failure Clinic. Congestive Heart Failure. Hosenpud J and Greenberg B 1999.
17. **Silver MA.** Resource Utilization in Cardiac Disease. Klein and Calvin Eds. Kluwer, 1999.
18. **Silver MA** Congestive Heart Failure can now be managed. Bottom Line Health. 13(8):7 Aug., 1999.
19. **Silver MA.** Congestive heart failure clinics and other strategies for cost effective management. Resource Utilization in Cardiology, 1999;216:169-180.
20. **Silver MA.** Heart Failure: Method of. Conn's Current Therapy 2003. ISBN 0-7216-8745-8, Article 93; pps 336-339, published by Saunders, The Curtis Center, Philadelphia, PA.
21. Keating GM, Goa KL, & manuscript review by: Aronson D, Burger AJ, Cleland JG, Ghali JK, Le Jemtel TH, Mills RM, **Silver MA.** Nesiritide: A review of its use in acute decompensated heart failure. Drugs 2003;63(1):47-70.
22. **Silver MA,** Cianci P, Pisano C. Outpatient management of heart failure: Program development and experience in clinical practice. A monograph for the clinician. Critical Pathways in Cardiology, 2(2)Supplement 1, June 2003.
23. Allegra J, Ander D, Collins S, Diercks D, Emerman C, Kirk JD, Starling R, **Silver MA,** Summers R, Peacock WF. Management of acute decompensated heart failure in the emergency department. A

- CME monograph sponsored by The Cleveland Clinic Center of Continuing Education. 5/1/03; and Congestive Heart Failure, 2003:Sept/Oct:Supp 1.
24. Silver, Marc A. Dietary Research In Heart Failure. *Journal of the American College of Cardiology* 42.7 (2003): 1224-1225
  25. **Silver MA**. Heart Failure: Method of. Conn's Current Therapy 2004. ISBN 0-7216-0401-3; pps 341-345, published by Saunders, The Curtis Center, Philadelphia, PA.
  26. **Silver MA**, Silber EN, Lieb D. In Memoriam Ruth Pick, M.D. *Circulation* 2004;109:694-695.
  27. **Silver, MA**, Gonzalez-Caamano, A, The Interamerican Society of Heart Failure, *Insuficiencia Cardiaca* Preface pages III and IV, Mar. 2005.
  28. Hutter, A, Januzzi, JL, Maisel, AS, **Silver MA**, BNP: Understanding its clinical utility. *Cardiosource newsletter ACC Conversations with Experts*. [www.conversations.acc.org](http://www.conversations.acc.org).
  29. **Silver MA**. The natriuretic peptide system: Kidney and cardiovascular effects. Section in: *Current Opinion in Nephrology and Hypertension: Hormones, autocooids, neurotransmitters and growth factors*. 2006.
  30. **Silver MA**. Heart Failure: Method of. Conn's Current Therapy 2006;409-414. Published by Saunders, Philadelphia, PA. ISBN 1-4160-2376-3
  31. **Silver MA**. Success with Heart Failure. Help and Hope for those coping with congestive heart failure. Fourth Edition. De Capo Press, Cambridge, MA, 2006 ISBN 13:978-0-7382-1072-8
  32. **Silver MA**. End-of-Life Considerations. *Congestive Heart Failure*, 3<sup>rd</sup> Ed, 2007. Hosenpud J and Greenberg B eds, published by Lippincott Williams & Wilkins.
  33. Khan SN, **Silver MA**. Permanent Ventricular Assist Devices (VADs). *International Society of Heart and Lung Transplantation Monograph on Advance Heart Failure*. Elseiver. Jessep M, Banner N eds. 2009; 573-586.
  34. Stamos TD, **Silver, MA**. Management if Anemia in Heart Failure. *Current Opinions in Cardiology*. Haddad H, ed. Lippincott, Williams &Wilkins (London), March 2010;25(2):148-154.doi: 10.1097/HCO.0b013e3283357fe0
  35. **Silver MA**. Heart Failure: Current Clinical Understanding Book Review. *Congestive Heart Failure* 2010:
  36. **Physician Burnout in America: A Roadmap for Restoring Joy and Purpose to Medicine**. The Johnson Foundation Wingspread Task Force. November, 2015. Report currently being presented the US Surgeon General. Publication in progress

## INTERNET PROGRAMS

1. Remote Monitoring: Creating a Clinical Consensus now and for the future. Recorded as part of a satellite program of the 12th Annual HFSA Meeting, Sept 2007. Access: <http://www.theheart.org/article/808363.do>
2. Get With The Guidelines Heart Failure Program: Substantial Opportunities to Improve Outcomes
3. Live Presentation/Internet Posting. A presentation in collaboration with the American Heart Association, Illinois Critical Access Hospital Network, Illinois Health Education Consortium and the Southern Illinois University School of Medicine/Telehealth Networks and Programs. Springfield, IL January 15, 2009.
4. TEDMEDLive 2015. Served as Ambassador for Advocate Christ Medical Center and curated live streaming of two days of this annual event (total participation > 500)
5. "Get With The Guidelines® - 360°: Aldosterone Antagonist at Discharge Webinar"  
Presented by Marc A. Silver, MD, FAHA, FHFSA July 2019/ongoing
- 6.

## ABSTRACTS

1. Association between systemic hypertension and saccular or fusiform aortic aneurysms: an analysis of 80 necropsy patients. **Silver MA**, Roberts WC. 18th Annual Meeting. USPHS Professional Associations. Arlington, VA. May 30, 1983.
2. Association between systemic hypertension and saccular or fusiform aortic aneurysms. An analysis of 85 necropsy patients. **Silver MA**, Roberts WC. *Chest*. 1983;84:350.
3. Positive association between systemic hypertension and saccular or fusiform aortic aneurysm: analysis of 83 necropsy patients. **Silver MA**, Roberts WC. *Circulation*. 1983;68:III-92.
4. Kaposi's sarcoma of the heart in the acquired immune deficiency syndrome. **Silver MA**, Macher AM, Reichert CM, Parrillo JE, Lo SC, Roberts WC. *J Am Coll Cardiol*. 1984;3:599.
5. Late degenerative changes in simultaneously implanted and explanted tricuspid and mitral porcine (Hancock) bioprostheses. Cohen SR, **Silver MA**, McIntosh CL, Jones M, Roberts WC. *J Am Coll Cardiol*. 1984;3:602.
6. Pericardial effusion following orthotopic heart transplantation in relation to acute allograft rejection. **Silver MA**, Costanzo-Nordin MR, O'Connell JB, Pifarre R, Grady KL, Winters GL, Sullivan HJ, Montoya A, Bakhos M, Grieco JG, Robinson JA. *Clin Res*. 1986;34:901A.
7. Kaposi's sarcoma occurring in an HTLV-III negative cardiac transplant recipient. **Silver MA**, O'Connell JB, Costanzo-Nordin MR, Pifarre R, Robinson JA. *Clin Res*. 1986;34:901A.
8. Successful reversal of cardiac allograft rejection with OKT\*3 monoclonal antibody. Costanzo-Nordin MR, **Silver MA**, O'Connell JB, Pifarre R, Grady KL, Robinson JA. *Clin Res*. 1986;34:892A.
9. Eosinophilic myocarditis in orthotopic heart transplant recipient hearts. b, Winters GL, Costanzo-Nordin MR, O'Connell JB, Robinson JA. *J Heart Transplant*. 1986;5:374 (#47).
10. Kaposi's sarcoma occurring in an HTLV-III negative cardiac transplant recipient. **Silver MA**, Costanzo-Nordin MR, O'Connell JB, Pifarre R, Robinson JA. *J Heart Transplant*. 1986;5:380 (#70).
11. Localization of infiltrates in murine coxsackie B3 myocarditis. **Silver MA**, Ruppert C, Kowalczyk, Moran S, O'Connell JB, Robinson JA. *J Heart Transplant*. 1986;5:381 (#74).
12. Successful reversal of cardiac allograft rejection with OKT\*3 monoclonal antibody. Costanzo-Nordin MR, **Silver MA**, O'Connell JB, Pifarre R, Grady KL, Robinson JA. *Circulation*. 1986;74:II-159 (#634).
13. Right atrial tamponade simulating tricuspid stenosis post-AMI. Reply to AHJ-5719. Letters to the Editor, Reply by author. **Silver MA**. *Am Heart J*. 1986;112:1343.
14. Eosinophilic myocarditis in heart transplant recipient hearts. **Silver MA**, Winters GL, Costanzo-Nordin MR, O'Connell JB, Scanlon PJ, Robinson JA. *J Am Coll Cardiol*. 1987;9:144A.
15. Hemodynamic alterations caused by Interleukin-2 cancer immunotherapy. Ferraro ME, Creekmore SP, Fisher RI, Stricklin LA, **Silver MA**, Thomas JX. *Fed Proc*. 1987;46:1147.
16. Gallium67 is not useful in detecting cardiac allograft rejection. **Silver MA**, Henkin RE, Dillehay GL, Lipson BD, Grusk BB, Costanzo-Nordin MR, Sobotka PA, Robinson JA, Scanlon PJ. *Clin Res*. 1987;35:838A.
17. A favorable experience with Ganciclovir in the treatment of cytomegalovirus pneumonia in heart transplant patients. Tucker P, Costanzo-Nordin MR, **Silver MA**, Sobotka P, Robinson JA, O'Keefe JP. *Clin Res*. 1987;35:860A.
18. Cyclosporine-Induced seizures following cardiac transplantation: Fact or fiction? Grigg MM, Costanzo-Nordin MR, Celesia GG, Kelly MA, **Silver MA**, Sobotka PA, Robinson JA. *Clin Res*. 1987;35:831A.
19. Successful reversal of recalcitrant cardiac allograft rejection with methotrexate. Costanzo-Nordin MR, Grusk BB, **Silver MA**, Sobotka PA, O'Connell JB, Pifarre R, Robinson JA. *Clin Res*. 1987;35:829A.
20. Non-cardiac surgery is safe in patients following orthotopic heart transplantation. **Silver MA**, Grusk BB, Grady KL, Costanzo-Nordin MR, Sobotka PA, Zucker MJ, Egan KM, Robinson JA, Pifarre R. *J Heart Transplant*. 1988;7:66.

21. Gallium67 scanning is not useful in detecting cardiac allograft rejection. **Silver MA**, Grusk BB, Dillehay GL, Henkin RE, Lipson BD, Costanzo-Nordin MR, Sobotka PA, Zucker MJ, Robinson JA. *J Heart Transplant*. 1988;7:65 (#87).
22. Morphology of explanted hearts in patients with dilated cardiomyopathy undergoing heart transplantation. **Silver MA**, Winters GL. *J Heart Transplant*. 1988;7:65 (#88).
23. Successful reversal of recalcitrant cardiac allograft rejection with methotrexate. Costanzo-Nordin MR, Grusk BB, **Silver MA**, Sobotka PA, O'Connell JB, Pifarre R, Robinson JA. *Circulation*. 1987;76:IV-205 (#816).
24. Phenytoin may compromise efficacy of cyclosporine immunosuppression in cardiac transplant patients. Grigg-Damberger MM, Nordin MR, Kelly MA, Bahmon-Dussan JE, **Silver MA**, Zucker MJ, Celesia GG. *Epilepsy*. 1988;29:693.
25. Predictors of late acute orthotopic heart transplant rejection. Winters GA, Costanzo-Nordin MR, **Silver MA**, Zucker MJ, Robinson JA, Scanlon PJ. *Circulation*. 1988;78:II-279 (#1112).
26. Abnormalities of ventricular relaxation in heart transplant patients. Rauh RA, Zucker MJ, **Silver MA**, Costanzo-Nordin MR, Pifarre R, Sobotka PA. *Circulation*. 1988;78:II-525 (#2097).
27. Cardioprotection and ACE inhibition. Weber KT, Brilla CG, Pick R, Janicki JS, **Silver MA**, *J Vasc Biol Med*. 1990.
28. Heterogeneous patterns of experimental fibrosis in the hypertrophied rat ventricle. **Silver MA**, Pick R, Brilla C, Jalil J, Janicki JS, Weber KT. *Clin Res*. 1990;38:543A.
29. Exercise thallium scintigraphy in patients with right bundle branch block. Shirani J, Komatireddy HR, **Silver MA**, Bekerman C, Blend J. *Clin Res*. 1990; 38:885A.
30. Endomyocardial biopsy accurately reflects collagen volume fraction in systemic hypertension. **Silver MA**, Pick R, Weber KT. *Clin Res*. 1990; 38:854A.
31. Long term follow up of patients with severe pulmonary hypertension/right ventricular failure treated with chronic outpatient phosphodiesterase inhibitor infusions. **Silver MA**, Jackson A, Cahill JM. (Slide Presentation, ACCP Annual Meeting) *Chest* 1992;102:94S.
32. Delay and sampling error are the reasons for low endomyocardial biopsy detection of myocarditis. **Silver MA**, Guo Y, Law T. *J Am Coll Cardiol*. 1993;21:198A (#894-65).
33. Pathologic quantitation of myocardial fibrosis correlates with QRS duration. O'Toole MF, Moran JF, Pick R, **Silver MA**. *PACE*. 1993;16:912 (#219).
34. Relation of resting oxygen consumption to anaerobic threshold and peak oxygen consumption in patients with heart failure. **Silver MA**, Toussaint J, Tucker AM, Moran JF. *Journal of Heart Failure*. 1993;1:347.
35. Ambulatory hypotension is common in patients with heart failure. **Silver MA**, Merz D, Dahl P. *Journal of Heart Failure* 1993;1:621.
36. Hemoglobin levels in heart failure--impact on oxygen consumption, ejection fraction and plasma norepinephrine. **Silver MA**, Tucker AM, Toussaint J, Keeler CA, Enger E. *Journal of Heart Failure*. 1993;1:711.
37. Importance of the collagen matrix in young patients with hypertrophic cardiomyopathy and sudden death. Shirani J, Pick R, **Silver MA**, Roberts WC, Maron BJ. *Am J Cardiol*. 1994;1A: 110A (#725-2).
38. Difficult cases in heart failure. (Acute Myocardial Infarction in an Elderly Woman with Severe Valvular Aortic Stenosis) Shirani J, Strom JA, Klapholz M, Monrad ES, LeJemtel TH, **Silver MA**. *Congestive Heart Failure*. 1995;1(4):40-41.
39. Oxygen consumption and plasma norepinephrine are similar in young and elderly patients. **Silver MA**, Toussaint J. *Am J Geriatric Cardiol*. 1995;1:
40. Seasonal variation in death among patients with heart failure. **Silver MA**, Tucker AM, Colandrea JM. *Am J Geriatric Cardiol*. 1995.
41. Short atrioventricular delay pacing improves symptoms in ischemic cardiomyopathy. O'Toole MF, Rauh A, Fitts SM, Nora M, Kieval RS, **Silver MA**. *PACE* .1996;19:567 (#7).



42. Management strategies for advanced heart failure--The role of intravenous inotropic therapy. **Silver MA**. *The Journal of Heart Failure*. 1996;3(1):114 (#454).
43. Shirani J, Bonin M, Sundram P, **Silver MA**. Difficult cases in heart failure. (Acute MI and cardiac tamponade secondary to undiagnosed adenocarcinoma of the lung). *Congestive Heart Failure*. 1996;2(4):39-41.
44. Screening for heart failure--Another approach for the next decade. **Silver MA**. *The Journal of Heart Failure*. 1996;3(1):150 (#604).
45. Cost effectiveness of metoprolol in idiopathic dilated cardiomyopathy. Waagstein F, MDC Study Group (**Silver MA**). *J Am Coll of Cardiol*. 1997;29(2):325A.
46. Oral Gancyclovir prophylaxis decreases cytomegalovirus disease after heart transplantation. Mullen GM, **Silver MA**, Lawless C, Lichtenberg R, Barath P, Pande A, Malinowska K, Bedlek A, O'Keefe P, Robinson J, Yeldandi V. *American Society of Transplant Physicians*. 1997;283:155.
47. Difficult Cases in Heart (Failure Diuretic Resistance in Heart Failure: Solutions in the Kitchen Cabinet) Humphrey JS, Mehra MR, Porche M, Smart FW, Stapleton DD, Ventura HO, **Silver MA**. *Congestive Heart Failure*. 1997;3(4):63-64.
48. Abnormal vascular compliance following orthotopic heart transplant--Utility of non-invasive pulse wave analysis. Silver MA, Cohn JN, Malinowska K, Nacpil J, Cortez C, Sajdak L. First Scientific Session of Heart Failure Society of America, Baltimore, MD September 21-24, 1997.
49. Oral Ganciclovir prophylaxis reduces Cytomegalovirus disease in heart transplant recipients. Mullen GM, **Silver MA**, Lawless C, Mendez J, Barath P, Malinowska K, O'Keefe P, Robinson JA, Yeldani V. The International Congress on Immunosuppression in Orlando, FL. December 11-13, 1997. P#243.
50. OKT3 therapy for acute allograft rejection after heart transplantation. Mullen GM, **Silver MA**, Lawless C, Mendez J, Barath P, Malinowska K, Robinson JA. Transplantation Proceedings. The International Congress on Immunosuppression in Orlando, FL. December 11-13, 1997. P#244.
51. Methotrexate therapy for acute allograft rejection after heart transplantation is effective over long-term. Mullen GM, **Silver MA**, Lawless C, Mendez J, Barath P, Malinowska K, Robinson JA. The International Congress on Immunosuppression in Orlando, FL. December 11-13, 1997. P#245.
52. Oral Ganciclovir prophylaxis reduces Cytomegalovirus disease in during the first year after heart transplantation. Mullen GM, **Silver MA**, Lawless C, Mendez J, Barath P, Malinowska K, Pisani BA, O'Keefe P, Robinson JA, Yeldani V. *JACC*. 1998; 31:157A.
53. Hospital recovery after cardiomyopathy surgery: Relationship to surgeon experience in a multi-center trial. Lonchyna VA, Kirklin JK on behalf of the C-SMART Investigators (**Silver MA**). *JACC* 1998;31:504A.
54. Effective long-term Methotrexate therapy for acute allograft rejection after heart transplantation. Mullen GM, **Silver MA**, Lawless C, Mendez J, Barath P, Malinowska K, Pisani BA, Robinson JA. *JACC*. 1998;31:34A-35A.
55. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. Pisani BA, Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Barath PC, Robinson JA. *Journal of Heart and Lung Transplantation*. 1998;17:52.
56. Long-term follow-up of heart transplant recipients treated for acute allograft rejections with Methotrexate. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Pisani BA, Mendez J, Barath PC, Robinson JA. *Journal of Heart and Lung Transplantation*. 1998;17:90-91.
57. Did clinical features distinguish low from normal ejection fraction in chronic heart failure in the DIG trial. Philbin EF, Hunsberger S, Garg R, Kouz S, Lader E, Thadani U, Weeks A, McSherry F, Silver **MA**. *JACC*. 1998;31:116A-117A
58. Long-term follow-up of heart transplant recipients treated for acute allograft rejections with Methotrexate. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Pisani BA, Mendez J, Barath PC, Robinson JA. *Journal of Investigative Medicine*. 1998;46:201 A.

59. One year survival of heart transplant recipients on intra-aortic balloon pump before transplantation. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA, Lonchyna V, Foy B, Bakhos M. *Journal of Investigative Medicine*. 1998, 46:201 A.
60. One year follow-up of patients bridged to heart transplantation with Jarvik 7 and Cardiowest total artificial hearts. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA, Lonchyna V, Foy B, Bakhos M. *Journal of Investigative Medicine*. 1998, 46:202 A.
61. The effect of ischemic time on rejection and survival in cardiac transplant recipients. Pisani BA, Malinowska K, Mullen GM, **Silver MA**, Lawless CE, Mendez J. *Journal of Investigative Medicine*. 1998, 46:202 A.
62. Delayed acute allograft rejection occurring in patients who survive the first year post heart transplant. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA, Lonchyna V, Foy B, Bakhos M. *Journal of Investigative Medicine*. 1998, 46:202 A.
63. Cardiowest total artificial heart as successful bridge to heart transplantation in terminally ill heart failure patients. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA, Lonchyna V, Foy B, Bakhos M. *Journal of Investigative Medicine*. 1998, 46:206 A.
64. One year follow-up of heart transplant recipients treated with OKT3 for acute allograft rejection. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA. *Journal of Investigative Medicine*. 1998;46:206 A.
65. Reliability and cost effectiveness of baseline spirometry for evaluating pulmonary function in patients with advanced heart failure being considered of orthotopic heart transplantation. **Silver MA**, Bindingnavle U, Mullen GM, Malinowska K. *Transplantation*. 1998;65(8)S:133.
66. Delayed acute allograft rejection occurring in patients who survive the first year post heart transplant. Lawless CE, Mullen GM, **Silver MA**, Malinowska K, Mendez J, Pisani BA, Robinson JA. *Transplantation*. 1998;65(8)S:233.
67. Long term follow-up of heart transplant recipients treated for acute allograft rejection with Methotrexate and/or OKT3. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA. *Transplantation*. 1998;65(8)S:233.
68. The effect of ischemic time on rejection and survival in cardiac transplant recipients. Pisani BA, Malinowska K, Mullen GM, **Silver MA**, Lawless CE, Mendez J. *Transplantation*. 1998;65(8)S:236.
69. One year follow-up of patients bridged to heart transplantation with Jarvik 7 and Cardiowest total artificial heart. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Mendez J, Pisani BA, Robinson JA, Lonchyna V, Foy B, Bakhos M. *Transplantation*. 1998;65(8)S:237.
70. Cardiowest total artificial heart as successful bridge to heart transplantation in terminally ill heart failure patients. Mullen GM, **Silver MA**, Malinowska K, Lawless CE, Pisani BA, Mendez J, Robinson JA, Lonchyna V, Foy B, Bakhos M. *Transplantation*. 1998;65(8)S:237.
71. Effect of Nesiritide versus dobutamine on short-term outcomes in the treatment of acutely decompensated heart failure. **Silver MA**, Ghali JK, Horton DP, Elkayam U. *Heart Failure '99*. Goteborg, Sweden, June 5-8, 1999
72. Impact of heart failure education on functional status and quality of life. **Silver MA**, Cianci P. *Advocate Medical Journal*.
73. Mitral valve annuloplasty for ischemic mitral regurgitation and severe ventricular dysfunction. Slaughter MS, **Silver MA**, Hodakowski GT, Pappas PS. *J Cardiac Failure*. 1999;5(3)Suppl.1 #123, and *Cong Heart Failure*. 1999;5 Abstract Issue, September/October #123.
74. Thoracic bioimpedance accurately determines cardiac output in patients with left ventricular devices. **Silver MA**, Lazzara D, Slaughter MS, Szabo S, Pappas PS. *J Cardiac Failure*. 1999;5(3)Suppl.1 #134, and *Cong Heart Failure*. 1999;5 Abstract Issue, September/October #134.
75. Absence of detectable cardiac enzyme release in patients with decompensated heart failure. Patil H, **Silver MA**. *J Cardiac Failure*. 1999;5(3)Suppl.1 #295 and *Cong Heart Failure*. 1999;5 Abstract Issue, September/October #295

76. Utility and economic benefit of thoracic bioimpedance in critical care patients. Ahmad F, Parvathaneni L, **Silver MA**. *J Cardiac Failure*. 1999;5(3)Suppl.1 #307, and *Cong Heart Failure*. 1999;5 Abstract Issue, September/October #307.
77. Short term results of left ventricular assist and comprehensive medical management as bridge to recovery therapy for advanced heart failure. **Silver MA**, Slaughter MS, Pappas PS, Tatoes AJ, Szabo S. *JACC*. 2000;35:229A.
78. Rationale and design of the OPTIME CHF trial: Outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O'Connor CM, Pina I, Quigg R, **Silver MA**, Robinson LA, Leimberger JD, Gheorghiade M. *Amer Heart J*. 2000;1(139)#1.
79. Mitral valve repair and left ventricular assist: A reasonable form of therapy for treating advanced heart failure. **Silver MA**, Slaughter MS, Pappas PS, Tatoes AJ, Szabo S. Abstract #459, The Journal of Heart Failure-Abstracts of the 7th World Congress on Heart Failure - Mechanisms and Management, sponsored by the International Society of Heart Failure, Inc. Vancouver, Canada, July 9-12, 2000.
80. Improved and sustained early exercise oxygen kinetics with mitral valve repair and LVAD support accounts for improved functional status. Akrami BA, **Silver MA**, Earhart B, Slaughter MS. Abstract #145, Category 5, Poster presentation at the 4th Annual Scientific Meeting of the Heart Failure Society of America. Boca Raton, FL, September 12, 2000. Also in *Cong Heart Failure*. 2000;6(5) Supplement (Abstract Issue) #145, and *J of Cardiac Failure*. 2000; 6(3) Sept. Supplement 2, #145.
81. Rapid up-titration of beta blocker therapy in patients being supported with a Left Ventricular Assist Device. **Silver MA**, Cianci P, Lonergan-Thomas H, George TA, Szabo S. Abstract #150, Category 5, Poster presentation at the 4th Annual Scientific Meeting of the Heart Failure Society of America. Boca Raton, FL, September 12, 2000. Also in *Cong Heart Failure*. 2000;6(5)Supplement (Abstract Issue) #150, and *J of Cardiac Failure*. 2000; 6(3) September Supplement 2, #150.
82. Early results of planned bridge to recovery using Thoratec left ventricular assist device in severe idiopathic cardiomyopathy. *ASAIO*. J 2000; 46(2):186.
83. The effect of short-term therapy with Nesiritide ( $\beta$ -type natriuretic peptide) or dobutamine on long term survival. Elkayam U, **Silver MA**, Burger AJ, Horton DP, *Cong Heart Failure*. 2000;6(5) Supplement (Abstract Issue) #169, and *J of Cardiac Failure*. 2000; 6(3) Sept. Supplement 2, #169.
84. Effect of race on cause-specific cardiovascular mortality in BEST. Plehn J, Anand I, O'Connor C, White M, **Silver MA**, Gottlieb S, Carson P, Krause-Steinrauf H. *American Heart Association Scientific Sessions 2000 Program*, #3764, and *Circulation*. 2000.
85. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Ghani A, Zelinger A, Pappas P, Silverman P, **Silver MA**. *American Heart Association Scientific Sessions 2000*, #3873.
86. Noninvasive Revascularization by Enhanced External Counterpulsation (EECP): One year post-treatment analysis. Pisano C, Cianci P, **Silver MA**. *Advocate Health Care Nasset Forum 2001 Program*.
87. Low incidence of myocardial infarction in the BEST heart failure study. Gottlieb GS, Carson PE, Plehn JF, White M, Anand I, **Silver MA**, Anderson J, Krause-Steinrauf H, for the BEST Investigators. *American College of Cardiology Scientific Sessions 2001 Program*, Abstract #1168-67; and Poster Session on 3/19/01, Orange County Convention Center, Hall A4, 3:00-5:00PM.
88. Bucindolol decreases time to heart transplantation or mortality in non-black patients with advanced heart failure. White M, Gottlieb GS, Eichhorn E, Young J, Anand I, Carson PE, Clemson B, Krueger S, Linderfeld J, O'Connor C, Plehn J, **Silver MA**, Krause-Steinrauf H, for the BEST Investigators. *Canadian Cardiovascular Congress*.
89. Uterine leiomyomata are a marker for systemic hypertension. Elser DM, Fedirko B, **Silver MA**. *Obstet Gynecol* 2001;4:S23

90. Selective decline in tumor necrosis  $\alpha$  levels in patients receiving milrinone vs. dobutamine for advanced heart failure. Ahmad F, Cianci P, Pisano CL, **Silver MA**. *Heart Failure Society of America 5<sup>th</sup> Annual Scientific Meeting*, Abstract 3122 in category 3. Washington, DC.
91. Successful beta blocker titration for young adults with symptomatic heart failure due to congenital or dilated cardiomyopathy. Lonergan-Thomas H, Brennan S, Hahn E, **Silver MA**. *Heart Failure Society of America 5<sup>th</sup> Annual Scientific Meeting*, Abstract #377 in category 11. Washington DC.
92. A recommendation for standardization of anaerobic threshold determination during exercise testing. Bhan AK, Eaheart B, **Silver MA**. *Heart Failure Society of America 5<sup>th</sup> Annual Scientific Meeting*, Abstract #330 in category 11. Washington DC.
93. Initial experience with outpatient excursions using the Thoratec TLC II portable driver. Slaughter M, George T, Sobieski M, **Silver MA**. *World Artificial-Organ, Immunology and Transplantation Society 2001 Symposium (WAITS 2001)*, Abstract #31
94. The use of preprinted standing orders in patients with heart failure. Mau J, Pisano C, **Silver MA**, Craig A, Hefferan C, Ludwig-Beymer P. *J of Advocate Health Care*. 2002; 4(1):51.
95. Screening and early detection of left ventricular dysfunction: Role of B-type natriuretic peptide levels. Pisano C, **Silver MA**. *J of Advocate Health Care*. 2002; 4(1):54.
96. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass surgery. Cheruku KK, Bhani A, Ahmad F, Pappas P, Silverman P, Zelinger A, **Silver MA**. *JACC*. 2002;39:104A.
97. Neurologic and bleeding complications associated with Thoratec ventricular assist device. Slaughter MS, Pappas PS, **Silver MA**, Tatoes AJ. *Amer Society for Artificial Internal Organs 48<sup>th</sup> Annual Conference*. #250171.
98. Home discharge experience with the Thoratec LVAD TLC-II portable driver. Slaughter MS, **Silver MA**, Pappas PS, Tatoes AJ. *Amer Society for Artificial Internal Organs 48<sup>th</sup> Annual Conference*. #250210.
99. High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population—implications for heart failure screening programs. **Silver MA**, Pisano C. *Congestive Heart Failure*. 2003. May-June;9(3):127-132.
100. Long term survival following left ventricular assist and comprehensive medical management as bridge to recovery therapy for advanced heart failure. **Silver MA**, Slaughter MS, Pappas PS, Tatoes AJ, Szabo S. *J of Heart and Lung Transplantation*. 2003; 22(1S):S211.
101. Short-term attenuation of abnormal endothelial function with oral magnesium supplementation in patients with heart failure. Fuentes J, **Silver MA**. *Heart Failure Society of America 7<sup>th</sup> Annual Scientific Meeting*, Sept. 26, 2003 and *J of Card Failure*. 2003; 9(5) Supplement #257.
102. Statin Cardiomyopathy? A potential role of Co-Enzyme Q-10 therapy for statin-induced changes in diastolic LV performance. Patil H, Langsjoen PH, Szabo S, Zelinger A, **Silver MA**. *Biofactors*. 2003;18(1-4):125-7.
103. Bedside use of thoracic bioimpedance to document and monitor heart failure with preserved systolic function: Delineation of impaired stroke volume reserve. Cianci P, Lonergan-Thomas H, Brennan S, **Silver MA**. Poster at *Heart Failure Society of America 7<sup>th</sup> Annual Scientific Meeting*, September 26, 2003 and *J of Card Failure*. 2003; 9(5) Supplement #354.
104. Safety and efficacy of intermittent, short-term, outpatient nesiritide infusions for the treatment of decompensated heart failure. Mulki MG, Pisano C, Gallagher C, Cianci P, Dia M, Silver MA. *Heart Failure Society of America 7<sup>th</sup> Annual Scientific Meeting*, September 26, 2003 and *J of Card Failure*. 2003; 9(5) Supplement #246.
105. Images in clinical medicine (the CorCap Support Device). **Silver MA**. *J of Advocate Health Care*. 2003; 5(1):40.
106. Efficacy of intermittent outpatient nesiritide infusion for the treatment of decompensated heart failure. Pisano C, Gallagher C, Cianci P, Mulki MG, Dia M, **Silver MA**. *J of Advocate Health Care*. 2003; 5(1):52.

107. Long term survival following left ventricular assist and comprehensive medical management as bridge to recovery therapy for advanced heart failure. Silver MA, Slaughter MS, Pappas PS, Tatoes AJ, Szabo S. *ISHLT*. 2003; 22(1S):S211.
108. ACE inhibitors at discharge – A systemwide initiative to improve heart failure patient outcomes. Welsh C, Pisano C, Hefferan C, Kolosh K, **Silver MA**. *J of Advocate Health Care*. 2003; 5(1):57.
109. Management of patients with congestive heart failure after hospitalization: Results from the follow up serial infusions of nesiritide (FUSION) trial. Yancy C, Saltzberg M, Berkowitz RL, Horton DP, **Silver MA**, The FUSION investigators. *J of Card Failure*. 2003; 9(5) Supplement #034, and *Circ*. 2003; 108(17) Supplement IV #3156.
110. Nesiritide added to standard care results in favorable reductions in systolic blood pressure and heart rate compared to standard care alone. Emerman CL, Peacock WF, **Silver MA**, on behalf of the PROACTION study Group. *J of Card Failure*. 2003; 9(5) Supplement #221.
111. Epicardial blood flow: A comparative evaluation of the Thoratec PVAD and the HeartMate IP Ventricular Assist Devices. Slaughter MS, Pappas PS, **Silver MA**, Tatoes AJ. *ASAIO*, Washington, DC. 6/18/04 and *ASAIO Journal*. March/April 2004; 50(2).
112. Comparison of abbreviated versus full course of enhanced external counterpulsation in heart failure patients with one-year follow-up. Lawson WE, **Silver MA**, Barsness G, Hui JCK, Kennard E, Kelsey S. *J of Card Failure*. 2004.
113. Multivariate impedance cardiography composite score can predict the occurrence of major heart failure events: the PREDICT study. Abraham WT, Trupp RJ, Mehra MR, Lawless CE, Mitchell JE, LeJemtel TH, Smart FW, Bijou R, O'Connor CM, Yancy CW, Massie BM, **Silver MA**, Packer M. *American Heart Association Sessions 2004*; Abstract Poster Sessions APS.62.3.
114. Low incidence of myocardial infarction in the BEST heart failure study. Gottlieb GS, Carson PE, Plehn JF, White M, Anand I, **Silver MA**, Anderson J, Krause-Steinrauf, for the BEST Investigators. *JACC*. 2004;1168-67.
115. Impact of Left Ventricular Assist Device Destination Therapy on Ventricular Re- Synchronization. Agadi, SG, Thomas-Lonergan H, Brennan S, Cianci P, Slaughter M, **Silver, MA**, *J. of Congestive Heart Failure*. May/June 2005, and *Chest* 2005 poster.
116. The pedometer as a surrogate to prognostic markers in congestive heart failure. Patel V, **Silver MA**. *Journal of Cardiac Care*. 2005;11(6) Supplement #060; and poster presentation at *Heart Failure Society of America 9<sup>th</sup> Scientific Sessions*. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. Sept. 19, 2005.
117. Medication cost burden for patients with symptomatic heart failure. Pisano C, Cianci P, Sweis R, Gallagher C, **Silver MA**. *Journal of Cardiac Care*. 2005;11(6) Supplement #362; and *Heart Failure Society of America 9<sup>th</sup> Scientific Sessions*. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. September 19, 2005.
118. The prognostic value of high sensitivity c-reactive protein level in patients with chronic heart failure. Mulki GM, Cianci P, **Silver MA**. *Chest*. 2005;128(4) Supplement 281S, and *Circulation*. 112(17) Supplement II #1670.
119. Preoperative Risk Factors for Early Mortality Following use of Left-Ventricular Assist Device as Destination Therapy for End-Stage Heart Failure. Lietz K, Univ, Minnesota, Minneapolis, MN; Long J., Kfoury AG, LDS Hospital, Salt Lake City, UT; Slaughter MS, **Silver MA**, Advocate Christ Med. Ctr., Oak Lawn, IL; Milano CA, Rogers J, Duke Univ Med. Center Durham, NC; Miller, LW, Univ Minnesota, Minneapolis, MN. *Circulation*. 2005; 112(17) Supplement II #3383.
120. The impact of patient selection on long-term outcomes of left-ventricular assist device implantation as destination therapy for end-stage heart failure. Lietz K, Long J, Kfoury G, Slaughter MS, **Silver MA**, Milano CA, Rogers J, Miller LW. *JACC*. 2006; 47(4) Supplement A #825-4.
121. Risk score to predict survival to hospital discharge after left-ventricular assist device implantation as destination therapy. Lietz K, Long J, Kfoury G, Slaughter MS, **Silver MA**, Milano CA, Rogers J, Naka Y, Mancini D, Miller LW. *J of Cardiac Failure*. 2006; 12(6) Supplement 1:S4 #010.

122. Enhanced external counterpulsation in the treatment of angina patients with heart failure and diabetes. Lawson WE, Hui JCK, Kennard ED, Kelsey SF, **Silver MA**, Strobeck JE. *J of Card Failure*. 2006;12(6) Supplement 1:S130 #433.
123. Long term support with continuous flow LVAD: Effect of reduced pulsatility on renal function. Slaughter MS, Sobieski MA, Gallagher C, Dia M, **Silver MA**. *ISHLT 27<sup>th</sup> Annual Meeting and J Heart & Lung Transplantation*. 2007.
124. Effect of Heartmate II and continuous flow on the fibrinolytic system. Slaughter MS, Pappas PS, **Silver MA**, Tatoes AJ, Feldman CM, Sobieski MA. *ASAIO 53rd annual conference*.
125. Topical thermal therapy in the management of elderly patients with heart failure. Weber AA, Brennan S, Lonergan-Thomas H, Cianci P, Feldman C, **Silver MA**. *J of Investigative Medicine*. January 2007;55 Supplement 1.
126. Improvement in early oxygen uptake kinetics: A possible indicator of myocardial recovery with LVAD support. Feldman CM, Slaughter MS, Sobieski MA, Earhart B, **Silver MA**. Oral presentation. *ASAIO 53<sup>rd</sup> Annual Conference*, Chicago, June 9, 2007; *ASAIO Abstracts* pg 39A.
127. Low incidence of neurologic events during long-term support with HeartMate SVE. Slaughter MS, Feldman CM, **Silver MA**, Sobieski MA, Pappas PS, Tatoes AJ. Oral presentation. *ASAIO 53<sup>rd</sup> Annual Conference*, Chicago, June 9, 2007; *ASAIO Abstracts* pg 35A.
128. Effect of HeartMate II and continuous flow on fibrinolytic system. Slaughter MS, Pappas PS, **Silver MA**, Tatoes AJ, Feldman CM. *ASAIO 53<sup>rd</sup> Annual Conference*, Chicago, June 9, 2007; *ASAIO Abstracts* pg 49A.
129. Destination Therapy: Results of national and international travel. Coyle LA, Martin M, Feldman C, Kurien S, **Silver MA**, Slaughter MS. *ASAIO 53<sup>rd</sup> Annual Conference*, Chicago, June 9, 2007; *ASAIO Abstracts* pg 40A.
130. Center experience and outcomes of left-ventricular assist device implantation as destination therapy (DT) – Analysis of Thoratec DT registry 1998-2005. Lietz K, Long J, Kfoury A, Slaughter MS, **Silver MA**, Milano C, Rogers J, Naka Y, Mancini D, Miller LW. ACC, Mar. 26, 2007 poster presentation, *JACC*. Mar 6, 2007; 828-8, and *J of Heart & Lung Transplantation*. 2007;26(2S) #333.
131. Long term support with continuous flow LVAD: Effect of reduced pulsatility on renal function. Slaughter MS, Sobieski MA, Gallagher C, Dia M, **Silver MA**. *J of Heart & Lung Transplantation*. 2007;26(2S) S95 #98.
132. Effects of bucindolol on cardiovascular mortality and morbidity are determined by the Beta-1 389 Arg/Gly Receptor Polymorphism. White M, Carson P, Anand IS, Gottlieb SS, Lindenfeld J, O'Connor C, Miller A, Plehn J, **Silver MA**, Fiuzat M, Robertson AD, Bristow MR. Presentation #901 in Session: Genetics and Pharmacogenomics of Cardiovascular Disease Risk at *American Heart Association Scientific Session*.
133. Effect of  $\beta_1$  389 Arg/Gly  $\alpha_{2c}$  322-325 Wt/Del Genotypes on Adjudicated Hospitalizations in the BEST Trial. Carson P, White M, Anand I, Plehn J, Gottlieb S, **Silver M**, Lindenfeld JA, O'Connor C, Miller A, Fiuzat M, Liggett SB, Davis G, Robertson AD, Bristow MR. Presentation 2912 in Session: Heart Failure: Prognostic Markers at *American Heart Association Scientific Session*.
134. Chronic serial infusion of nesiritide is not associated with worsening renal function in chronic decompensated heart failure patients with renal insufficiency: An analysis from the FUSION-II Trial. Yancy C, Massie B, Krum H, **Silver MA**, Stevenson LW, Mills R. *J of Cardiac Failure*. 2007;13(6) Suppl. 2 #213.
135. Decline in the VE/VCO<sub>2</sub> from Anaerobic threshold to peak exercise predicts short term need for LVAD or transplant. Nutter AL, Kahn SN, Slaughter MS, **Silver MA**. *J Heart and Lung Transplantation*. 2008;27(2S) Abstract #239.
136. Differential slopes of VE/VCO<sub>2</sub> at anaerobic threshold and peak exercise: A possible indicator of myocardial recovery with LVAD support. Khan SN, Feldman CM, Slaughter MS, **Silver MA**. *J Heart and Lung Transplantation*. 2008;27(2S) Abstract #289.

137. Preferential Improvement in exercise time, oxygen consumption and ventilatory response in patients supported with pneumatic versus electric LVADs. Khan SN, Feldman CM, Slaughter MS, **Silver MA**. *J Heart and Lung Transplantation*. 2008;27(2S) Abstract #275.
138. Hemocompatibility in long term LVAD support: Continuous vs. pulsatile flow. Khan SN, Horrell TJ, Graham JD, Sobieski MA, **Silver MA**, Slaughter MS. *J Heart and Lung Transplantation*. 2008; 27(2S) Abstract #291.
139. Enhanced External Counterpulsation Improves One Year Mortality in Angina Patients With End Stage Coronary Disease. Lawson WE, Hui JCK, Kennard ED, **Silver MA**, Soran O, Kelsey SF, Barsness G, Michaels A. *JACC*. March 11, 2008; Abstract #1031-68.
140. Efficacy and safety of continuous aortic flow augmentation in patients hospitalized with acute decompensated heart failure: Results of the MOMENTUM trial. Greenberg B, Czerna B, Delgado RM, Bourge R, Zile MR, **Silver MA**, Klapholz M, Hausslein E, Mather P, Abraham WT, Neaton JD, Brown BS, Parker IC, Konstam MA. *American College of Cardiology 57<sup>th</sup> Annual Scientific Session*, Chicago, IL, April 1, 2008. *JACC*. 2008.
141. Characteristics of the premortal heart failure admission. Cooke GL, **Silver MA**. *J Cardiac Failure*. 2008;14:S98.
142. Can we detect fatal heart failure? Pisano C, Nutter A, Perino B, Ziebarth C, Cooke G, Slaughter M, **Silver MA**. *J Cardiac Failure*. 2008;14:S116.
143. Does completion of enhanced external counterpulsation treatment course improve outcomes in heart failure patients? Lawson W, Hui JCK, **Silver M**, Henry T, Linnemeier G, Kennard E, Kelsey SF. *J Cardiac Failure*. 2008;14:S115.
144. Additive effects of  $\beta_1$  389 Arg/Gly  $\alpha_2$ 322-325 Wt/Del genotype combinations on adjudicated hospitalizations and death in the Beta-Blocker Evaluation of Survival Trial (BEST). O'Connor C, Anand I, Fiuzat M, Phlen J, Gottlieb S, **Silver M**, Lindenfeld J, Miller A, White M, Robertson A, Bristow M, Carson P. *J Cardiac Failure*. 2008;14:S69.
145. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (BEST). Carson P, Gottlieb S, Anand I, Phlen J, **Silver M**, Lindenfeld J, O'Connor C, Miller A, White M, Fiuzat M, Liggett S, Davis G, Robertson D, Bristow M. *J Cardiac Failure*. 2008;14:S93.
146. Evaluation of Six Prognostic Models in 80 Heart Failure Patients with a Fatal Heart Failure Admission. Nutter A, Tanawuttiwat T, **Silver MA**. *Journal Heart Lung Transplant*. 2009;28:S140.
147. Defibrillation Threshold Testing Should Not Be Abandoned in Patients Receiving an Implantable Cardioverter Defibrillator for Primary Prevention. Tanawuttiwat T, Bhan A, Harindhanavudhi T, Duggal M, **Silver MA**. *JACC*. 2009.
148. Initial Description of Cerebral Oximetry Measurement in Heart Failure Patients. Rifai L, Winters J, Friedman, **Silver MA**. *Journal of Investigative Medicine*. 2011;59:501-502.
149. Effect of Body mass Index on the Benefit of Implantable Cardioverter Defibrillator in Patients with Heart Failure. Firas Zahwe, Amine Segueni, Naoyo Mori, Mohamed Rahman, Andleeb Bangash, Vincent Keating, Alix J. Tercius, Ilhem Remmouche, **Marc A. Silver**, and M. Eyman Mortada. *Journal of the American College of Cardiology*, April 5, 2011;57:E40.
150. Vigilant Cardiac Function Monitoring in Childhood Cancer Survivors: A Specialized Team Approach. Emily Mueller, Linda Rivard, **Marc A. Silver**, Pamela Cianci, Sharon Brennan, Sharad Salvi, Jason Canner. *American Society of Pediatric Hematology Oncology*. Baltimore, Maryland. April 13-16, 2011.
151. Rest Cerebral Oximetry is a Biomarker in heart failure patients. Rifai L, Taylor W, Key K, **Silver MA**. *Journal of Heart and Lung Transplant*. 2012;31:S153-154.
152. Safety and Prognostic Value of Cerebral Oximetry Monitoring in Heart Failure Patients during Cardiopulmonary Exercise. Rifai L, Taylor W, Key K, **Silver MA**. *Journal of Heart and Lung Transplant*. 2012;31(4):s551-s552.
153. Combinatorial Pharmacogenetic Interactions of Bucindolol and  $B_{1, \alpha_2c}$  Adrenergic Receptor Polymorphisms. Christopher M. O'Connor, Mona Fluzat, Peter E. Carson, Inder S. Anand, Jonathan

- F. Plehn, Stephen S. Gottlieb, **Marc A. Silver**, JoAnn Lindenfeld, Alan B. Miller, Michel White, Ryan Walsh, Penny Nelson, Allen Medway, Gordon Davis, Alastair D. Robertson, J. David Prt, James Carr, Guinevere A. Murphy, Laura C. Lazzeroni, William T. Abraham, Stephen B. Liggett, Michael R. Bristow. *Journal of Heart and Lung Transplant*. October 2012;7 Issue 10:e44324.
154. Can Early Changes in Cerebral Oxygenation During Submaximal Exercise Predict Outcomes in Heart Failure Patients? **Marc Silver**. *CHEST*. October 2012;142:82A. doi:10.1378/chest.1389691
155. Safety and Prognostic Value of Cerebral Oximetry Monitoring in Heart Failure Patients during Cardiopulmonary Exercise. Luay Rifai, Kemisa Key, Winna Taylor, **Marc A. Silver**. *Journal of Cardiac Failure: Abstracts from the 16<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America*. September 2012.
156. Higher Serum Galectin-3 Levels Correlate to Lower Cerebral Tissue Oxygenation in Heart Failure Patients. L. Rifai, C. Pisano, M. Upadhyaya, **M.A. Silver**. *International Journal of Heart and Lung Transplant*. 2014;33(4s):s274-s275.
157. Can a Pedometer Serve as a Surrogate for Key Exercise Prognostic Markers in Heart Failure? **Marc A. Silver**. *Chest*. 2015; 148(4\_MeetingAbstracts):20A. doi: 10.1378/chest.2265508
158. Additive Utility of Peak Expiratory Flow Rate in the Assessment of Chronic Stable Heart Failure Patients. Hesam Keshmiri, Jeffrey Ziffra, Fadi Obeid, Luay Rifai, **Marc A. Silver**. *CHEST* 2015; 148: 56A DOI:10.1378/chest.2278832
159. Can Supplemental Oxygen Blunt Declines in Peripheral and Cerebral Oxygen Saturation in Heart Failure Patients? Jeffrey Ziffra, Hesam Keshmiri, Luay Rifai, Tariq Yousuf, Jalal Vargha, **Marc Silver**. *Chest* 10/2015; 148(4\_MeetingAbstracts):59A. DOI:10.1378/chest.2267528
160. Home hospitalization for Acute Decompensated Heart Failure: Opportunities and Strategies for Improved Health Outcomes. Marc A. Silver, *Cardiology*, 2018, In Press.



### **INVITED LECTURES, PRESENTATIONS & PROFESSIONAL ACTIVITIES**

1. Cardiac transplantation. Rotary Meeting. Maywood, Illinois, February 2, 1987.
2. Role of heart transplantation. Myocarditis: Prospects for the solution of a dilemma. American College of Cardiology, Chicago, Illinois, May 2, 1987.
3. Role of beta adrenergic blockade in congestive heart failure. Symposium - Current treatment of congestive heart failure. Chicago Cardiology Group, Chicago, Illinois, May 14, 1987.
4. Cardiac Angiosarcoma. Grand Rounds, Department of Medicine, Loyola University Medical Center, Maywood, Illinois, July 7, 1987.
5. Pericardial and myocardial heart disease. Cook County Graduate School Board Review in Internal Medicine, Chicago, Illinois, August 4, 1987.
6. Cardiac transplantation at Loyola University Medical Center. 25th Reunion - Stritch School of Medicine, Lake Geneva, Wisconsin, August 15, 1987.
7. Anatomic substrate of ventricular tachyarrhythmias. Midwestern Arrhythmia Symposium. American College of Cardiology, St. Louis, Missouri, September 17, 1987.
8. Primary myocardial disease. Cook County Graduate School of Medicine-Cardiovascular Diseases Board Review. Chicago, Illinois, September 30, 1987.
9. Pericardial Heart Disease. Cook County Graduate School of Medicine-Cardiovascular Diseases Board Review. Chicago, Illinois, September 30, 1987.
10. Cardiac pathology review - Clinico-pathologic correlation conference. Section of Cardiology. Rush-Presbyterian-St Luke's Medical Center. Chicago, Illinois, October 8, 1987.
11. Cardiomyopathy and Congestive Heart Failure. Kiswaukee Community Hospital, Dekalb, Illinois, October 27, 1987.
12. Myocarditis - Medical Grand Rounds. St Joseph Hospital, Chicago, Illinois, December 30, 1987.
13. Morphology of dilated cardiomyopathy-Poster presentation. Chicago Cardiology Group. January 14, 1988.
14. Invited Lecturer. Clinicopathologic correlations conference. Rush-Presbyterian-St. Luke's Medical Center, Section of Cardiology. February 22, 1988.
15. Aortic valve disease and disease of the aorta. Loyola/Hines, Internal Medicine Review Course. 2/23/8.
16. Innovations in the treatment of congestive heart failure. Memorial Hospital. South Bend, Indiana, May 13, 1988.
17. Endomyocardial biopsy in 1988. Invited lecture. Rush-Presbyterian-St. Luke's Medical Center, Cardiac Catheterization Laboratory. Chicago, Illinois, May 19, 1988.
18. Cardiomyopathies. Departments of Medicine, Copley Memorial and Mercy Medical Center, Aurora, IL June 21, 1988.
19. Pericardial Heart Disease and Cardiomyopathy. Cook County Graduate School of Medicine. Internal Medicine Board Review Course. Chicago, Illinois, August 2, 1988.
20. Heart and heart/lung transplantation. Core Curriculum. Cardiovascular Institute. Michael Reese Hospital and Medical Center. Chicago, Illinois, December 20, 1988.
21. Endomyocardial biopsy. Core Curriculum. Cardiovascular Institute. Michael Reese Hospital and Medical Center. Chicago, Illinois, January 10, 1989.
22. Endomyocardial biopsy. One small bite from man. Grand Rounds, Michael Reese Hospital and Medical Center. Chicago, Illinois, January 25, 1989.
23. Update on current heart failure strategies and therapies. Department of Pathology. Michael Reese Hospital and Medical Center. Chicago, Illinois, March 13, 1989.

24. Emergency management of acute myocardial infarction. Michael Reese Hospital and Medical Center, Department of Medicine. Chicago, Illinois, June 28, 1989.
25. Inhibition of structural changes by the treatment of heart failure. International Symposium on Heart Failure and Arrhythmias. Heidelberg, Federal Republic of Germany. July 29, 1989.
26. Clinical and Pathological Aspects of Heart Transplantation. Department of Pathology, Michael Reese Hospital and Medical Center. Chicago, Illinois, August 11, 1989.
27. Pericardial and Myocardial Heart Disease. Cook County Graduate School of Medicine Board Review in Internal Medicine. Chicago, Illinois, August 12, 1989.
28. Myocardial heart disease and heart failure. American College of Physicians MKSAP VIII Review Course. Oak Brook, Illinois, August 14, 1989.
29. Pericardial Heart Disease. Cook County Graduate School of Medicine, Board Review in Cardiovascular Diseases. Chicago, Illinois, September 13, 1989.
30. Pathophysiology and treatment of Heart Failure. The Carle Clinic. Urbana, Illinois, September 14, 1989.
31. Orthotopic heart transplantation. Core Curriculum. Cardiovascular Institute. Chicago, Illinois, September 1, 1989.
32. Endomyocardial biopsy diagnosis of extracellular matrix remodeling in the hypertrophied myocardium. Chicago Cardiology Group. Chicago, Illinois, October 19, 1989.
33. Current strategies in heart failure. Department of Medicine, Riverside Hospital, Kankakee, Illinois, October 23, 1989.
34. Current strategies for Heart Failure. Mercy-Copley Combined Grand Rounds. Aurora, Illinois, November 21, 1989.
35. Advanced heart failure; diagnostics and therapeutics. Bi-County Community Hospital, Hospital Grand Rounds. Warren, Michigan, November 27, 1989.
36. Update on Heart Transplantation. Illinois Masonic Medical Center. State of the Art Lecture. November 28, 1989.
37. Pathogenesis and treatment of heart failure. MacNeal Hospital. Medical Grand Rounds. Berwyn, IL, December 20, 1989.
38. MKSAP VIII Review, Director Cardiology Section. Northwestern University. Chicago, IL,
39. Advances in Understanding and Treatment of Congestive Heart Failure: An Update on Unloading Therapy, New Inotropic Drugs and Transplantation. Hinsdale Hospital, Rooney Heart Institute, Cardiovascular CME Institute, Hinsdale, Illinois, January 24, 1990.
40. Endomyocardial Biopsy. Core Curriculum. Cardiovascular Institute, Michael Reese Hospital and Medical Center. Chicago, Illinois, February 27, 1990.
41. Congestive Heart Failure. Advances in Family Medicine. Cook County Graduate School of Medicine. Chicago, Illinois, March 13, 1990.
42. Myocarditis. Cardiology Clinico-Pathologic Case Presentation. Cook County Hospital. Chicago, Illinois, March 22, 1990.
43. Outpatient Management of Heart Failure. Primary Care Seminar Series. Michael Reese Hospital and Medical Center. Chicago, Illinois, April 5, 1990.
44. Collagen remodeling in pressure overload hypertrophy: a case for interstitial heart disease and its potential management. New Directions in Clinical Cardiology in the 1990's. Squibb U.S. Pharmaceuticals, Newport Beach, California, June 1, 1990.
45. Indications and use of the flow-directed, balloon-tipped pulmonary artery catheter. Core Curriculum. Michael Reese Hospital Center, Chicago, Illinois, August 7, 1990.
46. An approach to "unusual" forms of cardiomyopathy; and Adriamycin Cardiomyopathy. Grand Rounds. Mercy Center, Aurora, Illinois, August 8, 1990.
47. Myocardial Remodeling in Heart Failure. Heart Failure Symposium American College of Chest Physicians. Annual Meeting, Toronto, CANADA, October 25, 1990.
48. Case studies in Heart Failure. Medical Grand Rounds, St. Francis Hospital, Evanston, Illinois, November 2, 1990.

49. Endomyocardial biopsy accurately reflects collagen volume fraction in systemic hypertension. American Federation for Clinical Research Midwest Meeting. Chicago, Illinois, November 2, 1990.
50. An approach to evaluation and treatment of heart failure. Visiting Consultant. Division of Cardiology. Mission Memorial Hospital, Asheville, North Carolina, February 1, 1991.
51. Evaluation and treatment of heart failure. Invited Lecturer, Grand Rounds, Department of Medicine, Hurley Medical Center, Flint, Michigan, February 18, 1991.
52. Heart Failure. Advances in Family Medicine. Cook County Graduate School of Medicine, Chicago, Illinois, March 8, 1991.
53. Co-Chairman - Extracellular matrix of the heart symposium. Society for Cardiovascular Pathology, Chicago, Illinois, March 17, 1991.
54. Cardiac remodeling in systemic hypertension. Extracellular matrix of the heart symposium. Society for Cardiovascular Pathology, Chicago, Illinois, March 17, 1991.
55. Congestive heart failure in the 100's: Drugs, devices and cardiac transplantation. Chicago Medical Society Annual Midwest Clinical Conference. Chicago, Illinois, March 22, 1991.
56. Myocarditis/Endomyocardial biopsy. Cardiology Grand Rounds. Cook County Hospital. Chicago, IL, March 27, 1991.
57. Pathogenesis and therapy of right ventricular failure. Department Medicine Grand Rounds. St. Margaret's Hospital. Hammond, Indiana, March 28, 1991.
58. Heart failure. Visiting Professor of Medicine. St. Vincent Hospital, Indianapolis, Indiana, April 2, 1991.
59. Cardiomyopathy - A case Study. Department of Critical Care Nursing. Humana Hospital- Michael Reese. Chicago, Illinois, April 3, 1991.
60. Evaluation and treatments of patients with heart failure. Medical Grand Rounds, Department of Medicine. Mercy Hospital and Medical Center. Chicago, Illinois, April 9, 1991.
61. Heart Failure in the 90's. Cardiac Update: Symposium. Mercy Center for Health Sciences. Aurora, IL, April 24, 1991.
62. Approaches to the treatment of heart failure. Cardiology Grand Rounds. University of Illinois School of Medicine, Chicago, Illinois, April 25, 1991.
63. Heart Failure in the 90's. AHA, DuPage County Division. Bloomingdale, Illinois, April 27-28, 1991.
64. Current approach to heart failure. Visiting Professor. Johnston-Willis Hospital. Richmond, Virginia, May 9, 1991.
65. Update on heart failure. Union Hospital. Terre Haute, Indiana, May 16, 1991.
66. Remodeling of cardio protection of the extracellular matrix of the heart in systemic hypertension. As part of the symposium on New Concepts in Hypertension for the Next Decade. Hakone, JAPAN, May 25, 1991.
67. Role of heart transplantation in management of heart failure. Cook County Hospital. Chicago, Illinois, June 19, 1991.
68. The Management of Cardiovascular Diseases in the 1990's - Heart Failure. Kings Island Conference Center, Cincinnati, Ohio, August 24, 1991.
69. An approach to right and left ventricular heart failure. Buckeye Anesthesia Study Society. Dayton, Ohio, September 10, 1991.
70. Diagnosis and management of Cardiomyopathy. Specialty Review in Cardiovascular Disease. Cook County Graduate School of Medicine. Chicago, Illinois, September 24, 1991.
71. Newer inotropic therapies. Medical Grand Rounds. University of Indiana School of Medicine. Bloomington Hospital. Bloomington, Indiana, October 4, 1991.
72. Congestive Heart Failure. Challenge for the 90's. Gwynne K. Neufeld Memorial Lecture. The 9th Annual Lewen R. Nelson Cardiovascular Conference. Methodist Medical Center. Peoria, Illinois, October 31, 1991.
73. Success with Heart Failure. Primary Care Lecture Series. Department of Medicine. Humana Hospital-Michael Reese. Chicago, Illinois, November 21, 1991.

74. An approach to heart failure in the 90's. Northwestern University Cardiology Curriculum. Chicago, IL, December 11, 1991.
75. Heart Failure. Senior Advantage. Mercy Center. Aurora, Illinois, March 18, 1992.
76. Heart Failure - Evaluation and treatment. Edward Hospital Cardiology Grand Rounds. Naperville, Illinois, March 19, 1992.
77. Heart Failure - "Challenge for the 90's". Symposium Organizer/Director. Ritz Carlton Hotel, Chicago, Illinois, March 28, 1992. (Jay Cohn, Robert Cody, Wilson Colucci, Donna Mancini).
78. Out patient inotrope infusions. Medical Grand Rounds. Mercy Center for Health Sciences. Aurora, IL, April 1, 1992.
79. Cardiac rehabilitation for patients with heart failure. Elmhurst Hospital. Elmhurst, Illinois, May 20, 1992.
80. Myocardial remodeling- Interstitial Heart Disease. Henry Ford Hospital Research Conference. Detroit, MI, May 27, 1992.
81. American College of Physicians. MKSAP IX Cardiovascular Medicine Review Course. Subspecialty Chairman; Lecturer on Heart Failure. Chicago Hilton and Towers. Chicago, Illinois, August 11, 1992.
82. New Approaches to Heart Failure. Opening Meeting-Medicine Grand Rounds. St. Anthony Medical Center, University of Illinois, Rockford, Illinois, September 11, 1992.
83. Current Concepts in the Management of Congestive Heart Failure. Cardiology Update Symposium. The Institute for Medical Studies. Chicago, Illinois, September 25, 1992.
84. Management of chronic heart failure. Medical Grand Rounds. St. Joseph Hospital. Flint, Michigan, October 1, 1992.
85. New approaches to heart failure--value of the guided diagnostic approach. Division of Medicine. McLaren Hospital. Flint, Michigan, October 1, 1992.
86. Chronic Heart Failure--A Master Approach. The Como Inn. Chicago, Illinois, October 21, 1992.
87. Heart Transplantation in the 1990's. Department of Medicine. St. Joseph Hospital and Medical Center. Pontiac, Michigan, October 30, 1992.
88. Approach to Heart Failure in the 1990's. The Fourth Annual Virginia Heart Symposium. Fairfax, VA, November 5-7 1992.
89. The elderly patient with heart failure. Ninth Annual Geriatric Symposium. Elmhurst Memorial Hospital. Elmhurst, Illinois, November 10, 1992.
90. Heart Failure Quandaries- The Who, What Where, When and Why of Heart Failure. Midwest Heart Research Symposium. Oak Brook, Illinois, December 12, 1992.
91. Newer therapeutic approaches in heart failure. Medinah Country Club. Medinah, IL, December 18, 1992.
92. An update on congestive heart failure. Medical Grand Rounds. Holy Cross Hospital. Chicago, IL, January 6, 1993.
93. Delay and sampling error account for low diagnostic yield by endomyocardial biopsy. Presentation to Chicago Cardiology Group. Rush-Pres. St. Luke's Medical Center. Chicago, Illinois, January 7, 1993.
94. What is heart failure and what can you do! Heart Month Lecture. Mercy Center for Health Care Services. Aurora, Illinois, February 15, 1993.
95. Newer aspects of diagnosis and treatment for Heart Failure. Cardiac Care in the 90's: A symposium for St. Joseph Medical Center. Lisle, Illinois, March 6, 1993.
96. Heart Failure--Special Issues for the Elderly. Illinois Geriatric Society. St. Mary of Nazareth Hospital. Chicago, Illinois, March 31, 1993.
97. Newer treatment modalities for Heart Failure. Medical Grand Rounds. Michael Reese Hospital and Medical Center. Chicago, Illinois, April 1, 1993.
98. New Treatments in Heart Failure. Cardiology Grand Rounds. St. Joseph Hospital. Joliet, Illinois, April 8, 1993.

99. Myocarditis--Relation to Heart Failure, Diagnosis and Pathogenesis. Visiting Professor/ Grand Rounds. Christ Hospital. Oak Lawn, Illinois, April 30, 1993.
100. Evaluation of Cardiomyopathy. St. Vincent Medical Center. Los Angeles, California, May 27, 1993.
101. New Therapies in Heart Failure. San Joaquin Hospital. Cardiology Series 1993 Lecture. Bakersfield, CA, May 27, 1993.
102. Heart Failure and Transplantation. Medical Grand Rounds. Kern Medical Center. Bakersfield, CA, May 28, 1993.
103. Heart Failure: Evaluation and New Treatments for the 90's. Edward Cardiovascular Institute/ Medical Grand Rounds. Naperville, Illinois, June 8, 1993.
104. Emergency Department concepts for the heart failure patient. Emergency Medicine Conference. EHS. Downers Grove, Illinois, June 8, 1993.
105. New Developments in the Treatment of Heart Failure. Piedmont Hospital/Emory University. Medical Grand Rounds. Atlanta, Georgia, June 18, 1993.
106. Heart Failure--Overview and Update. Mended Hearts Meeting. Good Samaritan Hospital. Downers Grove, Illinois, September 1, 1993.
107. New treatments for Heart Failure. Joint Meeting of Kentucky Chapters of American College of Cardiology and American College of Chest Physicians. Commonwealth Convention Center. Louisville, Kentucky, September 29, 1993.
108. Useful Approaches to Heart Failure. Diagnosis and Treatment in the Nineties. American Heart Association, Annual Meeting of Puerto Rico. Caribe Hilton Hotel. San Juan, Puerto Rico, October 1, 1993.
109. Uses of Inotropes in Heart Failure and Pulmonary Hypertension. American Heart Association, Annual Meeting of Puerto Rico. Caribe Hilton Hotel. San Juan, Puerto Rico. October 2, 1993.
110. Heart Failure in the Elderly: New Problems and Answers for Older Folks. Annual Symposium. Midwest Heart Research Foundation. Oak Brook Hills Hotel. Oak Brook, Illinois, October 16, 1993.
111. Diagnosis and Management Strategies for Heart Failure. First Annual Medicine/Cardiology Symposium. St. Joseph Emmanuel Hospital and Mankato Clinic. Mankato, Minnesota, February 18, 1994.
112. Heart Failure--Information Session on Congestive Heart Failure. Community Education Program. Good Samaritan Medical Center. Naperville, Illinois, February 21, 1994
113. Heart Failure--Maximizing Care through Understanding. College of Du Page Cardiovascular Symposium. Current Concepts and Treatment Modalities. Oak Brook, Illinois, February 25, 1994.
114. An update on the role of neurohormones in the pathogenesis of heart failure. Regional Scientific Liaison Meeting. Merck Shape Dohme. Oak Brook, Illinois, March 2, 1994.
115. Diagnosis and therapy for heart failure. A meeting with the Medical Director, Blue Cross/Blue Shield Minnesota. Minneapolis, Minnesota, March 7, 1994.
116. Importance of gas-exchange exercise testing for the heart failure patient. International Meeting Medical Graphics Corporation. Minneapolis, Minnesota, April 18, 1994
117. Exercise for the Heart Failure Patient. Cardiac Rehabilitation Program. Edward Cardiovascular Institute. Naperville, Illinois, April 19, 1994.
118. Use of Inotropes in the Management of Heart Failure Patients. 40th Anniversary Celebration Lecture. Community Nursing Service West. Riverside Country Club. Riverside, IL, April 20, 1994.
119. Should we diagnose and treat the asymptomatic patient with heart failure? Medical Grand Rounds. Elmhurst Memorial Hospital. Elmhurst, Illinois, May 10, 1994.
120. Heart Failure--New Paradigms for Drug Treatment. Sanofi Winthrop Business Meeting Presentation. O'Hare Hilton. Chicago, Illinois, May 11, 1994.
121. A new paradigm for the treatment of heart failure. Medical Grand Rounds. Bi-County Community Hospital. Warren, Michigan, May 23, 1994.
122. Managing Heart Failure: Fundamentals and Controversy. Cardiology Grand Rounds. University of Oklahoma Health Science Center. Oklahoma City, Oklahoma, September 9, 1994.

123. What can be done about heart failure? American Association of Critical Care Nurses--Southside Chicago Area. Harvey, Illinois, September 12, 1994.
124. The management of heart failure in the 1990's. Medical Grand Rounds. Long Beach Memorial Medical Center. Long Beach, California, September 22, 1994.
125. The role of gas exchange testing in cardiovascular disease. Cardiology Journal Club. Long Beach Memorial Medical Center. Long Beach, California, September 22, 1994.
126. The role of gas exchange testing in cardiovascular disease. Visiting Cardiovascular Lecture. Minneapolis Heart Institute. Minneapolis, Minnesota, September 23, 1994.
127. Heart failure for the health care professional--lessons we need to know. Annual Meeting of the Minnesota Society of Respiratory Therapists. Minneapolis, Minnesota, September 23, 1994.
128. The role of gas exchange testing in cardiovascular disease. Luncheon Meeting. Medical Graphics Corporation. Minneapolis, Minnesota, September 23, 1994.
129. A new paradigm for understanding heart failure. Annual Symposium. Ocala Heart Institute. Ocala, FL, September 24, 1994.
130. Heart failure in the 1990's--a new approach. St. Mary's of Nazareth Medical Center. Chicago, Illinois, September 27, 1994.
131. Can Heart Failure Be Prevented? First International Symposium on Prevention. World Health Organization Sponsored. Charleston, West Virginia, October 28, 1994.
132. Understanding the Economics of Heart Failure. The Elgin Cardiology Group. Elgin, Illinois, November 2, 1994.
133. Heart Failure Strategies for the 90's and Beyond. St. Francis Regional Medical Center Annual Cardiovascular Symposium. Wichita, Kansas, November 4, 1994.
134. An Approach to the Management of Acute Heart Failure: Decisions, Drugs and Devices. Republic of China Society of Cardiology Symposium on Critical Care. Taichung, Taiwan CHINA (ROC), December 4, 1994.
135. The Role of Cardiopulmonary Exercise Testing in Heart Failure. Asia-Pacific Congress on the Diseases of the Chest. Hong Kong, CHINA, December 7, 1994.
136. What You Need To Know About Heart Failure. Bethlehem Woods Retirement Center. La Grange Park, IL, January 8, 1995.
137. Visiting Professor Grand Rounds. Saving America from Failing Hearts. Evanston Hospital Department of Medicine. Evanston, Illinois, January 13, 1995.
138. A current view of the pathophysiology of heart failure. Loyola University Stritch School of Medicine Organ Systems Course. Maywood, Illinois, February 20, 1995.
139. A practical view at neurohormones in heart failure. Primary care physicians lecture. Morton's Restaurant. Westchester, Illinois, February 22, 1995.
140. A current view of heart failure. Cardiology Grand Rounds. University of Chicago. Chicago, Illinois, March 1, 1995.
141. Practical aspects of delivering intravenous inotropes. The Galichia Medical Group. Wichita, Kansas, March 1, 1995.
142. Salvaging the patient with a failing heart. St. Joseph Hospital Special Conference on Heart Failure. Wichita, Kansas, March 2, 1995.
143. Practical aspects of a CHF program. St. Joseph Hospital. Wichita, Kansas, March 2, 1995.
144. Current issues and answers in managing patients with advanced heart failure. Medical Grand Rounds. St. Francis Medical Center. Wichita, Kansas, March 2, 1995.
145. Current issues and answers in managing patients with advanced heart failure. Medical Grand Rounds. Halstead Hospital. Halstead, Kansas, March 2, 1995.
146. A current approach to the management of patients with advanced heart failure. Cardiology Grand Rounds. Hahnemann University. Philadelphia, Pennsylvania, March 3, 1995.
147. A current approach to the management of patients with advanced heart failure. Special Research Cardiology Conference. Temple University. Philadelphia, Pennsylvania, March 3, 1995.

148. A practical approach to the problem of congestive heart failure. Special Symposium on CHF- Keynote Address. Aultman Hospital. Canton, Ohio, March 9, 1995.
149. Saving America from Congestive Heart Failure. Visiting Professor Lecture. Michael Reese Hospital. Chicago, Illinois, April 13, 1995.
150. Current approaches and options for heart failure. Porter Memorial Hospital. Valparaiso, Indiana, April 27, 1995.
151. Advances in heart failure management. Northwest Community Hospital. Arlington Heights, Illinois, April 28, 1995.
152. Controversy and fundamentals in heart failure management. Medical Grand Rounds. Memorial Hospital. Hollywood, Florida, May 3, 1995.
153. Innovative approaches to heart failure. Interim Health Care. Ft. Lauderdale, Florida, May 3, 1995.
154. Treating heart failure; strategies and controversies. Oklahoma Heart Research and Education Foundation Symposium. Tulsa, Oklahoma, May 5, 1995.
155. New advances in heart failure. The Heart Institute. Omaha, Nebraska, June 22, 1995.
156. Therapeutic considerations in the treatment of heart failure. Italo-American Medical Society. Villa Park, Illinois, August 23, 1995.
157. Present status of Milrinone in the United States. The 43rd Annual Meeting of the Japanese College of Cardiology. Yokohama, JAPAN, September 15, 1995.
158. Exercise testing in Heart Failure. The Second Sino-American Cardiology Review Course. Beijing, CHINA, October 9-11, 1995.
159. Profiling and Prognostication in Heart Failure. The Second Sino-American Cardiology Review Course. Beijing, CHINA, October 9-11, 1995.
160. Heart transplantation: Indications, Prognosis and Management. The Second Sino-American Cardiology Review Course. Beijing, CHINA, October 9-11, 1995.
161. LUMC should not be treat patients with heart failure. Medical Grand Rounds. Loyola University Medical Center. Maywood, Illinois, October 24, 1995.
162. What can be done about heart failure? Legacy Hospital Group. Portland, Oregon, October 25, 1996.
163. Newer Advances for Heart Failure Treatment. St. Vincent's Hospital. Portland, Oregon, October 26, 1995.
164. Newer Advances for Heart Failure Treatment. University of Washington. Seattle, Washington, October 26, 1995.
165. Modern Approaches to Evaluating and Treating Patients with Heart Failure. Satellite Symposium for the Canadian Cardiovascular Society. Toronto, CANADA, October 27, 1995.
166. Heart Failure Management. St. Catherine's Hospital. Medical Grand Rounds. East Chicago, IN, November 30, 1995.
167. Approaches to heart failure management. Alexian Brothers Hospital. Elk Grove Village, Illinois, January 9, 1998.
168. Improving Life Quality for patients with heart failure. Medicine for today. Hoffman Estates Medical Center. Hoffman Estates, Illinois, February 21, 1996.
169. Managing Advanced Heart Failure. Christ Hospital and Medical Center. Oak Lawn, Illinois, February 29, 1996.
170. A nurses' impact on advanced heart failure. Loyola University Nursing Forum. Maywood, Illinois, March 5, 1996.
171. Strategies for Advanced Heart failure. Kansas City Cardiology Roundtable. Kansas City, Missouri, March 12, 1996.
172. Strategies for Advanced Heart failure. Kansas City University Medical Center. Medical Grand Rounds. Kansas City, Missouri, March 12, 1996.
173. Use of Inotropes for Heart Failure. University of Missouri Medical Grand Rounds. Kansas City, MO, March 13, 1996.

174. Management of Resistant CHF. State of the Art Management of Coronary Artery Disease, Oak Brook, IL, April 20 1996.
175. Success with Heart Failure. Management Strategies in Heart Failure. Optimizing Practice, Outcome, and Cost. Boston, Massachusetts, June 13, 1996.
176. Success With Heart Failure. Keynote Address. Annual National Meeting of Mended Hearts. Atlanta, GA, July 3, 1996.
177. Heart Failure. WBEZ Radio Maura Tapp/Quentin Young Show. Chicago, Illinois, July 23, 1996.
178. Cardiopulmonary Exercise Testing in the Diagnosis and Management of Heart Failure. Satellite Symposium. European Society of Cardiology Meeting. Birmingham, ENGLAND, August 27, 1996.
179. Transition from the Emergency Ward to the Out-Patient Center. Pivotal Role of the Emergency Physician in the Management of Advanced Heart Failure. National Meeting of the American College of Emergency Physicians. New Orleans, Louisiana, September 10, 1996.
180. The Role of Inotropic Therapy in Heart Failure. Cardiology Grand Rounds. St. Michael's Hospital. Toronto, CANADA, September 16, 1996.
181. The Economics of Heart Failure. Cardiology Grand Rounds. The Toronto General Hospital. Toronto, CANADA, September 16, 1996.
182. Advances in Heart Failure Management. Canadian Cardiac Group. Toronto, CANADA, September 16, 1996.
183. Role of Inotropes in Advanced Heart Failure. Visiting Professor/ Cardiology Grand Rounds Hospital Laval. Quebec, CANADA, September 17, 1996.
184. New Approaches to Heart Failure Treatment. Societe Cardiologie de Quebec. Quebec, CANADA, September 17, 1996.
185. Success With Heart Failure. Motorola National Headquarters. Schaumburg, Illinois, September, 1996.
186. Heart Failure--What You Can Do. Hines Veterans Administration Cardiac Club. Hines, Illinois, September 26, 1996.
187. Infusion Therapies: Rationale, Outcomes and Choices of Drugs. Heart Failure Tutorial. Midwest Heart Specialists. Oak Brook, Illinois, October 10, 1996.
188. Cutting Edge Television Program--Heart Failure. The Discovery Channel, December 12, 1996. (And rebroadcasts throughout 1997.)
189. Current Approaches for Heart Failure. Washington University/Jewish Hospital Educational Consortium Meeting. Morton's Restaurant. St. Louis, Missouri, January 15, 1997.
190. Success With Heart Failure--Establishing a Heart Failure Program. Southern Illinois Cardiac Institute. St. Elizabeth's Hospital. Belleville, Illinois, January 16, 1997.
191. Success with Heart Failure. Cardiovascular Alliance Forum. Emerging Approaches to Cardiac Patient Management--Harnessing Change--Transforming Care. Huntington Beach, California, January 18, 1997.
192. Help and Hope for Heart Failure. The Mended Hearts Meeting. Central DuPage Hospital Winfield, IL, January 20, 1997.
193. Advances in Heart Failure. Cardiology in the New Millenium--Clocktower Conference Center Rockford, IL, February 3, 1997.
194. Out-Patient Heart Failure Clinics and the Use of Inotropic Agents. University of Minnesota. Rasmussen Heart Clinic. Minneapolis, Minnesota, March. 25, 1997.
195. Treatment of Advanced Heart Failure. Loyola/Hines Pulmonary/Critical Care Lecture Series Hines VA Hospital. Hines, Illinois, April 2, 1997.
196. New Strategies for Heart Failure. Genesis Medical Center, Cardiology Grand Rounds. Davenport, IA, April 10, 1997.
197. New Treatments for Heart Failure--A New Heart Failure Center. Loyola University Medical Center/ Hines VA Hospital. Department of Medicine Grand Rounds. Hines, Illinois, May 6, 1997.
198. Success With Heart Failure. Success with Heart Failure Center at Union Hospital. Union Hospital/Atlanticare Medical Center. Grand Rounds. Lynn, Massachusetts, May 7, 1997.



199. New Strategies for Advanced Heart Failure. Miriam Hospital/ Rhode Island Medical Center, Cardiology Grand Rounds. Providence, Rhode Island, May 7, 1997.
200. What's New in Heart Failure? Patient Progress in the Management of Cardiovascular Disease. Loyola University of Chicago, Stritch School of Medicine. Oak Brook, Illinois, September 6, 1997.
201. An Update on Dynamic Cardiomyoplasty --The Loyola Experience. Cardiovascular Grand Rounds. Mayo Clinic/Mayo Foundation. Rochester, Minnesota, September 12, 1997.
202. The Role of Out-Patient Inotropes in Heart Failure. First Annual Scientific Meeting of Heart Failure Society of America. The Convention Center at Inner Harbor. Baltimore, Maryland, September 21-24, 1997.
203. How to establish and run an out-patient heart failure center. First Annual Scientific Meeting of Heart Failure Society of America, The Convention Center at Inner Harbor. Baltimore, Maryland, September 21-24, 1997.
204. Pulmonary and cardiac rehabilitation in the home. Program chairman and speaker, Annual Scientific Meeting, American College of Chest Physicians. New Orleans, Louisiana, October 27, 1997.
205. Heart Failure in the Elderly. Annual Scientific Meeting, Gerontologic Society of America. Cincinnati, Ohio, November 18, 1997.
206. Dosing and use of beta blockade in heart failure. Drake Oak Brook, Oak Brook, IL, December 8, 1997.
207. Cardiomyoplasty -- Update. Medical Grand Rounds, Loyola University Medical Center. Maywood, Illinois, February 3, 1998.
208. Visiting Professor, University of Iowa Hospitals and Clinics, Heart Failure / Heart Transplant Program, (Lectures/ fellow case presentations and program review). Iowa City, Iowa, March 6, 1998.
209. Newer Approaches for Advanced Heart Failure. Cardiology Grand Rounds, Ochsner Clinic and Hospital. New Orleans, Louisiana, April 8, 1998.
210. Success With Heart Failure, Medicine Grand Rounds, Ochsner Clinic and Hospital. New Orleans, LA, April 8, 1998.
211. Successful Strategies for Heart Failure-Development of a CHF Program. Provena-St. Joseph Medical Center. Joliet, Illinois, April 15, 1998.
212. Current Management of Heart Failure: From Digitalis to the Digital Age. Medical Grand Rounds, St. Mary's Hospital. Kankakee, Illinois, May 12, 1998.
213. Management of Congestive Heart Failure. Primary Care Lecture for Darien, Wheaton and Willowbrook Physicians. Darien Primary Care Site, LUHS. Darien, Illinois, May 14, 1998.
214. New Surgical Approaches for Heart Failure. The International Cardiostim Meeting, Roundtable Presentation; Dr. Alain Carpentier, Chair. Nice, FRANCE, June 17, 1998.
215. CHF in Y2K: Approaches for the New Millennium. Department of Medicine Grand Rounds, Illinois Masonic Medical Center. Chicago, Illinois, July 31, 1998.
216. Integrating Complementary and Alternative Medicine in the Academic Medical Center. First Intra-American Conference on Complementary and Alternative Medicine. Universidad Cental del Caribe. San Juan, Puerto Rico, August 21, 1998.
217. Mind-Body Perspective in Cardiovascular Disease. First Intra-American Conference on Complementary and Alternative Medicine. Universidad Cental del Caribe. San Juan, Puerto Rico, August 22, 1998.
218. Success with Heart Failure. Christ Hospital Nursing Continuing Medical Education. Chicago, IL, November 19, 1998.
219. Cardiology Workforce Needs and Requirements for the New Millennium. Chicago Cardiology Group. Chicago, Illinois, December 4, 1998.
220. Intermittent Inotropic Infusion. South Suburban Hospital. Chicago, Illinois, December 7, 1998
221. Managing Chronic HF: Is there a role for a subspecialty clinic? Visiting Professor Rounds. Ottawa Heart Institute, University of Ottawa. Ottawa, Ontario, Canada, January 6, 1999.

222. Is there a role for inotrope/vasodilator drugs in the management of chronic heart failure; or is it prolonging the inevitable? Visiting Professor Rounds. Ottawa Heart Institute, University of Ottawa. Ottawa, Ontario, Canada, January 6, 1999.
223. Success with heart failure. Christ Hospital CHF Support Group, Christ Hospital. Oak Lawn, Illinois, January 19, 1999.
224. New Therapies in Congestive Heart Failure. Family Medicine Grand Rounds, Christ Hospital. Oak Lawn, Illinois, February 2, 1999.
225. Heart Failure for Primary Care Physicians. Family Medicine Grand Rounds, Christ Hospital. Oak Lawn, Illinois, February 17, 1999.
226. Breakthroughs in cardiac care. Community Education Program, Riviera Country Club. Oak Lawn, IL, February 24, 1999.
227. The cutting edge in acute decompensated heart failure: An expanded spectrum of therapy. American College of Cardiology Annual Meeting, New Orleans, Louisiana, March 6, 1999.
228. Acute CHF: New options on the horizon. Albert Einstein and Montefiore Medical Center. Oak Lawn, IL, April 6, 1999.
229. Success with heart failure. Community Education Program, St. Michael's Parish. Oak Lawn, Illinois, April 8, 1999.
230. Restoring sexual function in patients with heart disease. Community Education Program, Christ Hospital. Oak Lawn, Illinois, April 9, 1999.
231. The use of h-BNP in the treatment of acute decompensated CHF. The Lodge. Oak Brook, Illinois, April 20, 1999.
232. Current strategies in heart failure management. Fifth Chicago area Roundtable, Drury Lane Conference Center. Oak Brook, Illinois, April 24, 1999.
233. Advances in heart failure. Heart Group's 4th Annual Cardiology Symposium. Evansville, Indiana, April 24, 1999.
234. Angiotension receptor blockers. Oak Brook Marriot Hotel, sponsored by Novartis. Oak Brook, Illinois, June 19, 1999.
235. Improved clinical utility: The Thoratec VAD System. Chicago, Illinois, June 19, 1999.
236. Heart failure for Primary Care and Emergency Medicine Physicians. Internal Medicine Grand Rounds, Christ Hospital. Oak Lawn, Illinois, July 22, 1999.
237. New therapies in congestive heart failure. Downers Grove Marriot Hotel, sponsored by Novartis. Downers Grove, Illinois, August 18, 1999.
238. Modern approaches to the treatment of heart failure. Internal Medicine Grand Rounds, Westlake Hospital, Melrose Park, Illinois, August 24, 1999.
239. Acute congestive heart failure: New options on the horizon. Public Landing, sponsored by Roche Pharmaceuticals. Lockport, Illinois, August 31, 1999.
240. New standards in the management of patients with congestive heart failure. Mercy Medical Center, Dubuque, Iowa, September 10, 1999.
241. New standards in the management of patients with congestive heart failure. C'est Michele, sponsored by Trinity Medical Center, Rock Island, Illinois, September 10, 1999.
242. ACE inhibitors work by reducing the levels of angiotensin II. Moderator, Third Annual Scientific Meeting of HFSA, San Francisco, CA, September 23, 1999.
243. Anticoagulants should routinely be used in heart failure patients with moderate or severe LV dysfunction. Moderator, Third Annual Scientific Meeting of HFSA, San Francisco, CA, September 23, 1999.
244. Update on ICD therapy trials for heart failure patients. Third Annual Scientific Meeting of HFSA, San Francisco, CA, September 24, 1999.
245. Circulatory support devices as a potential treatment for heart failure. WorldHeart Symposium, University of Ottawa Heart Institute, Ottawa, Ontario, Canada, October 20, 1999.
246. Acute MI and heart failure: Strategies to improve patient care. Nursing Continuing Education Program, Christ Hospital and Medical Center. Oak Lawn, Illinois, October 25, 1999.

247. Heart Failure Management in the New Millennium. The Lodge, sponsored by Sanofi Pharmaceuticals. Oak Brook, Illinois, November 17, 1999
248. Heart Failure Management in the New Millennium. St. Margaret's Hospital, Blue Island, Illinois. November 18, 1999.
249. How to set up a Heart Failure Clinic. Third Annual Scientific Meeting of HFSA, San Francisco, CA, November 23, 1999.
250. Managing Congestive Heart Failure. Hinsdale Hospital, Hinsdale, Illinois. December 1, 1999.
251. Economics and Demographics of Heart Failure; Approaches for the Decompensated Patient and Strategies for the Emergency Department and Hospital; New Drug Therapies for Heart Failure and When to Use Left Ventricular Assist Devices. American College of Cardiology, Williamsburg Conference on Heart Disease, Williamsburg, VA. December 5, 1999.
252. Out-patient management of congestive heart failure. Christ Hospital, Family Practice, Oak Lawn, IL. January 21, 2000.
253. New approaches to the management of advanced heart failure. 3 Lectures at Washington University School of Med., St. Louis Missouri. January 24, 2000.
254. What you should know about heart failure; One of America's silent epidemics. Community lecture series sponsored by Advocate Healthcare. Oak Lawn Hilton, Oak Lawn, IL. February 14, 2000.
255. Heart failure in the new millennium. Italian-American Medical Association, Maggiano's Little Italy, sponsored by Sanofi-Synthelabo. February 16, 2000.
256. Pulmonary hypertension. Speaker: Dr. Stuart Rich, hosted by: Dr. Marc Silver on behalf of the Chicagoland Heart Failure Forum. Sponsor: Merck. Como Inn, Chicago, IL, February 29, 2000.
257. Congestive heart failure and the use of ventricular assist devices in its treatment. Illinois State Perfusion Society, 2000 Annual Meeting. Sponsors: Baxter, Cobe, Medtronic, Sorin & Thoratec. Christ Hospital, Oak Lawn, IL, March 4, 2000.
258. Into the new millennium: Successful strategies for heart failure. The Chicago Society of Internal Medicine in conjunction with the Chicago Medical Society. Sponsored by Merck. Drake Hotel, Chicago, IL, March 20, 2000.
259. Chronic Heart Failure. Emergency Medicine Lecture, Christ Hospital, Oak Lawn, IL, April 4, 2000.
260. New approaches to heart failure. Continuing Medical Education Program sponsored by Roche/SmithKline Beecham. Courtright's, Willow Springs, IL, April 18, 2000.
261. Beta Blockers in congestive heart failure. Cardiology Grand Rounds, Christ Hospital, Oak Lawn, IL, April 27, 2000.
262. Interventions for Success: Developing a heart failure program. Sponsored by the Illinois Foundation for Quality Health Care. Radisson Hotel, Lisle, IL, April 28, 2000.
263. Strategies for successful weaning from ventricular assist devices. Tulane University, New Orleans, LA, May 10, 2000.
264. Complementary Medicine: Implications for clinical practice and research. Panel discussant, Eighth Annual Naurice Nasset Research Forum, sponsored by Advocate HealthCare. Drury Lane, Oakbrook Terrace, May 16, 2000.
265. Successful strategies in the treatment of heart failure. Cardiology Lecture, Munster Community Hospital. Munster, IN, May 24, 2000.
266. Enhanced External Counter Pulsation. Cardiology Fellowship Lecture Series, Christ Hospital & Medical Center. Oak Lawn, IL, May 26, 2000
267. Management of heart failure. Continuing Medical Education Program, Northwest Community Hospital. Arlington Heights, IL, June 1, 2000.
268. Approaches to heart failure in the new millennium. Continuing Medical Education Program, Alexian Brothers Medical Center. Elk Grove Village, IL, June 1, 2000.
269. New approaches to heart failure. Continuing Medical Education Program sponsored by Roche/SmithKline Beecham. Courtright's, Willow Springs, IL, June 6, 2000.
270. Thoratec's Surgical Training: Patient selection. Surgical training program sponsored by Thoratec Laboratories. Christ Hospital, Oak Lawn, IL, June 12, 2000.

271. Managing the CHF patient. Grand Rounds lecture, Sponsored by SmithKline Beecham. Mercy Hospital and Medical Center, Chicago, IL, June 13, 2000.
272. Pursuing solutions for the management of heart failure. SCD-HeFT Heart Failure Trial: Overview and current status, sponsored by Medtronic. Hilton DFW Lakes, Grapevine, TX, June 15, 2000.
273. Mitral valve repair and left ventricular assist: A reasonable form of therapy for treating advanced heart failure. 7th World Congress on Heart Failure - Mechanisms and Management, sponsored by the International Society of Heart Failure, Inc. Vancouver, B.C., Canada, July 12, 2000.
274. Congestive heart failure: Key elements of performance management. Sponsored by Advocate Christ Hospital Health Partners. Christ Hospital, Oak Lawn, IL, July 28, 2000.
275. Left ventricular assist for advanced heart failure; A bridge to somewhere. 25th Annual Louis N. Katz Memorial Lecture. Research and Education Foundation and the Cardiovascular Institute, Michael Reese Hospital, Chicago, IL, October 19, 2000.
276. Latest conclusions on the HOPE trial. Grand Rounds, Advocate Christ Medical Center. Oak Lawn, IL, January 18, 2001.
277. Success with heart failure. Community education lecture, Advocate Christ Medical Center. Oak Lawn, IL, February 14, 2001.
278. Heart failure awareness. Grand Round lecture, Advocate Christ Medical Center. Oak Lawn, IL, February 15, 2001.
279. Enoxaparin and medically ill patients. Rosemont Theater, Rosemont, IL, February 25, 2001.
280. Heart Failure: A disease that affects all – Unique solutions. Midwest Clinical Conference of the Chicago Medical Society. Chicago, IL, March 2, 2001.
281. Evaluation of the patient with idiopathic cardiomyopathy: How far to go? Session Chair #0318; American College of Cardiology 50<sup>th</sup> Annual Scientific Session Meeting. Orlando, FL, March 20, 2001.
282. Alternative therapies for heart failure: Nutraceuticals and life style changes. Panel Member #0517; American College of Cardiology 50<sup>th</sup> Annual Scientific Session Meeting. Orlando, FL, March 20, 2001.
283. Advances in heart failure therapy. Grand Round lecture, University of Illinois at Chicago. Chicago, IL, March 29, 2001.
284. Update on activities within Advocate Christ Medical Center. University of Ottawa Heart Institute, Cardiovascular Devices Division. Institute de Cardiologie de L'Universite D'Ottawa, Ottawa, Ontario, Canada, April 4/5, 2001.
285. Success with Heart Failure. CME presentation sponsor: United Healthcare. Marriott Hotel, Oakbrook, IL, June 27, 2001.
286. World Artificial-Organ, Immunology and Transplantation Society 2001 Symposium. Session Chair, Technique and Knowledge for Health. (WAITS 2001). Ottawa Congress Centre, Ottawa, Canada, August 17-19, 2001.
287. How to incorporate end-of-life issues into care? Moderator, How-To Session; 5<sup>th</sup> Annual Scientific Meeting, Heart Failure Society of America, Washington, DC, September 10, 2001.
288. Lifestyle modification in the management of heart failure— why and how., How-To Session; 5<sup>th</sup> Annual Scientific Meeting, Heart Failure Society of America, Washington, DC, September 11, 2001.
289. The answers to questions about living with heart failure. Heart Failure Support Group, Advocate Christ Medical Center, Oak Lawn, IL, September 18, 2001.
290. BNP (brain natriuretic peptide) – A new way to assess heart failure. Grand Round Lecture, Advocate Christ Medical Center, Oak Lawn, IL. Sponsored by BioSite. September 19, 2001.
291. BNP (brain natriuretic peptide) – A new way to assess heart failure. Physician's Dinner Lecture, The Clubhouse, Oakbrook, IL. Sponsored by BioSite. September 19, 2001.
292. 1<sup>st</sup> community wide screening for heart failure, using the BNP (brain natriuretic peptide) test. Advocate Christ Medical Center, Oak Lawn, IL. Sponsored by BioSite. September 20, 2001.

293. BNP (brain natriuretic peptide) testing—practical issues that heart failure specialists need to know. Speaker and host on behalf of the Chicagoland Heart Failure Forum. Maggiano's, Oakbrook, IL. Sponsors: Merck and BioSite. September 26, 2001.
294. Recent medical advancements in the detection and treatment of heart failure. Physician's Dinner Lecture, Spiaggia's, Chicago, IL. Sponsored by GlaxoSmithKline. October 2, 2001.
295. Latest medical treatment in acute congestive heart failure. Grand Round Lecture, St. Mary of Nazareth Hospital, Chicago, IL. Sponsored by Scios. October 5, 2001.
296. Latest medical treatment in acute congestive heart failure. Grand Round Lecture, St. Mary of Nazareth Hospital, Chicago, IL. Sponsored by Scios. October 5, 2001.
297. New hope for heart failure. Happy Hearts Support Group. Advocate Christ Medical Center, Oak Lawn, IL, October 9, 2001.
298. Latest medical treatment in acute congestive heart failure. Grand Round Lecture, Indianapolis, IN. October 11, 2001.
299. Success with heart failure: the role of conventional therapies, and disease management in caring for heart failure patients. Cardiology Symposium, Wyndham Drake Hotel, Oakbrook, IL. Sponsored by South Suburban Hospital, Continuing Medical Education Department. October 27, 2001.
300. 2<sup>nd</sup> community wide screening for heart failure, using the BNP (brain natriuretic peptide) test. Advocate Christ Medical Center, Oak Lawn, IL. Sponsored by BioSite. November 14, 2001.
301. Latest medical treatment in acute congestive heart failure. Round Table, Capital Grill, Chicago, IL. December 3, 2001.
302. Latest medical treatment in acute congestive heart failure. Nick & Tonys, Chicago, IL. December 12, 2001.
303. Understanding the natriuretic peptide system, the diagnostic role of BNP and the therapeutic role of nesiritide. Courtright's, Willow Springs, IL. Sponsored by Scios. January 15, 2002.
304. Right Ventricular Dysplasia, Cardiology Fellowship Conference, Advocate Christ Hospital, Oak Lawn, IL. January 28, 2002.
305. Latest medical treatment in acute congestive heart failure. St Joseph Hospital Cardiology Lecture at Ambria. Chicago, IL. Sponsored by SCIOS. February 5, 2002.
306. Heart disease: A family affair. Hilton Oak Lawn, sponsored by Advocate Health Care. February 16, 2002.
307. Latest medical treatment in acute congestive heart failure. West Suburban Hospital, Oak Park, IL. February 20, 2002.
308. Acute decompensated congestive heart failure. Michael Reese Hospital, Chicago, IL. February 28, 2002.
309. Acute decompensated congestive heart failure. Holy Cross Hospital, Chicago, IL. February 28, 2002.
310. Latest medical treatment in acute congestive heart failure. Lutheran General Hospital, Park Ridge, IL. March 5, 2002.
311. Latest medical treatment in acute congestive heart failure. Munster Community Hospital, Munster, IN. March 13, 2002.
312. Latest medical treatment in acute congestive heart failure. LaGrange Memorial Hospital, LaGrange, IL. April 9, 2002.
313. Latest medical treatment in acute congestive heart failure. Shula's Restaurant, Schaumburg, IL. April 9, 2002.
314. Development and application of thoracic bioimpedance. U of IL Fellowship Program. Chicago, IL. August 16, 2002.
315. PEECH Trial. Symposium on EECF and Heart Failure. Heart Failure Society of America Annual Meeting; Satellite Symposium. Boca Raton, FL. September 22, 2002
316. Dizziness as a presenting Symptom of Heart Failure. Common Signs and Symptoms of Heart Failure. Heart Failure Society of America Annual Meeting; Satellite Symposium. Boca Raton, FL. September 25, 2002

317. Prevention of Heart Failure: Reality or Myth. Department of Preventive Medicine Grand Rounds. Rush Presbyterian St. Luke's Medical Center. Chicago, IL October 29, 2002.
318. Role of B-type Natriuretic peptides as diagnostic and therapeutic agents. National Cardiac, Trauma and Critical Care Issues Symposium. Hyatt Regency McCormick Place. Chicago, IL. October 31, 2002
319. An update on Heart Failure for Primary Care Physicians. Advocate Sykes Center. Chicago, IL. November 6, 2002.
320. Application of the Natriuretic Peptide System in Heart Failure. Cardiology Grand Rounds, Medical College of Wisconsin. Milwaukee, WI. November 6, 2002.
321. Latest medical treatment in acute congestive heart failure. Lecture to Family Practice and Internal Medicine Physicians, Courtright's, Willow Springs, IL. Sponsored by SCIOS. November 12, 2002.
322. Statin Cardiomyopathy? A potential role for Coenzyme Q 10 therapy for statin-induced changes in diastolic LV performance. The Third Conference of the International Coenzyme Q10 Association, Hilton Metropole, London, United Kingdom. November 23, 2002.
323. Latest medical treatment in acute congestive heart failure, current CHF guidelines. South Suburban Hospital, Hazel Crest, IL. Sponsored by SCIOS. December 2, 2002.
324. Long term survival following left ventricular assist and comprehensive medical management as bridge to recovery therapy for advanced heart failure. Mechanical Circulatory Support; Today's facts and future trends. Ruhr University of Bochum, Bad Oeynhausen, Germany. December 5, 2002.
325. Latest medical treatment in acute congestive heart failure. Nick & Tony's Restaurant, Northbrook, IL. December 12, 2002.
326. End of life care; Ethics for lunch. Advocate Christ Medical Center, Oak Lawn, IL. January 24, 2003.
327. Diagnostic testing – When and How to use echo and BNP in the evaluation of the Heart Failure Patient. Heart Failure 2003, sponsored by the Heart Failure Society of America. New Orleans, LA. February 1, 2003.
328. Success with Heart Failure. Cardiology in the New Millennium. Sponsored by the Swedish American Health System, Giovanni's Restaurant and Conference Center, Rockford, IL. February 3, 2003.
329. Advances in the management of cardiovascular disease: Understanding the Emerging Role of the Natriuretic Peptide System. Sponsored by Rush-Copley Medical Center, Chicago, IL. February 19, 2003.
330. Outpatient Nesiritide treatment. Sponsored by Scios, W.A. Frost's Restaurant, Minneapolis, MN. April 4, 2003.
331. Outpatient Nesiritide treatment. Sponsored by Scios, Hyatt Whitney Hotel, Minneapolis, MN. April 5, 2003.
332. Visiting Professor, Illinois Institute of Technology, Pritzker Institute of Biomedical Engineering. History and Current Clinical Application of Circulatory Support for Heart Failure. Chicago, IL. April 9, 2003.
333. Long term survival following left ventricular assist and comprehensive medical management as bridge to recovery therapy for advanced heart failure. Oral Abstract Presentation; Session: Mechanical & Circulatory Support-The science of myocardial recovery with LVADs. Sponsored by the International Society for Heart and Lung Transplantation 23<sup>rd</sup> Annual Meeting and Scientific Sessions. Vienna, Austria. April 12, 2003.
334. The role of outpatient nesiritide. Sponsored by the ADHERE longitudinal meeting, Washington, DC. May 5, 2003.
335. Success with heart failure. Condell Symposium on Cardiovascular Health. Libertyville, IL. May 17, 2003.
336. Latest medical treatment in acute congestive heart failure, current CHF guidelines. Sponsored by the Will County Medical Society & Scios, Al's Steak House, Joliet, Illinois. May 29, 2003.

337. Visiting Professor- Rationale for out-patient intravenous therapies. Mayo Clinic, Rochester, MN. June 3, 2003.
338. The use of nesiritide in acute decompensated heart failure. Henry Ford Heart & Vascular Institute, Troy, MI. June 6, 2003.
339. Abstract reviewer for the 2003 American College of Cardiology Scientific Sessions. June 27, 2003.
340. Museum of Science & Industry 21<sup>st</sup> Century Program, Task Force Participant, Chicago, IL. July 21 & October 16-17 2003.
341. Success with Heart Failure, Grand Rounds and Visiting Professor. Sponsored by Scios, Illinois Masonic Hospital, Chicago, IL. July 30, 2003.
342. Ethical decision making for the heart failure patient. Lunch & Learn Session, Heart Failure Society of America 7<sup>th</sup> Scientific Sessions. Mandalay Bay Hotel, Las Vegas, NV. September 22, 2003.
343. End-of-Life decisions in severe heart failure. Symposium at Heart Failure Society of America 7<sup>th</sup> Scientific Sessions. Mandalay Bay Hotel, Las Vegas, NV. September 22, 2003.
344. Hearts and Uteri: A story of relationships. Hyde Park Hypotheses at Heart Failure Society of America 7<sup>th</sup> Scientific Sessions. Mandalay Bay Hotel, Las Vegas, NV. September 23, 2003.
345. Beyond the four quadrants: The critical emerging role of impedance cardiography in heart failure; ICG in acute heart failure. Co-Chair of Continuing Medical Education Symposium. Sponsored by the University of Minnesota. Mandalay Bay Hotel, Las Vegas, NV. September 24, 2003.
346. Heart failure: treatment plans for acute management. Sponsored by the University of Ohio. St Vincent's Mercy Medical Center, Toledo, OH. September 26, 2003.
347. Success with heart failure, Grand Rounds. Sponsored by Resurrection Healthcare Network, St Francis' Hospital, Evanston, IL. October 7, 2003.
348. Current and future treatments for the management of advanced heart failure, Key Note Speaker at Ascension Healthcare Heart Failure Symposium. Chicago, IL October 27, 2003.
349. New ACC/AHA Guidelines: From hypertension to heart failure. Sponsored by Glaxo SmithKline, teleconference speaker. October 29, 2003.
350. Understanding the natriuretic peptide system in congestive heart failure, Grand Rounds. Delnor Community Hospital, Geneva, IL. October 30, 2003.
351. New ACC/AHA Guidelines: From hypertension to heart failure. Presented to Glaxo SmithKline by Glaxo SmithKline. Indian Lakes, IL October 29, 2003.
352. Heart Failure and the results of the COMET trial interview with the Illinois Radio Network public affairs program: "Eye on Illinois." Chicago, IL. November 13, 2003
353. The role of BNP testing for heart failure patients in the physician's office. Live Broadcast, sponsored by Biosite, Inc. Teleconference Faculty: Marc Silver, MD, Alan Maisel, MD and Regina Massaro, MD.
354. Success with heart failure. Sponsored by Glaxo SmithKline, Tampa General Hospital, Tampa, FL. November 17, 2003.
355. Success with heart failure. Sponsored by Glaxo SmithKline, Ruth's Chris Steakhouse, Tampa, FL. November 17, 2003.
356. Success with heart failure. Adel Sidkey MD Lecture, Boyton Beach, FL. November 18, 2003.
357. New ACC/AHA Guidelines: From hypertension to heart failure. Delray Medical Center, Delray, FL. November 18, 2003.
358. Success with heart failure. Heart and Vascular Institute, Safety Harbor, FL. November 19, 2003.
359. New ACC/AHA Guidelines: From hypertension to heart failure. Teleconference speaker. November 25, 2003.
360. New ACC/AHA Guidelines: From hypertension to heart failure. Teleconference speaker. December 2, 2003.
361. Faculty Member. Heart Failure Society of America, 1<sup>st</sup> Fellows' Symposium. Boca Raton, FL, 1/16-18/04.
362. Key Note Speaker. Cardiovascular Risk and Prevention. Advocate Health Fair for the Orland and Tinley Park Community. Georgio's, Orland Park, IL, January 31, 2004.

363. Management of the Patient with End-Stage Heart Failure-What Are the Options? Heart Failure 2004: Update for the Primary Care Physician. Jointly sponsored by the Heart Failure Society of America and the University of Minnesota. Adolphus Hotel, Dallas, Texas, February 7, 2004.
364. BNP for the Primary Care Physician. Sponsored by BioSite. Smith & Wollensky's, Chicago, IL, February 10, 2004.
365. Congestive Heart Failure: Innovations in Medical and Surgical Therapy Symposium. Sponsored by Advocate Christ Medical Center. Hyatt Regency, Chicago, Illinois, February 21, 2004.
366. American College of Cardiology 53rd Annual Meeting. New Orleans, LA, March 5-10, 2004
367. The Society of Geriatric Cardiology. Annual Scientific Sessions. End of Life Care. Should cardiologists discuss end of life issues with their congestive heart failure patients: The negative point of view. New Orleans, LA March 6, 2004.
368. Radio Interview, WKZN-FM, New Orleans, LA, March 8, 2004.
369. Chair – American College of Cardiology 2004 Panel Discussion. How to Set Up a Heart Failure Management Program. New Orleans, LA, March 8, 2004.
370. Live Radio Interview, KNNO-AM, New Orleans, LA, March 11, 2004.
371. New Advances in Heart Failure. Midwest Medical Society Annual Meeting. Chicago, IL, March 25, 2004.
372. Understanding the Natriuretic Peptide System in Heart Failure, Grand Rounds Lecture. Sponsored by Scios. St. Joseph's Hospital, Chicago, IL, March 31, 2004.
373. Current and potential roles of brain natriuretic peptide in heart failure management. First Latin American Symposium on Heart Failure. Crowne Plaza Panamericano, Buenos Aires, Argentina, April 23, 2004.
374. Using beta blockers in Stage A and B patients: Pharmacological prevention of heart failure. First Latin American Symposium on Heart Failure. Crowne Plaza Panamericano, Buenos Aires, Argentina, April 23, 2004.
375. Angiotensin receptor blockers in heart failure. First Latin American Symposium on Heart Failure. Crowne Plaza Panamericano, Buenos Aires, Argentina, April 24, 2004.
376. Decompensated Heart Failure in the Emergency Department: Treating Beyond Triage. Intercontinental Hotel, Chicago, IL, April 30, 2004.
377. Audio-Digest Foundation. Teaching faculty CME/CE program: Audio-Digest Internal Medicine, Volume 51, Issue 10, May 21, 2004, ISSN 0271-1303.
378. Update on B-type natriuretic peptide: the impact of early diagnosis and treatment. Satellite symposium sponsored by Scios Inc. and Biosite Diagnostics at the Heart Failure Society of America 8<sup>th</sup> Scientific Sessions. Metro Toronto Convention Center, Toronto, Ontario, Canada. September 13, 2004.
379. How to prevent hospital readmissions using evidence-based practices. How-To Session -Heart Failure Society of America 8<sup>th</sup> Scientific Sessions. Metro Toronto Convention Center, Toronto, Ontario, Canada. September 14, 2004.
380. The three wishes . . . Goals for heart failure nurses. Keynote comments, Great Lakes Regional Nurses' Dinner Meeting. Heart Failure Society of America 8<sup>th</sup> Scientific Sessions. Metro Toronto Convention Center, Toronto, Ontario, Canada. September 14, 2004.
381. Comparison of abbreviated versus full course of enhanced external counterpulsation in heart failure patients with one-year follow-up. Poster presentation at the Heart Failure Society of America 8<sup>th</sup> Scientific Sessions. Metro Toronto Convention Center, Toronto, Ontario, Canada. September 14, 2004.
382. New directions in outpatient management of the heart failure patient. Symposium moderator at the Heart Failure Society of America 8<sup>th</sup> Scientific Sessions. Metro Toronto Convention Center, Toronto, Ontario, Canada. September 15, 2004.
383. Overview of the natriuretic peptides. Presented to the Latin American Physicians' Association at the Heart Failure Society of America 8<sup>th</sup> Scientific Sessions. Metro Toronto Convention Center, Toronto, Ontario, Canada. September 15, 2004.



384. Understanding the Natriuretic Peptide System in Heart Failure. Lecture given to IPC Hospitalists group. Sponsored by Glaxo Smith Kline. Maggiano's, Oakbrook, IL, September 17, 2004.
385. A Focus on the Management of Patients with Post-MI LVD and HF. Grand Round lecture at St. James' Hospital, Olympia Fields, IL. October 29, 2004.
386. Keynote Speaker: Guidelines for Heart Failure. The ABCD's of Heart Failure: Practical Guidelines for the Primary Care Physician, Resident Physician and Nursing Specialist. Drury Lane Oakbrook Terrace, IL. February 2, 2005.
387. End of life decisions: What we should tell our patients and when. Heart Failure 2005: Update for the Primary Care Physician. The Doubletree Hotel, Sacramento, CA. February 12, 2005.
388. Visiting Professor and Cardiology Grand Rounds at the University of Tennessee. Memphis, TN. February 15-16, 2005.
389. Cardiology risk factors - Panel member. Sister-to-Sister 2005 Heart Symposium. Merchandise Mart, Chicago, IL. February 18, 2005.
390. Design and function of left-ventricular support and devices. History of Artificial Hearts Class. Illinois Institute of Technology, Chicago, IL. March 2, 2005.
391. 4th World Conference of International CoenzymeQ10 Association. Beverly Hilton, Beverly Hills, CA, April 14-17, 2005.
392. Congestive Heart Failure Guidelines, Advocate Christ Medical Center, April 18, 2005.
393. Advances in the Prevention, Diagnosis and Treatment of Heart Failure, Rosalind Franklin University of Medicine and Science, April 20, 2005.
394. Successful Advocates: Effective Communication, 5th Annual Dimensions of Excellence Conference, Donald E. Stephens Convention Center, Rosemont, IL, May 4, 2005.
395. Update on Clinical Approaches for the Use of Natriuretic Peptides in Cardiovascular Disease, online CME program sponsored by Bayer Healthcare Diagnostics.
396. Heart Failure: Dealing with difficult cases. End of life decisions: What should we tell our patients and when? Audio-Digest CME/CE program. Audio-Digest Family Practice, Vol. 53 Issue 32, August 28, 2005. ISSN 0271-1362.
397. Managing the Heart Failure Patient with an Implanted Device Satellite Symposium, Boca Raton Resort & Club, Boca Raton, FL, September 18-21, 2005.
398. Current perspectives in the management of Decompensated Heart Failure - Satellite Symposium; Post-discharge heart failure management. Heart Failure Society of America 9th Scientific Sessions. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. September 18, 2005.
399. How to manage fluid overload. Heart Failure Society of America 9th Scientific Sessions. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. September 19, 2005.
400. Pedometer as a surrogate to prognostic markers in congestive heart failure – Poster presentation with Vikas Patel, MD at Heart Failure Society of America 9th Scientific Sessions. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. September 18, 2005.
401. Medication cost burden for patients with symptomatic heart failure - Poster presentation with Pamela Cianci RN, MSN and Carol Pisano, RN, BSN at Heart Failure Society of America 9th Scientific Sessions. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. September 18, 2005.
402. Role of heart failure clinics in the management of patients with implanted cardiac devices – Satellite Symposium; Implications for heart failure clinics. Mizner Center, Boca Raton Resort & Club, Boca Raton, FL. September 20, 2005.
403. Heart Failure Guidelines. Grand Rounds presentation at Advocate Christ Medical Center, Oak Lawn, IL, October 20, 2005.
404. Heart Failure Guidelines: the science behind get with the guidelines. Get with the Guidelines-Heart Failure, Getting started workshop. Chicago Athletic Association, Chicago, IL January 12, 2006.
405. Update on Heart Failure. Grand Rounds, Adventist La Grange Memorial Hospital, La Grange, IL, February 21, 2006.

406. Five best ways to keep your heart healthy. Community lecture at the Advocate Christ Family Practice Center, Hometown, IL, February 28, 2006.
407. Clinical and engineering advances in ventricular assist for heart failure. IIT Department of Biomedical Engineering. Chicago, IL, April 24, 2006.
408. ACC/AHA Guidelines for heart failure therapy. Louie's Chophouse. Oak Lawn, IL May 16, 2006.
409. Fluid status and activity: Ongoing assessment and the impact on patient management in heart failure. Satellite symposium of the 10<sup>th</sup> Annual Meeting of the Heart Failure Society of America. Seattle, WA, September 10, 2006.
410. What are these guidelines we are supposed to be getting with? Hospital Leadership Summit sponsored by American Heart Association, Greater Midwest Affiliate, Get with the Guidelines Committee. Oakbrook Drake Hotel, October 27, 2006.
411. Cardiovascular risks of chemotherapeutic agents. - Late Effects in childhood cancer survivors; Recognition and interventions. Oak Lawn Hilton Hotel, Oak Lawn, IL, November 1, 2006.
412. 7<sup>th</sup> annual heart failure symposium for Internists and primary care physicians – Evidence based approaches to treating heart failure in the office setting – What the guidelines tell us and how the experts do it. U.S. Grant Hotel, San Diego, CA, February 3, 2007.
413. Heart failure update 2007: Quality of care in heart failure. Lindner Center, Lombard, IL, February 14, 2007.
414. Hypertension as a national health epidemic. 2007 Annual Midwest Clinical Conference, Hyatt Regency McCormick Place, Chicago, IL. March 16, 2007.
415. Pulmonary arterial hypertension: Today and tomorrow, Moderator. Marriot Oakbrook Hotel, Oakbrook, IL April 14, 2007.
416. Getting to the heart of diabetes management: Making the link between diabetes and heart disease. Drury Lane, Oakbrook Terrace; June 26, 2007.
417. Remote monitoring: Creating a clinical consensus now and for the future. Chairman of Satellite Symposium at 11<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America, Marriot Wardman Park Hotel, Washington DC, September 16, 2007.
418. How to work up new onset heart failure. How-To Session at 11<sup>th</sup> Annual Scientific Meeting of the Heart Failure Society of America, Marriot Wardman Park Hotel, Washington DC, September 18, 2007.
419. 2007 Innovations in heart failure and pulmonary hypertension: Acute decompensated heart failure today - Patient characteristics and treatment options framing how we think about heart failure. Allegheny General Hospital, Pittsburgh, PA, September 28, 2007.
420. Cardiovascular Symposium: From prevention to cure, Avoiding pitfalls in managing patients with congestive heart failure. Advocate Christ Medical Center, September 29, 2007.
421. Treating acute decompensated heart failure: A Comprehensive Approach. Schaumburg Renaissance Hotel, Schaumburg, IL, October 2, 2007.
422. Decompensated heart failure. Grand Rounds lecture at Lutheran General Hospital, Park Ridge, IL, November 9, 2007.
423. Current approaches for heart failure management. Community Hospital, Munster, IN, February 13, 2008.
424. Cardiomyopathies: Hypertrophic vs. restrictive vs. dilated. Resident's noon conference, Advocate Christ Medical Center. March 13, 2008.
425. Hemodynamic assessment in heart failure. American College of Cardiology 57<sup>th</sup> Annual Scientific Session, Chicago, IL, March 31, 2008.
426. Enhanced External Counterpulsation Improves One Year Mortality in Angina Patients With End Stage Coronary Disease. Lawson WE, Hui JCK, Kennard ED, **Silver MA**, Soran O, Kelsey SF, Barsness G, Michaels A. Poster # 1031-68 at American College of Cardiology 57<sup>th</sup> Annual Scientific Session, Chicago, IL, April 1, 2008.
427. Sleep apnea and heart failure. Co-chair of symposium #680 at American College of Cardiology 57<sup>th</sup> Annual Scientific Session, Chicago, IL, April 1, 2008.

428. Clinical and engineering advances and needs in ventricular assist for heart failure. Department of Biomedical Engineering lecture at Illinois Institute of Technology, Chicago, IL April 16, 2008.
429. Where Does Diuretic Therapy End And Ultra Filtration Begin In Heart Failure Management: A Review Of The Data. Presented at Heart Failure Summit: Failure in not an option. Supported by the American Heart Association. Sheraton Parsippany, NJ, June 2, 2008.
430. Update on Heart Failure. Advocate Parish Nurses Organization. Advocate Christ Medical Center, Oak Lawn, IL, August 28, 2008.
431. An Approach to the Patient Admitted for Acute Decompensated Heart Failure. Cardiovascular Disease Fellowship Program. Advocate Illinois Masonic Medical Center, Chicago, IL, August 29, 2008.
432. How to Manage the Out Patient with a Left Ventricular Assist Device. Session Chairman. 12<sup>th</sup> Annual Scientific Meeting, Heart Failure Society of America. Toronto, CANADA September 23, 2008
433. Commentary on the PARTNERS HF Trial. Late Breaking Clinical Trial Session. 12<sup>th</sup> Annual Scientific Meeting, Heart Failure Society of America. Toronto, CANADA September 24, 2008
434. Translational Hemodynamics. Lecture to Residents and Cardiology Fellows. UIC/ACMC. Oak Lawn, IL November 19, 2008.
435. Technology for Heart Failure: Separating Future from Futile. Part of Symposium, entitled, "21<sup>st</sup> Century Medical Challenges: Issues of Development and Delivery. American Academy for the Advancement of Science (AAAS) Annual Meeting. February 15, 2009, Chicago, IL
436. Depression and Heart Failure. 2009 Heart Brain Summit. Bakken Institute at the Cleveland Clinic/Heart-Brain Society. Chicago, IL October 15, 2009.
437. Understanding the Guidelines for Heart Failure. Lecture to Residents, Students and Attendings. UIC/ACMC. Oak Lawn, IL October 22, 2009.
438. Current Heart Failure Therapies—Guidelines and Beyond. 21<sup>st</sup> Annual Cardiopulmonary Rehabilitation Education Conference. Advocate Christ Medical Center Conference Center. Oak Lawn, IL March 5-6, 2010.
439. Office Management of Heart Failure. Rush-Copley 7<sup>th</sup> Annual Women's Heart Symposium. Northern Illinois University Campus, Naperville, IL. March 10, 2010.
440. Co-Chair, Managing Co-morbidities in Heart Failure. American College of Cardiology Annual Meeting, Atlanta, GA. March 15, 2010.
441. Treating Heart Failure Beyond Practice Guidelines: Role of Thermal Therapy for Heart Failure. American College of Cardiology Annual Meeting, Atlanta, GA. March 16, 2010.
442. Diastolic Heart Failure. Clinical Management of Pulmonary Hypertension: State of the Art Conference. Advocate Christ Medical Center. Oak Lawn, IL. Saturday May 22, 2010
443. Cardiac Risk and Disease in Childhood Cancer Survivors: Tools for Prevention. Update in Pediatric Hematology/ Oncology. Advocate Hope Children's Hospital Symposium. Oak Lawn, IL November 3, 2010.
444. Current Therapies and Approaches for the Patient With Heart Failure. Grand Rounds, Advocate South Suburban Hospital, Hazel crest, IL. July 7, 2011.
445. A SWOT Analysis of Heart Failure. Keynote Lecture. 15<sup>th</sup> Annual Cardiovascular Symposium. Advocate South Suburban Hospital. Burr Ridge, IL October 15, 2011.
446. Implantable Devices for Following Patients in the Outpatient Setting. Heart Failure Society of America, 2011 HFSA Comprehensive Review & Update. The Practical Management of Heart Failure: From Prevention to Advanced Disease. Chicago, IL October 23, 2011.
447. A SWOT Analysis of Heart Failure. Illinois American College of Cardiology Annual Meeting. Chicago, IL May 11, 2012.
448. AHA Scientific Sessions 2012 Abstract Reviewer Scientific Sessions 2012.
449. How to Maximize Adherence to Heart Failure Performance Measures in the Inpatient and Outpatient Settings. Heart Failure Society of America 16<sup>th</sup> Annual Scientific Meeting 2012 Program. Seattle, WA September 10, 2012.

450. Safety and Prognostic Value of Cerebral Oximetry Monitoring in Heart Failure Patients during Cardiopulmonary Exercise. Luay Rifai, Kemisha Key, Winna Taylor, **Marc A. Silver**. Heart Failure Society of America 16<sup>th</sup> Annual Scientific Meeting, September 10, 2012.
451. Can Early Changes in Cerebral Oxygenation During Submaximal Exercise Predict Outcomes in Heart Failure Patients? Heart Failure Session, CHEST, Atlanta 2012.
452. Obesity and Cardiovascular Disease: A Common Co-Mingling Set of Co-Morbidities. Advocate Good Samaritan Hospital, Obesity Awareness Symposium October 26, 2012.
453. EECF: Current Evidence and Clinical Application. ACOMC Department of Medicine Grand Rounds. May 2013
454. Impact of DASH Diet on Endothelial Function in Heart Failure Patients. American Heart Association Scientific Sessions. Dallas 2013, November 16-20.
455. 1<sup>st</sup> Annual Shared Care Symposium. ACOMC, Advanced Heart Failure Team. September 6, 2013
456. Is the DASH Diet the Optimal diet for Heart Failure Patients? International Academy of Cardiology Annual Scientific Session. Boston, MA 2014, July 25-28.
457. Heart Failure Clinics: The Phoenix of Chronic Disease Management. ACOMC 2<sup>nd</sup> Annual Advanced Heart Failure Symposium. Oak Lawn, IL November 7, 2014.
458. AHA Heart Failure Innovation Forum. Handling the hurdles of heart failure management. Chicago, IL November 14, 2014.
459. North Shore/Mayo Clinic Valvular Heart Disease Symposium. What should we do with Functional MR in CHF? Chicago, IL, April 24, 2015.
460. Workers' Compensation Lawyers Association Special Spring Medical Seminar. Heart Failure Primer: 2015. Chicago, IL, April 28, 2015.
461. The Heart Failure Clinic: Taking Center Stage in Chronic Disease Management. International Academy of Cardiology Annual Scientific Session, 2015. 20<sup>th</sup> World Congress on Heart Disease. Vancouver, British Columbia, Canada, July 25-27, 2015.
462. Global Barriers to Effective Heart Failure Care. 3<sup>rd</sup> annual Advanced Heart Failure Symposium. Oak Lawn, IL. November 6, 2015.
463. Healing Gives Me Joy—Restoring Purpose to Medicine. Wingspread Retreat. 2.5 Days of top level conversations on health caregiver “burnout” and its impact on American Health. Multiple sponsors including Institute for Healthcare Excellence, Experience Innovation Network and The Johnson Foundation. Johnson Foundation Wingspread Conference Center. November 11-13, 2015.
464. Multiple Small Feedings of the Mind. ACP Illinois 2015. Session Moderator and Presenter—HfpEF. University Club, Chicago, IL November 12, 2015.
465. TEDMEDLive 2015. Live Feed Ambassador. November 19-20, 2015
466. External Enhanced Counterpulsation-Platform for Chronic Disease and Population Management. Visiting Professor and Cardiovascular Grand Rounds. St. Luke's Medical Center/ Mid America Heart Institute. January 20-21, 2016.
467. Drafting Blueprints: Co-Designing Healthcare. Closing Keynote for the Experience Innovation Network/CXO Roundtable. San Francisco, CA May 3-4, 2016
468. Angina: Prequel or Sequel to Heart Failure? Chronic Heart Failure Management Symposium. European Society of Heart Failure, Paris, May 1, 2017
469. Home hospitalization for Acute Decompensated Heart Failure: Opportunities and Strategies for Improved Health Outcome. International Congress of Cardiology, Invited Speaker, Plenary Session. Boston, MA July 28, 2018.
470. Strategic Heart Failure: Strategies for Optimal Care and Outcomes. KEYNOTE LECTURE. Aurora Healthcare, Milwaukee, WI May 4, 2019.
471. Presenter, "Get With The Guidelines® - 360°: Aldosterone Antagonist at Discharge Webinar" June 19, 2019.

<b><i>Content Information</i></b>	<b><i>Page Number</i></b>
-----------------------------------	---------------------------

Personal Information	1
Education and Training	1
Academic Appointments	1-2
Certifications	3
Additional Leadership Roles	4
Licensure and Awards	4
Editorial Activities	5
Manuscript Reviews	6
Professional Associations	6-9
Disclosure	10
Sponsored Research Grants and Clinical Trials	11-14
Publications	15-27
Book Chapters and other Publications	28-29
Internet Programs/ Lectures	30
Abstracts	31-41
Invited Lectures and Presentations	41-60

<b><i>Item</i></b>	<b><i>Totals</i></b>
--------------------	----------------------

Sponsored Grants and Clinical Trials	75
Publications	193
Book Chapters, Editorials and other Publications	36
Internet Programs and Lectures	5
Abstracts	159
Invited Lectures and Presentations	471

Updated on June 2019